Dihydroxypyrimidine carboxamide inhibitors of hiv integrase

ABSTRACT

4,5-Dihydroxypyrimidine-6-carboxamides of formula (I); are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R 1 , R 2 , R 3  and R 4  are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

FIELD OF THE INVENTION

The present invention is directed to 5,6-dihydroxypyrimidine-4-carboxamides and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of the HIV integrase enzyme. The compounds and pharmaceutically acceptable salts thereof of the present invention are useful for preventing or treating infection by HIV and for treating or delaying the onset of AIDS.

BACKGROUND OF THE INVENTION

A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus replication is the insertion by virally-encoded integrase of proviral DNA into the host cell genome, a required step in HIV replication in human T-lymphoid and monocytoid cells. Integration is believed to be mediated by integrase in three steps: assembly of a stable nucleoprotein complex with viral DNA sequences; cleavage of two nucleotides from the 3′ termini of the linear proviral DNA; covalent joining of the recessed 3′ OH termini of the proviral DNA at a staggered cut made at the host target site. The fourth step in the process, repair synthesis of the resultant gap, may be accomplished by cellular enzymes.

Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)]. Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, integrase and an HIV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M. D. et al., Science, 231, 1567 (1986); Pearl, L. H. et al., Nature, 329, 351 (1987)]. All three enzymes have been shown to be essential for the replication of HIV.

It is known that some antiviral compounds which act as inhibitors of HIV replication are effective agents in the treatment of AIDS and similar diseases, including reverse transcriptase inhibitors such as azidothymidine (AZT) and efavirenz and protease inhbitors such as indinavir and nelfinavir. The compounds of this invention are inhibitors of HIV integrase and inhibitors of HIV replication. The inhibition of integrase in vitro and HIV replication in cells is a direct result of inhibiting the strand transfer reaction catalyzed by the recombinant integrase in vitro in HIV infected cells. The particular advantage of the present invention is highly specific inhibition of HIV integrase and HIV replication.

SUMMARY OF THE INVENTION

The present invention is directed to novel dihydroxypyrimidine carboxamides. These compounds are useful in the inhibition of HIV integrase, the prevention of infection by HIV, the treatment of infection by HIV and in the prevention, treatment, and delay in the onset of AIDS, either as compounds or their pharmaceutically acceptable salts or hydrates (when appropriate), or as pharmaceutical composition ingredients, whether or not in combination with other HIV/AIDS antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. More particularly, the present invention includes a compound of Formula (I):

wherein

-   R¹ is     -   (1) —H,     -   (2) —C₁₋₆ alkyl, which is optionally substituted with one or         more substituents each of which is independently halogen, —OH,         —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—C₀₋₆         alkyl-N(R^(a)R^(b)), N(R^(a))—C(═O)—C₀₋₆ alkyl-N(R^(b)R^(c)),         —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)),         —N(R^(a))—C(═O)R^(b),     -    —N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)),         or —N(R^(a))C(═O)OR^(b),     -   (3) —O—C₁₋₆ alkyl, which is optionally substituted with one or         more substituents each of which is independently halogen, —OH,         —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—C₀₋₆         alkyl-N(R^(a)R^(b)), N(R^(a))—C(═O)—C₀₋₆ alkyl-N(R^(b)R^(c)),         —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or         —N(R^(a))—C(R^(b))═O,     -   (4) —R^(k),     -   (5) —C₁₋₆ alkyl-R^(k), wherein the alkyl is optionally         substituted with one or more substituents each of which is         independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆         haloalkyl, —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b),         —N(R^(a))C(═O)—C₀₋₆ alkyl-N(R^(b)R^(c)), or —N(R^(a))—C₂₋₆         alkyl-OH with the proviso that the —OH is not attached to the         carbon alpha to N(R^(a)),     -   (6) —C₂₋₅ alkenyl-R^(k),     -   (7) —C₂₋₅ alkynyl-R^(k),     -   (8) —C₀₋₆ alkyl-O—C₀₋₆ alkyl-R^(k),     -   (9) —C₀₋₆ alkyl-S(O)_(n)—C₀₋₆ alkyl-R^(k),     -   (10) —O—C₁₋₆ alkyl-OR^(k),     -   (11) —O—C₁₋₆ alkyl-O—C₁₋₆ alkyl-R^(k),     -   (12) —O—C₁₋₆ alkyl-S(O)_(n)R^(k),     -   (13) —C₀₋₆ alkyl-N(R^(a))—R^(k),     -   (14) —C₀₋₆ alkyl-N(R^(a))—C₁₋₆ alkyl-R^(k),     -   (15) —C₀₋₆ alkyl-N(R^(a))—C₁₋₆ alkyl-OR^(k),     -   (16) —C₀₋₆ alkyl-C(═O)—R^(k),     -   (17) —C₀₋₆ alkyl-C(═O)N(R^(a))—C₀₋₆ alkyl-R^(k),     -   (18) —C₀₋₆ alkyl-N(R^(a))C(═O)—C₀₋₆ alkyl-R^(k),     -   (19) —C₀₋₆ alkyl-N(R^(a))C(═O)—O—C⁰⁻⁶ alkyl-R^(k),     -   (20) —C₁₋₆ alkyl which is:         -   (i) substituted with aryl or —O-aryl, wherein the aryl is             optionally substituted with one or more substituents each of             which is independently halogen, —OH, —C₁₋₆ alkyl, —C₁₋₆             alkyl-OR^(a), —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆             haloalkyl, methylenedioxy attached to two adjacent carbon             atoms, or aryl, or         -   (ii) substituted with —R^(k), —C₁₋₆ alkyl-R^(k),             —N(R^(a))—C(═O)—C₀₋₆ alkyl-R^(k), —C₀₋₆ alkyl-N(R^(a))—C₀₋₆             alkyl-R^(k), —C₀₋₆ alkyl-O—C₀₋₆ alkyl-R^(k), or —C₀₋₆             alkyl-N(R^(a))—C(═O)—C₀₋₆ alkyl-R^(k); and         -   (iii) optionally substituted with one or more substituents             each of which is independently halogen, —OH, —CN, —O—C₁₋₆             alkyl, —O—C₁₋₆ haloalkyl, or —N(R^(a)R^(b)), or     -   (21) —C₁₋₆ alkyl, substituted with —O—C₁₋₆ alkyl, and with a         substituent selected from the group consisting of         —N(R^(a))C(═O)R^(k) and —N(R^(a))C₁₋₆ alkyl-R^(k), -   R² is —H or —C₁₋₆ alkyl which is optionally substituted with one or     more substituents each of which is independently     -   (1) halogen,     -   (2) —OH,     -   (3) —CN,     -   (4) —O—C₁₋₆ alkyl,     -   (5) —O—C₁₋₆ haloalkyl,     -   (6) —C(═O)R^(a),     -   (7) —CO₂R^(a),     -   (8) —SR^(a),     -   (9) —S(═O)R^(a),     -   (10) —N(R^(a)R^(b)),     -   (11) —C(═O)N(R^(a)R^(b)),     -   (12) —N(R^(a))—C(═O)—C₁₋₆ alkyl-N(R^(b)R^(c)),     -   (13) —SO₂R^(a),     -   (14) —N(R^(a))SO₂R^(b),     -   (15) —SO₂N(R^(a)R^(b)),     -   (16) —N(R^(a))—C(R^(b))═O,     -   (17) —C₃₋₈ cycloalkyl,     -   (18) aryl, wherein the aryl is optionally substituted with one         or more substituents each of which is independently halogen,         —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl,         —C₀₋₆ alkyl-N(R^(a)R^(b)), or —C₁₋₆ alkyl substituted with a 5-         or 6-membered saturated heterocyclic ring containing from 1 to 4         heteroatoms independently selected from N, O and S;         -   wherein the saturated heterocyclic ring is optionally             substituted with from 1 to 3 substituents each of which is             independently —C₁₋₆ alky, oxo, or a 5- or 6-membered             heteroaromatic ring containing from 1 to 4 heteroatoms             independently selected from N, O and S; or     -   (19) a 5- to 8-membered monocyclic heterocycle which is         saturated or unsaturated and contains from 1 to 4 heteroatoms         independently selected from N, O and S; wherein the heterocycle         is optionally substituted with one or more substituents each of         which is independently —C₁₋₆ alkyl, —O—C₁₋₆ alky, oxo, phenyl,         or naphthyl; -   R³ is —H or —C₁₋₆ alkyl; -   R⁴ is     -   (1) H,     -   (2) C₁₋₆ alkyl which is optionally substituted with one or more         substituents each of which is independently halogen, —OH, O—C₁₋₆         alky, —O—C₁₋₆ haloalkyl, —NO₂, —N(R^(a)R^(b)), —C(═O)R^(a),         —CO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), or         —N(R^(a))CO₂R^(b),     -   (3) C₁₋₆ alkyl which is optionally substituted with one or more         substituents each of which is independently halogen, —OH, or         O—C₁₋₄ alkyl, and which is substituted with 1 or 2 substituents         each of which is independently:         -   (i) C₃₋₈ cycloalkyl,         -   (ii) aryl,         -   (iii) a fused bicyclic carbocycle consisting of a benzene             ring fused to a C₅₋₇ cycloalkyl,         -   (iv) a 5- or 6-membered saturated heterocyclic ring             containing from 1 to 4 heteroatoms independently selected             from N, O and S,         -   (v) a 5- or 6-membered heteroaromatic ring containing from 1             to 4 heteroatoms independently selected from N, O and S, or         -   (vi) a 9- or 10-membered fused bicyclic heterocycle             containing from 1 to 4 heteroatoms independently selected             from N, O and S, wherein at least one of the rings is             aromatic,     -   (4) C₂₋₅ alkynyl optionally substituted with aryl,     -   (5) C₃₋₈ cycloalkyl optionally substituted with aryl,     -   (6) aryl,     -   (7) a fused bicyclic carbocycle consisting of a benzene ring         fused to a C₅₋₇ cycloalkyl,     -   (8) a 5- or 6-membered saturated heterocyclic ring containing         from 1 to 4 heteroatoms independently selected from N, O and S,     -   (9) a 5- or 6-membered heteroaromatic ring containing from 1 to         4 heteroatoms independently selected from N, O and S, or     -   (10) a 9- or 10-membered fused bicyclic heterocycle containing         from 1 to 4 heteroatoms independently selected from N, O and S,         wherein at least one of the rings is aromatic;     -   wherein         -   each aryl in (3)(ii) or the aryl (4), (5) or (6) or each             fused carbocycle in (3)(iii) or the fused carbocycle in (7)             is optionally substituted with one or more substituents each             of which is independently halogen, —OH, —C₁₋₆ alkyl, —C₁₋₆             alkyl-OR^(a), —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆             haloalkyl, —CN, —NO₂, —N(R^(a)R^(b)), —C₁₋₆             alkyl-N(R^(a)R^(b)), —C(═O)N(R^(a)R^(b)), —C(═O)R^(a),             —CO₂R^(a), —C₁₋₆ alkyl-CO₂R^(a), —OCO₂R^(a), —SR^(a),             —S(═O)R^(a), —SO₂R^(a), —N(R^(a))SO₂R^(b),             —SO₂N(R^(a)R^(b)), —N(R^(a))C(═O)R^(b), —N(R^(a))CO₂R^(b),             —C₁₋₆ alkyl-N(R^(a))CO₂R^(b), aryl, —C₁₋₆ alkyl-aryl,             —O-aryl, or —C₀₋₆ alkyl-het wherein het is a 5- or             6-membered heteroaromatic ring containing from 1 to 4             heteroatoms independently selected from N, O and S, and het             is optionally fused with a benzene ring, and is optionally             substituted with one or more substituents each of which is             independently —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl,             —O—C₁₋₆ haloalkyl, oxo, or —CO₂R^(a);         -   each saturated heterocyclic ring in (3)(iv) or the saturated             heterocyclic ring in (8) is optionally substituted with one             or more substituents each of which is independently halogen,             —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆             haloalkyl, oxo, aryl, or a 5- or 6-membered heteroaromatic             ring containing from 1 to 4 heteroatoms independently             selected from N, O and S; and         -   each heteroaromatic ring in (3)(v) or the heteroaromatic             ring in (9) or each fused bicyclic heterocycle in (3)(vi) or             the fused bicyclic heterocycle in (10) is optionally             substituted with one or more substituents each of which is             independently halogen, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆             alkyl, —O—C₁₋₆ haloalkyl, oxo, aryl, or —C₁₋₆ alkyl-aryl; -   or alternatively R³ and R⁴ together with the N to which both are     attached form a C₃₋₇ azacycloalkyl which is optionally substituted     with one or more substituents each of which is independently —C₁₋₆     alkyl or oxo; -   each R^(a), R^(b), R^(c), and R^(d) is independently —H or —C₁₋₆     alkyl; -   R^(k) is carbocycle or heterocycle, wherein the carbocycle or     heterocycle is optionally substituted with one or more substituents     each of which is independently     -   (1) halogen,     -   (2) —OH,     -   (3) —CN,     -   (4) —C₁₋₆ alkyl, which is optionally substituted with one or         more substituents each of which is independently halogen, —OH,         —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)),         —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (5) —O—C₁₋₆ alkyl, which is optionally substituted with one or         more substituents each of which is independently halogen, —OH,         —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)),         —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (6) —NO₂,     -   (7) oxo,     -   (8) ethylenedioxy, spiro substituted on a ring carbon in a         saturated ring of R^(k),     -   (9) —C(═O)R^(a),     -   (10) —CO₂R^(a),     -   (11) —SR^(a),     -   (12) —S(═O)R^(a),     -   (13) —N(R^(a)R^(b)),     -   (14) —C(═O)N(R^(a)R^(b)),     -   (15) —C(═O)—C₁₋₆ alkyl-N(R^(a)R^(b)),     -   (16) —N(R^(a))C(═O)R^(b),     -   (17) —SO₂R^(a),     -   (18) —SO₂N(R^(a)R^(b)),     -   (19) —N(R^(a))SO₂R^(b),     -   (20) —R^(m),     -   (21) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally         substituted with one or more substituents each of which is         independently halogen, —OH, —CN, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl,         —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a),         —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b),         —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (22) —C₀₋₆ alkyl-N(R^(a))—C₀₋₆ alkyl-R^(m),     -   (23) —C₀₋₆ alkyl-O—C₀₋₆ alkyl-R^(m),     -   (24) —C₀₋₆ alkyl-S—C₀₋₆ alkyl-R^(m),     -   (25) —C₀₋₆ alkyl-C(═O)—C₀₋₆ alkyl-R^(m),     -   (26) —C(═O)—O—C₀₋₆ alkyl-R^(m),     -   (27) —C(═O)N(R^(a))—C₀₋₆ alkyl-R^(m),     -   (28) —N(R^(a))C(═O)—R^(m),     -   (29) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is         optionally substituted with one or more substituents each of         which is independently halogen, —OH, —CN, —C₁₋₆ haloalkyl,         —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b),         —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or         —N(R^(a))—C(R^(b))═O,     -   (30) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₆ alkyl-R^(m),     -   (31) —N(R^(a))—C(═O)—O—C₀₋₆ alkyl-R^(m), or     -   (32) —N(R^(a))—C(═O)—N(R^(b))—SO₂—C₀₋₆ alkyl-R^(m); -   carbocycle in R^(k) is (i) a C₃ to C₈ monocyclic, saturated or     unsaturated ring, (ii) a C₇ to C₁₂ bicyclic ring system, or (iii) a     C₁₁ to C₁₆ tricyclic ring system, wherein each ring in (ii) or (iii)     is independent of or fused to the other ring or rings and each ring     is saturated or unsaturated; -   heterocycle in R^(k) is (i) a 4- to 8-membered, saturated or     unsaturated monocyclic ring, (ii) a 7- to 12-membered bicyclic ring     system, or (iii) an 11 to 16-membered tricyclic ring system; wherein     each ring in (ii) or (iii) is independent of or fused to or bridged     with or spiro to the other ring or rings and each ring is saturated     or unsaturated; the monocyclic ring, bicyclic ring system, or     tricyclic ring system contains from 1 to 6 heteroatoms selected from     N, O and S and a balance of carbon atoms; and wherein any one or     more of the nitrogen and sulfur heteroatoms is optionally be     oxidized, and any one or more of the nitrogen heteroatoms is     optionally quaternized; -   each R^(m) is independently C₃₋₈ cycloalkyl; aryl; a 5- to     8-membered monocyclic heterocycle which is saturated or unsaturated     and contains from 1 to 4 heteroatoms independently selected from N,     O and S; or a 9- to 10-membered bicyclic heterocycle which is     saturated or unsaturated and contains from 1 to 4 heteroatoms     independently selected from N, O and S; wherein any one or more of     the nitrogen and sulfur heteroatoms in the monocyclic or bicyclic     heterocycle is optionally oxidized and any one or more of the     nitrogen heteroatoms is optionally quaternized; and wherein     -   the cycloalkyl or the aryl is optionally substituted with one or         more substituents each of which is independently halogen, —C₁₋₆         alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl,         —N(R^(a)R^(b)), aryl, or —C₁₋₆ alkyl-aryl; and     -   the monocyclic or bicyclic heterocycle is optionally substituted         with one or more substituents each of which is independently         halogen, —C₁₋₆ alkyl optionally substituted with —O—C₁₋₆ alkyl,         —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, oxo, aryl,         —C₁₋₆ alkyl-aryl, —C(═O)-aryl, —CO₂-aryl, —CO₂—C₁₋₆ alkyl-aryl,         a 5- or 6-membered saturated heterocyclic ring containing from 1         to 4 heteroatoms independently selected from N, O and S, or a 5-         or 6-membered heteroaromatic ring containing from 1 to 4         heteroatoms independently selected from N, O and S; and -   each n is independently an integer equal to zero, 1 or 2; -   or a pharmaceutically acceptable salt thereof.

An embodiment of the present invention is a compound of Formula (I) as originally definedabove except that: (I) in the definition of R¹, R¹ is one of the groups (1) to (20), all of which are as defined aboveexcept that (2) of R¹ is —C₁₋₆ alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—C₀₋₆ alkyl-N(R^(a)R^(b)), N(R^(a))—C(═O)—C₀₋₆ alkyl-N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b), or

The present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions. The present invention further includes methods of treating AIDS, methods of delaying the onset of AIDS, methods of preventing AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV.

Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.

DETAILED DESCRIPTION OF THE INVENTION

The present invention includes the dihydroxypyrimidine carboxamides of Formula (I) above. These compounds and pharmaceutically acceptable salts thereof are HIV integrase inhibitors.

An embodiment of the present invention is a compound of Formula (I) exactly as defined above, except that in the definition of R^(k), R^(k) is optionally substituted with one or more substituents each of which is independently one of the substituents (1) to (19), and is optionally mono-substituted with one of the substituents (20) to (32).

Another embodiment of the present invention is a compound of Formula (I), wherein R¹ is:

-   (1) —H, -   (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to 5     substituents each of which is independently halogen, —OH, —CN,     —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a),     —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),     N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b),     —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b), -    —N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)), or     —N(R^(a))C(═O)OR^(b), -   (3) —R^(k), -   (4) —C₁₋₄ alkyl-R^(k), wherein the alkyl is optionally substituted     with 1 or 2 substituents each of which is independently halogen,     —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —N(R^(a)R^(b)), or     —N(R^(a))—(CH₂)₂₋₄—OH, -   (5) —O—(CH₂)₀₋₃—R^(k), -   (6) —C₁₋₄ alkyl-O—(CH₂)₀₋₃—R^(k), -   (7) —(CH₂)₀₋₃—S(O)_(n)—(CH₂)₀₋₃—R^(k), -   (8) —O—(CH₂)₁₋₃—OR^(k), -   (9) —O—(CH₂)₁₋₃—O—(CH₂)₁₋₃—R^(k), -   (10) —O—(CH₂)₁₋₃—S(O)_(n)R^(k), -   (11) —(CH₂)₀₋₃—N(R^(a))—R^(k), -   (12) —(CH₂)₀₋₃—N(R^(a))—(CH₂)₁₋₃—R^(k), -   (13) —(CH₂)₀₋₃—N(R^(a))—(CH₂)₁₋₃—OR^(k), -   (14) —(CH₂)₀₋₃—C(═O)—R^(k), -   (15) —(CH₂)₀₋₃—C(═O)N(R^(a))—(CH₂)₀₋₃—R^(k), -   (16) —(CH₂)₀₋₃—N(R^(a))C(═O)—(CH₂)₀₋₃—R^(k), -   (17) —(CH₂)₀₋₃—N(R^(a))C(═O)—O—(CH₂)₀₋₃—R^(k), -   (18) —C₁₋₆ alkyl which is:     -   (i) substituted with aryl or —O-aryl, wherein the aryl is         optionally substituted with from 1 to 3 substituents each of         which is independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄         alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl,         methylenedioxy attached to two adjacent carbon atoms, or aryl;     -   (ii) substituted with —R^(k), —(CH₂)₁₋₃—R^(k),         —N(R^(a))—C(═O)—(CH₂)₀₋₃—R^(k),         —(CH₂)₀₋₃—N(R^(a))—(CH₂)₀₋₃—R^(k), or —(CH₂)₀₋₃—O—(CH₂)₀₋₃—R^(k)         or —(CH₂)₀₋₃—N(R^(a))—C(═O)—(CH₂)₀₋₃—R^(k); and     -   (iii) optionally substituted with from 1 to 4 substituents each         of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl,         —O—C₁₋₄ haloalkyl, or —N(R^(a)R^(b)), -   (19) —C(CH₃)₂N(R^(a))C(═O)OCH₂R^(k), -   (20) —C(CH₃)₂N(R^(a))CH₂R^(k), -   (21) —C(CH₃)₂N(R^(a))C(═O)R^(k), or -   (22) —C(R^(b))(N(R^(a))C(═O)R^(k))(CH₂OR^(c)), -   (23) —C(R^(b))(N(R^(a))(CH₂)—R^(k))(CH₂OR^(c)), -   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

Still another embodiment of the present invention is a compound of Formula (I) as defined in the immediately preceding embodiment, except that R¹ is one of the groups (1) to (18), wherein (2) of R¹ is C₁₋₆ alkyl, which is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b), or

Another embodiment of the present invention is a compound of Formula (I), wherein R¹ is:

-   (1) —H, -   (2) —C₁₋₄ alkyl, which is optionally substituted with from 1 to 3     substituents each of which is independently halogen, —OH, —CN,     —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a),     —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),     N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b),     —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b), -    N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)), or     —N(R^(a))C(═O)OR^(b), -   (3) —R^(k), -   (4) —CH(CH₃)—R^(k), -   (5) —(CH₂)₁₋₄—R^(k), wherein the —(CH₂)₁₋₄— moiety is optionally     substituted with one of —N(R^(a)R^(b)) or —N(R^(a))—(CH₂)₂—OH, -   (6) —(CH₂)₁₋₂—O—(CH₂)₀₋₁—R^(k), -   (7) —(CH₂)₁₋₂—S(O)_(n)—(CH₂)₀₋₁—R^(k), -   (8) —O—(CH₂)₁₋₂—OR^(k), -   (9) —O—(CH₂)₁₋₂—O—(CH₂)₁₋₂—R^(k), -   (10) —O—(CH₂)₁₋₂—S(O)_(n)R^(k), -   (11) —(CH₂)₁₋₂—N(R^(a))—R^(k), -   (12) —(CH₂)₁₋₂—N(R^(a))—(CH₂)₁₋₃—R^(k), -   (13) —(CH₂)₁₋₂—N(R^(a))—(CH₂)₁₋₃—OR^(k), -   (14) —(CH₂)₀₋₂—C(═O)—R^(k), -   (15) —C(═O)N(R^(a))—(CH₂)₁₋₂—R^(k), -   (16) —(CH₂)₀₋₂—C(═O)N(R^(a))—(CH₂)₀₋₂—R^(k), -   (17) —(CH₂)₁₋₂—N(R^(a))C(═O)—(CH₂)₀₋₁—R^(k), -   (18) —(CH₂)₁₋₂—N(R^(a))C(═O)—O—(CH₂)₀₋₁—R^(k), -   (19) —C₁₋₄ alkyl which is:     -   (i) substituted with aryl or —O-aryl wherein the aryl is         optionally substituted with from 1 to 3 substituents each of         which is independently fluoro, chloro, —C₁₋₄ alkyl, —C₁₋₄         fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, methylenedioxy         attached to two adjacent carbon atoms, or phenyl;     -   (ii) substituted with —R^(k), —(CH₂)₁₋₃—R^(k),         —N(R^(a))—C(═O)—(CH₂)₀₋₃—R^(k), —N(R^(a))—(CH₂)₁₋₃—R^(k),         —O—(CH₂)₁₋₂—R^(k), or —N(R^(a))—C(═O)—(CH₂)₀₋₂—R^(k); and     -   (iii) optionally substituted with from 1 to 4 substituents each         of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl,         —O—C₁₋₄ haloalkyl, or —N(R^(a)R^(b)),     -   (20) —C(CH₃)₂N(R^(a))C(═O)OCH₂R^(k),     -   (21) —C(CH₃)₂N(R^(a))CH₂R^(k),     -   (22) —C(CH₃)₂N(R^(a))C(═O)R^(k),     -   (23) —C(R^(b))(N(R^(a))C(═O)R^(k))(CH₂OR^(c)), or     -   (24) —C(R^(b))(N(R^(a))(CH₂)—R^(k))(CH₂OR^(c)); -   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

In an aspect of this embodiment, R¹ is

-   (1) —H, -   (2) —C₁₋₄ alkyl, which is optionally substituted with from 1 to 3     substituents each of which is independently halogen, —OH, —CN,     —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a),     —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),     N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b),     —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b), or -   (3) —R^(k), -   (4) —CH(CH₃)—R^(k), -   (5) —(CH₂)₁₋₄—R^(k), wherein the —(CH₂)₁₋₄— moiety is optionally     substituted with one of —N(R^(a)R^(b)) or —N(R^(a))—(CH₂)₂—OH, -   (6) —(CH₂)₁₋₂—O—(CH₂)₀₋₁—R^(k), -   (7) —(CH₂)₁₋₂—S(O)_(n)—(CH₂)₀₋₁—R^(k), -   (8) —O—(CH₂)₁₋₂—OR^(k), -   (9) —O—(CH₂)₁₋₂—O—(CH₂)₁₋₂—R^(k), -   (10) —O—(CH₂)₁₋₂—S(O)_(n)R^(k), -   (11) —(CH₂)₁₋₂—N(R^(a))—R^(k), -   (12) —(CH₂)₁₋₂—N(R^(a))—(CH₂)₁₋₃—R^(k), -   (13) —(CH₂)₁₋₂—N(R^(a))—(CH₂)₁₋₃—OR^(k), -   (14) —(CH₂)₀₋₂—C(═O)—R^(k), -   (15) —C(═O)N(R^(a))—(CH₂)₁₋₂—R^(k), -   (16) —(CH₂)₀₋₂—C(═O)N(R^(a))—(CH₂)₀₋₂—R^(k), -   (17) —(CH₂)₁₋₂—N(R^(a))C(═O)—(CH₂)₀₋₁—R^(k), -   (18) —(CH₂)₁₋₂—N(R^(a))C(═O)—O—(CH₂)₀₋₁—R^(k), or -   (19) —C₁₋₄ alkyl which is:     -   (i) substituted with aryl or —O-aryl wherein the aryl is         optionally substituted with from 1 to 3 substituents each of         which is independently fluoro, chloro, —C₁₋₄ alkyl, —C₁₋₄         fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, methylenedioxy         attached to two adjacent carbon atoms, or phenyl;     -   (ii) substituted with —R^(k), —(CH₂)₁₋₃—R^(k),         —N(R^(a))—C(═O)—(CH₂)₀₋₃—R^(k), —N(R^(a))—(CH₂)₁₋₃—R^(k),         —O—(CH₂)₁₋₂—R^(k), or —N(R^(a))—C(═O)—(CH₂)₀₋₂—R^(k); and     -   (iii) optionally substituted with from 1 to 4 substituents each         of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl,         —O—C₁₋₄ haloalkyl, or —N(R^(a)R^(b)).

Another embodiment of the present invention is a compound of Formula (I), wherein

-   R^(k) is C₃₋₈ cycloalkyl; aryl selected from phenyl and naphthyl; a     bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a     5- or 6-membered saturated heterocyclic ring containing from 1 to 4     heteroatoms independently selected from N, O and S; a 5- or     6-membered heteroaromatic ring containing from 1 to 4 heteroatoms     independently selected from N, O and S; or a bicyclic heterocycle     which is a benzene ring fused to a 5- or 6-membered saturated or     unsaturated heterocyclic ring containing from 1 to 3 heteroatoms     independently selected from N, O and S;

wherein the cyloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently

-   -   (1) halogen,     -   (2) —OH,     -   (3) —CN,     -   (4) —C₁₋₄ haloalkyl,     -   (5) —C₁₋₄ alkyl, which is optionally substituted with from 1 to         3 substituents each of which is independently —OH, —CN, —O—C₁₋₄         alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a),         —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (6) —O—C₁₋₄ haloalkyl     -   (7) —O—C₁₋₄ alkyl, which is optionally substituted with from 1         to 3 substituents each of which is independently —OH, —CN,         —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)),         —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (8) —NO₂,     -   (9) oxo,     -   (10) —C(═O)R^(a),     -   (11) —CO₂R^(a),     -   (12) —SR^(a),     -   (13) —S(═O)R^(a),     -   (14) —N(R^(a)R^(b)),     -   (15) —C(═O)N(R^(a)R^(b)),     -   (16) —C(═O)—C₁₋₆ alkyl-N(R^(a)R^(b)),     -   (17) —N(R^(a))C(═O)R^(b),     -   (18) —SO₂R^(a),     -   (18) —SO₂N(R^(a)R^(b)),     -   (19) —N(R^(a))SO₂R^(b),     -   (20) —R^(m),     -   (21) —CH(CH₃)—R^(m),     -   (22) —(CH₂)₁₋₄—R^(m),     -   (23) —(CH₂)₀₋₂—N(R^(a))—(CH₂)₀₋₂—R^(m),     -   (24) —(CH₂)₀₋₂—O—(CH₂)₀₋₂—R^(m),     -   (25) —(CH₂)₀₋₂—S—(CH₂)₀₋₂—R^(m),     -   (26) —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m),     -   (27) —C(═O)—O—(CH₂)₀₋₂—R^(m),     -   (28) —C(═O)N(R^(a))—R^(m),     -   (29) —N(R^(a))C(═O)—R^(m),     -   (30) —N(R^(a))C(═O)—(CH₂)₀₋₃—R^(m), wherein the —(CH₂)₁₋₃—         moiety is optionally substituted with one of —N(R^(a)R^(b)),         —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b),         —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (31) —N(R^(a))—C(═O)—N(R^(b))—(CH₂)₁₋₂—R^(m),     -   (32) —N(R^(a))—C(═O)—O—(CH₂)₁₋₂—R^(m), or     -   (33) —N(R^(a))—C(═O)—N(R^(b))SO₂—R^(m);

-   and all other variables are as originally defined above;

-   or a pharmaceutically acceptable salt thereof.

In an aspect of this embodiment, R^(k) (i.e., the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle) is optionally substituted with from 1 to 4 substituents each of which is independently one of the substituents (1) to (19), and is optionally mono-substituted with one of the substituents (20) to (33). In a feature of this aspect, R^(k) is optionally substituted with from 1 to 4 substituents each of which is independently one of the substituents (1) to (19), and is mono-substituted with one of the substituents (20) to (33).

In another aspect of this embodiment, each R^(m) is independently C₅₋₇ cycloalkyl; aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered, saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S; wherein

-   -   the cycloalkyl or the aryl is optionally substituted with from 1         to 4 substituents each of which is independently halogen, —C₁₋₄         alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl,         —N(R^(a)R^(b)), phenyl, or —(CH₂)₁₋₂-phenyl;     -   the saturated heterocyclic ring is optionally substituted with         from 1 to 4 substituents each of which is independently C₁₋₄         alkyl optionally substituted with —O—C₁₋₄ alkyl, —C₁₋₄         haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl,         —(CH₂)₁₋₂-phenyl, —C(═O)phenyl, —CO₂-phenyl,         —CO₂—(CH₂)₁₋₂-phenyl, a 5- or 6-membered saturated heterocyclic         ring containing from 1 to 4 heteroatoms independently selected         from N, O and S, or a 5- or 6-membered heteroaromatic ring         containing from 1 to 4 heteroatoms independently selected from         N, O and S; and     -   the heteroaromatic ring or the bicyclic heterocycle is         optionally substituted with from 1 to 4 substituents each of         which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl, or         —(CH₂)₁₋₂-phenyl.

Another embodiment of the present invention is a compound of Formula (I), wherein R^(k) is cycloalkyl selected from cyclopropyl, cyclopentyl and cyclohexyl; aryl selected from phenyl and naphthyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyranyl, tetrahydrofuranyl, imidazolidinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isooxazolidinyl, and pyrazolidinyl; a 5- or 6-membered heteroaromatic ring selected from thienyl, pyridyl, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxopiperidinyl, oxazolyl, isooxazolyl, oxadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl; or a bicyclic heterocycle selected from indolyl, indolinyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, 1,4-dioxa-8-azaspiro[4.5]dec-8-yl, azabicyclo[2.2.1]hept-1-yl, azabicyclo[2.1.1]hex-1-yl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo-1,4-dioxinyl, and benzo-1,3-dioxolyl;

-   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

In an aspect of this embodiment, R^(k) is as just defined except that it excludes cyclopropyl, pyranyl, oxopiperidinyl, 1,4-dioxa-8-azaspiro[4.5]decyl, azabicyclo[2.2.1]heptyl, and azabicyclo[2.1.1]hexyl.

In another aspect of this embodiment, the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently

-   -   (1) fluoro,     -   (2) chloro,     -   (3) bromo,     -   (4) —CF₃,     -   (5) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2         substituents each of which is independently —OH, —CN, —O—C₁₋₄         alkyl, —OCF₃, —N(R^(a)R^(b)), —C(═O)N(R^(a)R^(b)), or         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)),     -   (6) —OCF₃,     -   (7) —O—C₁₋₄ alkyl     -   (8) —NO₂,     -   (9) oxo,     -   (10) —C(═O)R^(a),     -   (11) —CO₂R^(a),     -   (12) —SR^(a),     -   (13) —S(═O)R^(a),     -   (14) —N(R^(a)R^(b)),     -   (15) —C(═O)N(R^(a)R^(b)),     -   (16) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)),     -   (17) —N(R^(a))C(═O)R^(b),     -   (18) —SO₂R^(a),     -   (19) —R^(m),     -   (20) —CH(CH₃)—R^(m),     -   (21) —CH₂—R^(m),     -   (22) —(CH₂)₀₋₂—N(R^(a))—(CH₂)₀₋₂—R^(m),     -   (23) —O—(CH₂)₁₋₂—R^(m),     -   (24) —(CH₂)₀₋₁—S—(CH₂)₀₋₂—R^(m),     -   (25) —(CH₂)₀₋₁—C(═O)—(CH₂)₀₋₂—R^(m),     -   (26) —(CH₂)₀₋₁—C(═O)—O—(CH₂)₀₋₂—R^(m),     -   (27) —C(═O)N(R^(a))—R^(m),     -   (28) —N(R^(a))C(═O)—R^(m),     -   (29) —N(R^(a))C(═O)—(CH₂)₁₋₂—R^(m), wherein the —(CH₂)₁₋₂—         moiety is optionally substituted with —N(R^(a)R^(b)),     -   (30) —N(R^(a))—C(═O)—N(R^(b))—(CH₂)₁₋₂—R^(m),     -   (31) —N(R^(a))—C(═O)—O—(CH₂)₁₋₂—R^(m),     -   (32) —N(R^(a))—C(═O)—N(R^(b))SO₂—R^(m), or     -   (33) —OH.

In another aspect of this embodiment, the substituents are selected from substituents (1) to (32) just defined.

In another aspect of this aspect, the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently one of the substituents (1) to (18) as just defined in the preceding aspect, and is optionally mono-substituted with one of the substituents (19) to (32) as just defined in the preceding aspect.

In still another aspect of this embodiment, each R^(m) is independently aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, thiazolidinyl, and morpholinyl; or a 5- or 6-membered heteroaromatic ring selected from thienyl, pyridyl, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl; wherein

-   -   the aryl is optionally substituted with from 1 to 3 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —CF₃,         —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b));     -   the saturated heterocyclic ring is optionally substituted with 1         or 2 substituents each of which is independently —C₁₋₄ alkyl,         —CF₃, —O—C₁₋₄ alkyl, —OCF₃, oxo, phenyl, —(CH₂)₁₋₂-phenyl,         —C(═O)-phenyl, —CO₂-phenyl, or —CO₂—CH₂-phenyl; and     -   the heteroaromatic ring is optionally substituted with 1 or 2         substituents each of which is independently —C₁₋₄ alkyl, —CF₃,         —O—C₁₋₄ alkyl, —OCF₃, oxo, phenyl, or —(CH₂)₁₋₂-phenyl.

In an aspect of this embodiment, the 5- or 6-membered saturated heterocyclic ring is selected from pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl.

Another embodiment of the present invention is a compound of Formula (I), wherein R² is —H or —C₁₋₆ alkyl which is optionally substituted with one of:

-   -   (1) —N(R^(a)R^(b)),     -   (2) phenyl which is optionally substituted with from 1 to 4         substituents each of which is independently halogen, —C₁₋₄         alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or         —C₀₋₆ alkyl-N(R^(a)R^(b)), or         (3) a 5- or 6-membered saturated monocyclic heterocycle which         contains from 1 to 4 heteroatoms independently selected from N,         O and S; wherein the heterocycle is optionally substituted with         from 1 to 4 substituents each of which is independently —C₁₋₆         alky, —O—C₁₋₆ alkyl, oxo, or phenyl;         and all other variables are as originally defined above;         or a pharmaceutically acceptable salt thereof.

In an aspect of the preceding embodiment, R² is

(1) —H,

(2) —C₁₋₄ alkyl,

(3) —(CH₂)₁₋₃—N(R^(a)R^(b)),

(4) —(CH₂)₁₋₃-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, or —(CH₂)₁₋₃—N(R^(a)R^(b)); or

(5) —(CH₂)₁₋₃R^(t), wherein R^(t) is a 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S.

Other embodiments of the present invention include a compound wherein R² is —H or methyl; or R² is —H; and all other variables are as originally defined above; or a pharmaceutically acceptable salt thereof.

Another embodiment of the present invention is a compound of Formula (I), wherein R³ is —H or —C₁₋₄ alkyl;

-   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

In an aspect of this embodiment, R³ is —H or methyl. In another aspect of this embodiment, R³ is —H.

Another embodiment of the present invention is a compound of Formula (I), wherein R⁴ is

-   -   (1) C₁₋₄ alkyl,     -   (2) C₁₋₄ alkyl substituted with from 1 to 3 substituents each of         which is independently —OH, O—C₁₋₄ alkyl, or —O—C₁₋₄ haloalkyl,     -   (3) C₁₋₄ alkyl which is substituted with an aryl or with two         aryls which are the same or different, and is optionally         substituted with —OH,     -   (4) C₁₋₄ alkyl substituted with one of:         -   (i) C₅₋₇ cycloalkyl,         -   (ii) a fused bicyclic carbocycle consisting of a benzene             ring fused to a C₅₋₇ cycloalkyl,         -   (iii) a 5- or 6-membered saturated heterocyclic ring             containing from 1 to 4 heteroatoms independently selected             from N, O and S,         -   (iv) a 5- or 6-membered heteroaromatic ring containing from             1 to 4 heteroatoms independently selected from N, O and S,             or         -   (v) a 9- or 10-membered fused bicyclic heterocycle             containing from 1 to 4 heteroatoms independently selected             from N, O and S, wherein at least one of the rings is             aromatic;     -   (5) C₂₋₄ alkynyl optionally substituted with aryl,     -   (6) C₃₋₇ cycloalkyl optionally substituted with aryl,     -   (7) aryl,     -   (8) a fused bicyclic carbocycle consisting of a benzene ring         fused to a C₅₋₇ cycloalkyl,     -   (9) a 5- or 6-membered saturated heterocyclic ring containing         from 1 to 4 heteroatoms independently selected from N, O and S,     -   (10) a 5- or 6-membered heteroaromatic ring containing from 1 to         4 heteroatoms independently selected from N, O and S, or     -   (11) a 9- or 10-membered fused bicyclic heterocycle containing         from 1 to 4 heteroatoms independently selected from N, O and S,         wherein at least one of the rings is aromatic;     -   wherein         -   each aryl in (3) or the aryl in (5), (6) or (7) or the fused             carbocycle in (4)(ii) or (8) is optionally substituted with             from 1 to 4 substituents each of which is independently             halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄ alkyl-OR^(a), —C₁₋₄             haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —CN, —NO₂,             —N(R^(a)R^(b)), —C₁₋₄ alkyl-N(R^(a)R^(b)),             —C(═O)N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —C₁₋₄             alkyl-CO₂R^(a), —OCO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a),             —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))C(═O)R^(b),             —N(R^(a))CO₂R^(b), —C₁₋₄ alkyl-N(R^(a))CO₂R^(b), phenyl,             —C₁₋₄ alkyl-phenyl, —O—phenyl, or —(CH₂)₀₋₂-het wherein het             is a 5- or 6-membered heteroaromatic ring containing from 1             to 4 heteroatoms independently selected from N, O and S, and             het is optionally fused with a benzene ring, and is             optionally substituted with 1 or 2 substituents each of             which is independently —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄             alkyl, —O—C₁₋₄ haloalkyl, or —CO₂R^(a);         -   the saturated heterocyclic ring in (4)(iii) or (9) is             optionally substituted with from 1 to 4 substituents each of             which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄             haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl, or             a 5- or 6-membered heteroaromatic ring containing from 1 to             4 heteroatoms independently selected from N, O and S; and             the heteroaromatic ring in (4)(iv) or (10) or the fused             bicyclic heterocycle in (4)(v) or (11) is optionally             substituted with from 1 to 4 substituents each of which is             independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄             alkyl, —O—C₁₋₄ haloalkyl, oxo, or phenyl;             and all other variables are as originally defined above;             or a pharmaceutically acceptable salt thereof.

Another embodiment of the present invention is a compound of Formula (I), wherein R⁴ is:

-   (1) C₁₋₃ alkyl substituted with 1 or 2 phenyls, and is optionally     substituted with an —OH, -   (2) C₁₋₄ alkyl substituted with one of:     -   (i) cyclohexyl,     -   (ii) naphthyl,     -   (iii) a fused bicyclic carbocycle selected from     -   (iv) a saturated heterocyclic ring containing from zero to 1         oxygen atoms and from 1 to 3 nitrogen atoms,     -   (v) a 5- or 6-membered heteroaromatic ring containing from zero         to 1 heteroatoms selected from O and S and from 1 to 3 nitrogen         atoms, or     -   (vi) a fused bicyclic heterocycle selected from -   (3) wherein R^(u) is H or phenyl, -   (4) C₃₋₆ cycloalkyl optionally substituted with phenyl, -   (5) phenyl or naphthyl, -   (6) a fused bicyclic carbocycle selected from -   (7) a saturated heterocyclic ring containing from zero to 1 oxygen     atoms and from 1 to 3 nitrogen atoms, -   (8) a 5- or 6-membered heteroaromatic ring containing from zero to 1     heteroatoms selected from O and S and from 1 to 3 nitrogen atoms, or -   (9) a fused bicyclic heterocycle selected from     -   -   wherein Z¹ is —H or —OH;         -   each phenyl in (1) or the phenyl in (3) or (4) or (5) or the             naphthyl in (2)(ii) or (5) is optionally substituted with             from 1 to 3 substituents each of which is independently             fluoro, bromo, chloro, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄             alkyl, —OCF₃, —CN, —NO₂, —(CH₂)₁₋₂—N(R^(a)R^(b)),             —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a),             —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))CO₂R^(b);             and is additionally and optionally mono-substituted with             phenyl, —(CH₂)₁₋₂-phenyl, —O-phenyl, or —(CH₂)₀₋₂-het             wherein het is thiadiazolyl or indolyl, and het is             optionally substituted with —C₁₋₄ alkyl, —CF₃, —O—C₁₋₆             alkyl, —OCF₃, or —CO₂R^(a);         -   the saturated heterocyclic ring in (2)(iv) or (7) is             optionally substituted with from 1 to 3 substituents each of             which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄             alkyl, —OCF₃, oxo; and is additionally and optionally             mono-substituted with phenyl or a heteroaromatic ring             selected from pyridyl, pyrimidinyl, and pyrazinyl; and         -   the heteroaromatic ring in (2)(v) or (8) is optionally             substituted with from 1 to 3 substituents each of which is             independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl,             —OCF₃, or oxo; and is additionally and optionally             mono-substituted with phenyl; -   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

Another embodiment of the present invention is a compound of Formula (I), wherein R⁴ is:

wherein

-   Q is     -   (1) ethynyl optionally substituted with aryl,     -   (2) C₅₋₇ cycloalkyl,     -   (3) aryl,     -   (4) a fused bicyclic carbocycle consisting of a benzene ring         fused to a C₅₋₇ cycloalkyl,     -   (5) a 5- or 6-membered saturated heterocyclic ring containing         from 1 to 4 heteroatoms independently selected from N, O and S,     -   (6) a 5- or 6-membered heteroaromatic ring containing from 1 to         4 heteroatoms independently selected from N, O and S, or     -   (7) a 9- or 10-membered fused bicyclic heterocycle containing         from 1 to 4 heteroatoms independently selected from N, O and S,         wherein at least one of the rings is aromatic;     -   wherein         -   aryl in (1) or (3) or the fused carbocycle in (4) is             optionally substituted with from 1 to 4 substituents each of             which is independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄             alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄             haloalkyl, —CN, —NO₂, —N(R^(a)R^(b)), —C₁₋₄             alkyl-N(R^(a)R^(b)), —C(═O)N(R^(a)R^(b)), —C(═O)R^(a),             —CO₂R^(a), —C₁₋₄ alkyl-CO₂R^(a), —OCO₂R^(a), —SR^(a),             —S(═O)R^(a), —SO₂R^(a), —N(R^(a))SO₂R^(b),             —SO₂N(R^(a)R^(b)), —N(R^(a))C(═O)R^(b), —N(R^(a))CO₂R^(b),             —C₁₋₄ alkyl-N(R^(a))CO₂R^(b), phenyl, —C₁₋₄ alkyl-phenyl,             —O-phenyl, or —(CH₂)₀₋₂-het wherein het is a 5- or             6-membered heteroaromatic ring containing from 1 to 4             heteroatoms independently selected from N, O and S, and het             is optionally fused with a benzene ring, and is optionally             substituted with —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄             alkyl, —O—C₁₋₄ haloalkyl, or —CO₂R^(a);         -   the saturated heterocyclic ring in (5) is optionally             substituted with from 1 to 4 substituents each of which is             independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄             alkyl; —O—C₁₋₄ haloalkyl, oxo, phenyl, or a 5- or 6-membered             heteroaromatic ring containing from 1 to 4 heteroatoms             independently selected from N, O and S; and         -   the heteroaromatic ring in (6) or the fused bicyclic             heterocycle in (7) is optionally substituted with from 1 to             4 substituents each of which is independently halogen, —C₁₋₄             alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl,             oxo, or phenyl; -   R⁵ is H, methyl, or CH₂OH, with the proviso that when R⁵ is CH₂OH,     then Q is aryl; and -   p is an integer equal to zero, 1 or 2; -   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

In an aspect of the preceding embodiment, Q is

-   (1) —C≡C—R^(u) wherein R^(u) is H or phenyl, -   (2) phenyl or naphthyl, -   (3) cyclopentyl or cyclohexyl, -   (4) a fused bicyclic carbocycle selected from the group consisting     of indanyl, tetrahydronaphthalenyl, and benzocycloheptyl, -   (5) a saturated heterocyclic ring selected from the group consisting     of tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, piperidinyl,     piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl,     isothiazolidinyl, oxazolidinyl, isooxazolidinyl, and pyrazolidinyl, -   (6) a heteroaromatic ring selected from the group consisting of     thienyl, pyridyl, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl,     isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, pyrazinyl,     pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl, or -   (7) a fused bicyclic heterocycle selected from the group consisting     of benzothiophenyl, indolyl, pyridoimidazolyl, indazolyl,     2,3-dihydrobenzo-1,4-dioxinyl, dihydrobenzofuranyl,     benzo-1,3-dioxolyl, quinolinyl, and isoquinolinyl;     wherein     -   the phenyl in (1) or the phenyl or naphthyl in (2) is optionally         substituted with from 1 to 4 substituents each of which is         independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —CN, —NO₂, —C₁₋₄         alkyl-N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —C₁₋₄         alkyl-CO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —C₁₋₄         alkyl-N(R^(a))CO₂R^(b), phenyl, —(CH₂)₁₋₂-phenyl, —O-phenyl, or         —(CH₂)₀₋₂-het wherein het is pyrrolyl, pyrazolyl, imidazolyl,         triazolyl, thiazolyl, oxazolyl, isothiazolyl, isooxazolyl,         pyridyl, pyrazinyl, thiadiazolyl or indolyl, and het is         optionally substituted with —C₁₋₄ alkyl, —CF₃, —O—C₁₋₆ alkyl,         —OCF₃, oxo, or —CO₂R^(a);     -   the fused carbocycle in (4) is optionally substituted with from         1 to 4 substituents each of which is independently halogen, —OH,         —C₁₋₄ alkyl, —C₁₋₄haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl,         —C₁₋₄ alkyl-N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —SR^(a),         —S(═O)R^(a), —SO₂R^(a), —N(R^(a))CO₂R^(b), phenyl,         —(CH₂)₁₋₂-phenyl, or —O-phenyl;     -   the saturated heterocyclic ring in (5) is optionally substituted         with from 1 to 4 substituents each of which is independently         halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄         haloalkyl, oxo, phenyl, pyridyl, pyrazinyl, or pyrimidinyl; and     -   the heteroaromatic ring in (6) or the fused bicyclic heterocycle         in (7) is optionally substituted with from 1 to 4 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄         haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, or phenyl.

In another aspect of the preceding embodiment, Q is phenyl, which is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, —OH, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, —CN, —SR^(a), —(CH₂)₁₋₂—N(R^(a)R^(b)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —(CH₂)₀₋₂—CO₂R^(a)*, —(CH₂)₀₋₂—N(R^(a))CO₂R^(b)*, —NO₂, or ph

-   each R^(a) is independently H, methyl, or ethyl; -   each R^(b) is independently H, methyl, or ethyl; and -   each R^(a)* and R^(b)* is independently H or —C₁₋₄ alkyl.

In another aspect of the preceding embodiment, the phenyl substituents are independently selected from the group consisting of fluoro, bromo, chloro, —OH, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, —CN, —(CH₂)₁₋₂—N(R^(a)R^(b)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —(CH₂)₀₋₂—CO₂R^(a)*, —(CH₂)₀₋₂—N(R^(a))CO₂R^(b)*, —NO₂, and phenyl.

In still another aspect of the preceding embodiment, Q is phenyl which is optionally substituted with from 1 to 3 substituents, each of which is independently —F, —Br, —Cl, —OH, —C₁₋₄ alky, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, —CN, —SR^(a) or —SO₂R^(a). In still another aspect of the preceding embodiment, Q is phenyl which is optionally substituted with from 1 to 3 substituents, each of which is independently —F, —Br, —Cl, —OH, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alky, —O—C₁₋₄ fluoroalkyl, —CN, or —SO₂R^(a).

In still another aspect of the preceding embodiment, Q is p-fluorophenyl or 2,3-dimethoxyphenyl. In still another aspect of the preceding embodiment, Q is p-fluorophenyl.

In yet another aspect of the preceding embodiment, and also a feature of each of the preceding aspects thereof, R⁵ is H and p is zero.

A class of compounds of the present invention includes any compound of Formula (I), wherein

-   R¹ is —R^(k); -   R^(k) is a 5- or 6-membered heteroaromatic ring containing from 1 to     3 heteroatoms independently selected from N, O and S;

wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently

-   -   (1) halogen,     -   (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to         5 substituents each of which is independently halogen, —O—C₁₋₄         alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a),         —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (3) —NO₂,     -   (4) oxo,     -   (5) —C(═O)R^(a),     -   (6) —CO₂R^(a),     -   (7) —C(═O)N(R^(a)R^(b)),     -   (8) —C(═O)—C₁₋₄ alkyl-N(R^(a)R^(b)),     -   (9) —R^(m),     -   (10) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally         substituted with from 1 to 5 substituents each of which is         independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl,         —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a),         —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b),         —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (11) —C₀₋₄ alkyl-N(R^(a))—C₀₋₄ alkyl-R^(m),     -   (12) —C₀₋₄ alkyl-O—C₀₋₄ alkyl-R^(m),     -   (13) —C₀₋₄ alkyl-S—C₀₋₄ alkyl-R^(m),     -   (14) —C₀₋₄ alkyl-C(═O)—C₀₋₄ alkyl-R^(m),     -   (15) —C(═O)—O—C₀₋₄ alkyl-R^(m),     -   (16) —C(═O)N(R^(a))—C₀₋₄ alkyl-R^(m),     -   (17) —N(R^(a))C(═O)—R^(m),     -   (18) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is         optionally substituted with from 1 to 5 substituents each of         which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b),         —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or         —N(R^(a))—C(R^(b))═O,     -   (19) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₄ alkyl-R^(m),     -   (20) —N(R^(a))—C(═O)—O—C₀₋₄ alkyl-R^(m), or     -   (21) —N(R^(a))—C(═O)—N(R^(b))SO₂—C₀₋₄ alkyl-R^(m);

-   wherein each R^(m) is independently aryl selected from phenyl and     naphthyl or a 5- or 6-membered heteroaromatic ring containing from 1     to 3 heteroatoms independently selected from N, O and S; wherein     -   the aryl is optionally substituted with from 1 to 3 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —CF₃,         —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); and     -   the heteroaromatic ring is optionally substituted with 1 or 2         substituents each of which is independently —C₁₋₄ alkyl or oxo;         and

-   each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl;

-   and all other variables are as originally defined above;

-   or a pharmaeutically acceptable salt thereof.

A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I) exactly as defined in the class, except that in the definition of R^(k), R^(k) is optionally substituted with from 1 to 3 substituents each of which is independently one of the substituents (1) to (8), and is optionally mono-substituted with one of the substituents (9) to (21).

Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein R¹ is:

-   -   wherein X¹ is a single bond connecting the carbonyl carbon to         the carbon substituted with X², —O—, or —NH—;     -   X² is —H, —NH₂, or —N(H)CO₂R^(a);     -   Y¹ is —H, halo or —C₁₋₄ alkyl; and     -   r is an integer equal to zero, 1 or 2; and

-   R^(6b) is —H or —NO₂; and

-   R⁷ is —H or —C₁₋₄ alkyl;

-   and all other variables are as defined in the class;

-   or a pharmaceutically acceptable salt thereof.

In a feature of this sub-class, R^(6a) and R^(6b) are both —H; and R⁷ is —H or —CH₃.

Another class of compounds of the present invention includes any compound of Formula (I), wherein

-   R¹ is —R^(k); -   R^(k) is phenyl which is optionally substituted with from 1 to 3     substituents each of which is independently:     -   (1) halogen,     -   (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to         5 substituents each of which is independently halogen, —OH,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)),         —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (3) —NO₂,     -   (4) —C(═O)R^(a),     -   (5) —CO₂R^(a),     -   (6) —C(═O)N(R^(a)R^(b)),     -   (7) —C(═O)—C₁₋₄ alkyl-N(R^(a)R^(b)),     -   (8) —R^(m),     -   (9) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally         substituted with from 1 to 5 substituents each of which is         independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl,         —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a),         —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b),         —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (10) —C₀₋₄ alkyl-N(R^(a))—C₀₋₄ alkyl-R^(m),     -   (11) —C₀₋₄ alkyl-O—C₀₋₄ alkyl-R^(m),     -   (12) —C₀₋₄ alkyl-S—C₀₋₄ alkyl-R^(m),     -   (13) —C₀₋₄ alkyl-C(═O)—C₀₋₄ alkyl-R^(m),     -   (14) —C(═O)—O—C₀₋₄ alkyl-R^(m),     -   (15) —C(═O)N(R^(a))—C₀₋₄ alkyl-R^(m),     -   (16) —N(R^(a))C(═O)—R^(m),     -   (17) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is         optionally substituted with from 1 to 5 substituents each of         which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b),         —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or         —N(R^(a))—C(R^(b))═O,     -   (18) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₄ alkyl-R^(m),     -   (19) —N(R^(a))—C(═O)—O—C₀₋₄ alkyl-R^(m), or     -   (20) —N(R^(a))—C(═O)—N(R^(b))SO₂—C₀₋₄ alkyl-R^(m); -   wherein each R^(m) is independently aryl selected from phenyl and     naphthyl; a 5- or 6-membered saturated heterocyclic ring containing     from 1 to 3 heteroatoms independently selected from N, O and S; or a     5- or 6-membered heteroaromatic ring containing from 1 to 3     heteroatoms independently selected from N, O and S; wherein     -   the aryl is optionally substituted with from 1 to 3 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —CF₃,         —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b));     -   the saturated heterocyclic ring is optionally substituted with         from 1 to 3 substituents each of which is independently —C₁₋₄         alkyl or oxo, and is additionally optionally mono-substituted         with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, or         —CO₂—(CH₂)₁₋₂-phenyl; and     -   the heteroaromatic ring is optionally substituted with 1 or 2         substituents each of which is independently —C₁₋₄ alkyl or oxo; -   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I) exactly as defined in the class, except that in the definition of R^(k), R^(k) is optionally substituted with from 1 to 3 substituents each of which is independently one of the substituents (1) to (8), and is optionally mono-substituted with one of the substituents (9) to (20).

Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein R¹ is phenyl which is mono-substituted (e.g., para-substituted) with one of:

-   -   (1) fluoro, chloro, or bromo,     -   (2) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2         substituents each of which is independently —OH, —O—C₁₋₄ alkyl,         —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —N(R^(a)R^(b)), or         —C(═O)N(R^(a)R^(b)),     -   (3) —NO₂,     -   (4) —C₁₋₄ alkyl-R^(m),     -   (5) —O—(CH₂)₁₋₂—R^(m),     -   (6) —(CH₂)₀₋₂—S—(CH₂)₀₋₂—R^(m),     -   (7) —N(R^(a))C(═O)—R^(m),     -   (8) —N(R^(a))C(═O)—(CH₂)₁₋₂—R^(m), wherein the (CH₂)₁₋₂ moiety         is optionally mono-substituted with —N(R^(a)R^(b)) or         —N(R^(a))CO₂R^(b), or     -   (9) —N(R^(a))—C(═O)—N(R^(b))—(CH₂)₁₋₂—R^(m);         wherein R^(m) is aryl selected from phenyl and naphthyl; a 5- or         6-membered saturated heterocyclic ring containing 1 or 2         heteroatoms independently selected from N and O; or a 5- or         6-membered heteroaromatic ring containing from 1 or 2 nitrogens;         wherein     -   the aryl is optionally substituted with from 1 to 3 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —CF₃,         —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); and     -   the saturated heterocyclic ring is optionally substituted with         from 1 to 3 substituents each of which is independently —C₁₋₄         alkyl or oxo; and is additionally and optionally         mono-substituted with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl,         —CO₂-phenyl, or —CO₂—(CH₂)₁₋₂-phenyl; and     -   the heteroaromatic ring is optionally substituted with 1 or 2         substituents each of which is independently —C₁₋₄ alkyl or oxo;         and         each R^(a) and R^(b) is each independently —H or —C₁₋₄ alkyl;         and all other varaibles are as defined in the class;         or a pharmaceutically acceptable salt thereof.

Another class of compounds of the present invention includes any compound of Formula (I), wherein

-   R¹ is —R^(k); -   R^(k) is a 5- or 6-membered saturated heterocyclic ring containing     from 0 to 1 oxygen atoms and from 1 to 3 nitrogen atoms or a     bicyclic heterocycle which is a benzene ring fused to a 5- or     6-membered saturated heterocyclic ring containing from 0 to 1 oxygen     atoms and from 1 to 3 nitrogen atoms;

wherein the saturated heterocyclic ring or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently

-   -   (1) halogen,     -   (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to         5 substituents each of which is independently halogen, —O—C₁₋₄         alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a),         —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N (R^(a)R^(b)),         N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (3) —NO2,     -   (4) oxo,     -   (5) —C(═O)R^(a),     -   (6) —CO₂R^(a),     -   (7) —C(═O)N(R^(a)R^(b)),     -   (8) —C(═O)—C₁₋₄ alkyl-N(R^(a)R^(b)),     -   (9) —SR^(a),     -   (10) —S(═O)R^(a),     -   (11) —SO₂R^(a),     -   (12) —N(R^(a)R^(b)),     -   (13) —R^(m),     -   (14) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally         substituted with from 1 to 5 substituents each of which is         independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl,         —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a),         —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b),         —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O,     -   (15) —C₀₋₄ alkyl-N(R^(a))—C₀₋₄ alkyl-R^(m),     -   (16) —C₀₋₄ alkyl-O—C₀₋₄ alkyl-R^(m),     -   (17) —C₀₋₄ alkyl-S—C₀₋₄ alkyl-R^(m),     -   (18) —C₀₋₄ alkyl-C(═O)—C₀₋₄ alkyl-R^(m),     -   (19) —C(═O)—O—C₀₋₄ alkyl-R^(m),     -   (20) —C(═O)N(R^(a))C₀₋₄ alkyl-R^(m),     -   (21) —N(R^(a))C(═O)—R^(m),     -   (22) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is         optionally substituted with from 1 to 5 substituents each of         which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b),         —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or         —N(R^(a))—C(R^(b))═O,     -   (23) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₄ alkyl-R^(m),     -   (24) —N(R^(a))—C(═O)—O—C₀₋₄ alkyl-R^(m), or     -   (25) —N(R^(a))—C(═O)—N(R^(b))SO₂—C₀₋₄ alkyl-R^(m);

-   wherein each R^(m) is independently aryl selected from phenyl and     naphthyl; a 5- or 6-membered saturated heterocyclic ring containing     from 1 to 3 heteroatoms independently selected from N, O and S; a 5-     or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms     independently selected from N, O and S; or a 9- to 10-membered     bicyclic heterocycle which is saturated or unsaturated and contains     from 1 to 3 heteroatoms independently selected from N, O and S;     wherein     -   the aryl is optionally substituted with from 1 to 3 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —CF₃,         —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b));     -   the saturated heterocyclic ring is optionally substituted with         from 1 to 3 substituents each of which is independently —C₁₋₄         alkyl or oxo, and is additionally optionally mono-substituted         with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, or         —CO₂-(CH₂)₁₋₂-phenyl; and     -   the heteroaromatic ring or the bicyclic heterocycle is         optionally substituted with 1 or 2 substituents each of which is         independently —C₁₋₄ alkyl or oxo;

-   and all other variables are as originally defined above;

-   or a pharmaceutically acceptable salt thereof.

A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I) exactly as defined in the class, except that in the definition of R^(k), R^(k) is optionally substituted with from 1 to 3 substituents each of which is independently one of the substituents (1) to (12), and is optionally mono-substituted with one of the substituents (13) to (25).

Another subclass of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein

-   R⁸ is:     -   (1) —H,     -   (2) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2         substituents each of which is independently —OH, —O—C₁₋₄ alkyl,         —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —N(R^(a)R^(b)), or         —C(═O)N(R^(a)R^(b)),     -   (3) —C(═O)R^(a),     -   (4) —CO₂R^(a),     -   (5) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)),     -   (6) —SO₂R^(a),     -   (7) —(CH₂)₁₋₂—R^(m),     -   (8) —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m),     -   (9) —C(═O)—O—(CH₂)₀₋₂—R^(m), or     -   (10) —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m); -   R⁹ is —H, —C₁₋₄ alkyl, or oxo; -   R¹⁰ is —H, —OH, —C₁₋₄ alkyl, —O—C₁₋₄ alkyl, oxo, or     —O—(CH₂)₁₋₂—R^(m); -   R¹¹ is     -   (1) —H,     -   (2) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2         substituents each of which is independently —OH, —O—C₁₋₄ alkyl,         —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —N(R^(a)R^(b)), or         —C(═O)N(R^(a)R^(b)),     -   (3) —C(═O)R^(a),     -   (4) —CO₂R^(a),     -   (5) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b))     -   (6) —SO₂R^(a),     -   (7) —(CH₂)₁₋₂—R^(m),     -   (8) —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m),     -   (9) —C(═O)—O—(CH₂)₀₋₂—R^(m), or     -   (10) —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m); -   with the proviso that when one of R⁸ and R¹¹ is —(CH₂)₁₋₂—R^(m),     —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m), —C(═O)—O—(CH₂)₀₋₂—R^(m), or     —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m), then the other of R⁸ and R¹¹ is other     than —(CH₂)₁₋₂—R^(m), —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m),     —C(═O)—O—(CH₂)₀₋₂—R^(m), or —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m); -   R^(m) is aryl selected from phenyl and naphthyl; a 5- or 6-membered     saturated heterocyclic ring containing 1 or 2 heteroatoms     independently selected from N and O; a 5- or 6-membered     heteroaromatic ring containing from 1 to 3 heteroatoms selected from     N, O and S; or a bicyclic heterocycle which is a benzene ring fused     to a saturated or unsaturated heterocycle containing from 1 to 3     nitrogen atoms; wherein     -   the aryl is optionally substituted with from 1 to 3 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —CF₃,         —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); and     -   the saturated heterocyclic ring is optionally substituted with         from 1 to 3 substituents each of which is independently —C₁₋₄         alkyl or oxo; and is additionally and optionally         mono-substituted with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl,         —CO₂-phenyl, or —CO₂—(CH₂)₁₋₂-phenyl; and     -   the heteroaromatic ring or the bicyclic heterocycle is         optionally substituted with 1 or 2 substituents each of which is         independently —C₁₋₄ alkyl or oxo; and -   each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl; -   and all other variables are as defined in the class; -   or a pharmaceutically acceptable salt thereof.

Another embodiment of the present invention is a compound of Formula (I), wherein

-   R² is —H or methyl; -   R³ is —H; -   R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1     to 3 substituents each of which is independently —F, —Cl, —Br, —OH,     —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a);     and is additionally and optionally mono-substituted with     methylenedioxy attached to two adjacent ring carbon atoms, phenyl,     or —O-phenyl; -   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

In an aspect of this embodiment, R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alky, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl.

Aspects of this embodiment include a compound of Formula (I) in which R¹ is as defined in any of the preceding classes or sub-classes.

Another class of compounds of the present invention includes any compound of Formula (II):

-   wherein T is:     -   (1) —H,     -   (2) —OH,     -   (3) —C₁₋₄ haloalkyl,     -   (4) —C₁₋₃ alkyl, optionally substituted with —OH or —O—C₁₋₄         alkyl,     -   (5) —O—C₁₋₄ haloalkyl,     -   (6) —O—C₁₋₄ alkyl     -   (7) —N(R^(a)R^(b)),     -   (8) —N(R^(a))—(CH₂)₂—OH,     -   (9) —N(R^(a))—CO₂R^(b),     -   (10) —N(R^(a))—C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)),     -   (11) —R^(k),     -   (12) —(CH₂)₁₋₄—R^(k),     -   (13) —(CH₂)₀₋₂—O—(CH₂)₀₋₂—R^(k),     -   (14) —(CH₂)₀₋₂—N(R^(a))—(CH₂)₀₋₃—R^(k), or     -   (15) —(CH₂)₀₋₂—N(R^(a))—C(═O)—(CH₂)₀₋₂—R^(k); -   R^(k) is aryl selected from phenyl and naphthyl; a 5- or 6-membered     saturated heterocyclic ring containing from 1 to 3 heteroatoms     independently selected from N, O and S; a 5- or 6-membered     heteroaromatic ring containing from 1 to 3 heteroatoms independently     selected from N, O and S; or a bicyclic heterocycle which is a     benzene ring fused to a 5- or 6-membered saturated or unsaturated     heterocyclic ring containing from 1 to 3 heteroatoms independently     selected from N, O and S; wherein     -   the aryl is optionally substituted with from 1 to 4 substituents         each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄         alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl,         or —N(R^(a)R^(b)); and     -   the saturated heterocyclic ring is optionally substituted with         from 1 to 4 substituents each of which is independently —C₁₋₄         alkyl; —C₁₋₄ alkyl-OR^(a); —C₁₋₄ haloalkyl; —O—C₁₋₄ alkyl;         —O—C₁₋₄ haloalkyl; —C(═O)R^(a); oxo; ethylenedioxy spiro         substituted on a ring carbon; phenyl; —CH₂-phenyl; a 5- or         6-membered saturated heterocyclic ring containing from 1 to 4         heteroatoms independently selected from N, O and S;         —CH₂-saturated heterocycle which is a a 5- or 6-membered ring         containing from 1 to 4 heteroatoms independently selected from         N, O and S; or a 5- or 6-membered heteroaromatic ring containing         from 1 to 4 heteroatoms independently selected from N, O and S;     -   the heteroaromatic ring is optionally substituted with from 1 to         4 substituents each of which is independently —C₁₋₄ alkyl, —C₁₋₄         alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl,         or oxo; and     -   the bicyclic heterocycle is optionally substituted with from 1         to 4 substituents each of which is independently —C₁₋₄ alkyl or         oxo; -   R¹² is phenyl which is optionally substituted with from 1 to 3     substituents each of which is independently —F, —Cl, Br, —C₁₋₄     alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, methylenedioxy attached to two     adjacent carbon atoms, or phenyl; -   each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl; and -   s is an integer equal to zero, 1, 2, or 3; -   and all other variables are as originally defined above; -   or a pharmaceutically acceptable salt thereof.

A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (II) exactly as defined in the class, except that s is zero, 1 or 2; and with the proviso that when s is 1 or 2, T is —H.

Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (II), wherein

-   R³ is —H; and -   R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1     to 3 substituents each of which is independently —F, —Cl, —Br, —OH,     —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a);     and is additionally and optionally mono-substituted with     methylenedioxy attached to two adjacent ring carbon atoms, phenyl,     or —O-phenyl; -   and all other variables are as defined in the class; -   or a pharmaceutically acceptable salt thereof.

In a feature of this sub-class, R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl;

Still another class of compounds of the present invention includes any compound of Formula (III):

wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; each R^(a) is independently —H or —C₁₋₄ alkyl or a pharmaceutically acceptable salt thereof. In a subclass of this class, Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a).

Still another class of compounds of the present invention includes any compound of Formula (I), wherein

-   R¹ is     -   (1) —C₁₋₄ alkyl, which is optionally substituted with 1 to 3         substituents each of which is independently fluoro, chloro, —OH,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)),         —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         —N(R^(a))—C(═O)—(CH₂)₁₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(R^(b))═O,     -    —N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)),         or —N(R^(a))C(═O)OR^(b),     -   (2) —(CH₂)₁₋₃—R^(k),     -   (3) —(CH₂)₁₋₃—O—(CH₂)₀₋₂—R^(k),     -   (4) —(CH₂)₁₋₃—N—(CH₂)₀₋₂—R^(k),     -   (5) —(CH₂)₁₋₃—N(R^(a))C(═O)—(CH₂)₀₋₂—R^(k),     -   (6) —(CH₂)₁₋₃—N(R^(a))C(═O)—O—(CH₂)₀₋₂—R^(k),     -   (7) —(CH₂)₀₋₃—C(═O)N(R^(a))—(CH₂)₀₋₂—R^(k),     -   (8) —C(═O)—(CH₂)₀₋₂—R^(k),     -   (9) —C(CH₃)₂N(R^(a))C(═O)OCH₂R^(k),     -   (10) —C(CH₃)₂N(R^(a))CH₂R^(k),     -   (11) —C(CH₃)₂N(R^(a))C(═O)R^(k), or     -   (12) —C(R^(b))(N(R^(a))C(═O)R^(k))(CH₂OR^(c)), -   R^(k) is aryl selected from phenyl and naphthyl, with the proviso     that when R¹ is —(CH₂)₁₋₃—R^(k), then R^(k) is not phenyl; a     bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a     5- or 6-membered saturated heterocyclic ring containing from 1 to 4     heteroatoms independently selected from N, O and S; a 5- or     6-membered heteroaromatic ring containing from 1 to 4 heteroatoms     independently selected from N, O and S; or a bicyclic heterocycle     which is a benzene ring fused to a 5- or 6-membered saturated or     unsaturated heterocyclic ring containing from 1 to 3 heteroatoms     independently selected from N, O and S, with the proviso that the     bicyclic heterocycle is not benzo-1,3-dioxolyl;

wherein the aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently

-   -   (1) fluoro, chloro, or bromo,     -   (2) —OH,     -   (3) —CN,     -   (4) —CF₃,     -   (4) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2         substituents each of which is independently —OH, —O—C₁₋₄ alkyl,         —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), or —N(R^(a)R^(b)),     -   (5) —OCF₃,     -   (5) —O—C₁₋₄ alkyl,     -   (8) oxo,     -   (9) methylenedioxy attached to two adjacent ring carbon atoms,     -   (10) —C(═O)R^(a),     -   (11) —CO₂R^(a),     -   (12) —SR^(a),     -   (13) —S(═O)R^(a),     -   (14) —N(R^(a)R^(b)),     -   (15) —(CH₂)₀₋₂—C(═O)N(R^(a)R^(b)),     -   (16) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), or     -   (17) —SO₂R^(a);

-   and all other variables are as originally defined above;

-   or a pharmaceutically acceptable salt thereof.

In a sub-class of this class, R¹ is

-   -   (1) —C₁₋₄ alkyl, which is optionally substituted with 1 to 3         substituents each of which is independently fluoro, chloro, —OH,         —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a),         —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)),         —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)),         —N(R^(a))—C(═O)—(CH₂)₁₋₂N(R^(b)R^(c)), —SO₂R^(a),         —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(R^(b))═O, or     -   (2) —(CH₂)₁₋₃—R^(k),     -   (3) —(CH₂)₁₋₃—O—(CH₂)₀₋₂—R^(k),     -   (4) —(CH₂)₁₋₃—N—(CH₂)₀₋₂—R^(k),     -   (5) —(CH₂)₁₋₃—N(R^(a))C(═O)—(CH₂)₀₋₂—R^(k),     -   (6) —(CH₂)₁₋₃—N(R^(a))C(═O)—O—(CH₂)₀₋₂—R^(k),     -   (7) —(CH₂)₀₋₃—C(═O)N(R^(a))—(CH₂)₀₋₂—R^(k), or     -   (8) —C(═O)—(CH₂)₀₋₂—R^(k.)

A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein

-   R² is —H; and -   R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1     to 3 substituents each of which is independently —F, —Cl, —Br, —OH,     —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a);     and is additionally and optionally mono-substituted with     methylenedioxy attached to two adjacent ring carbon atoms, phenyl,     or —O-phenyl; -   each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl; -   R^(k) is aryl selected from phenyl and naphthyl, with the proviso     that when R¹ is —(CH₂)₁₋₃—R^(k), then R^(k) is not phenyl; a     bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a     5- or 6-membered saturated heterocyclic ring containing from 1 to 4     heteroatoms independently selected from N, O and S; a 5- or     6-membered heteroaromatic ring containing from 1 to 4 heteroatoms     independently selected from N, O and S; or a bicyclic heterocycle     which is a benzene ring fused to a 5- or 6-membered saturated or     unsaturated heterocyclic ring containing from 1 to 3 heteroatoms     independently selected from N, O and S, with the proviso that the     bicyclic heterocycle is not benzo-1,3-dioxolyl;

wherein the aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently

-   -   (1) fluoro, chloro, or bromo,     -   (2) —OH,     -   (3) —CN,     -   (4) —CF₃,     -   (4) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2         substituents each of which is independently —OH, —O—C₁₋₄ alkyl,         —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), or —N(R^(a)R^(b)),     -   (5) —OCF₃,     -   (5) —O—C₁₋₄ allyl,     -   (8) oxo,     -   (9) methylenedioxy attached to two adjacent ring carbon atoms,     -   (10) —C(═O)R^(a),     -   (11) —CO₂R^(a),     -   (12) —SR^(a),     -   (13) —S(═O)R^(a),     -   (14) —N(R^(a)R^(b)),     -   (15) —(CH₂)₀₋₂—C(═O)N(R^(a)R^(b)),     -   (16) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), or     -   (17) —SO₂R^(a);

-   and all other variables are as defined in the class;

-   or a pharmaceutically acceptable salt thereof.

In a feature of this sub-class, R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl;

Still another class of compounds of the present invention includes any compound of Formula (IV):

-   wherein Q is phenyl optionally substituted with from 1 to 3     substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄     alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a); and     is additionally and optionally mono-substituted with methylenedioxy     attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; -   each R^(a) is independently —H or —C₁₋₄ alkyl -   or a pharmaceutically acceptable salt thereof.

In a sub-class of this class, Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a).

Still another class of compounds of the present invention includes any compound of Formula (V):

wherein

-   R¹³ is —H or —C₁₋₆ alkyl; -   R¹⁴ is —H, —C₁₋₆ alkyl, —C(═O)—C₁₋₆ alkyl, —C(═O)—(CH₂)₀₋₂-J, or     —C(═O)—O—(CH₂)₀₋₂-J; wherein J is aryl selected from phenyl and     naphthyl; a 5- or 6-membered saturated heterocyclic ring containing     from 1 to 4 heteroatoms independently selected from N, O and S; or a     5- or 6-membered heteroaromatic ring containing from 1 to 4     heteroatoms independently selected from N, O and S; and     -   wherein the aryl is optionally substituted with from 1 to 3         substituents each of which is independently fluoro, chloro,         bromo, —CF₃, —C₁₋₄ alkyl, —OCF₃, or —O—C₁₋₄ alkyl; and     -   wherein the saturated heterocyclic ring or heteroaromatic ring         is optionally substituted with from 1 to 3 substituents each of         which is independently fluoro, chloro, bromo, —CF₃, —C₁₋₄ alkyl,         —OCF₃, —O—C₁₋₄ alkyl, or oxo; -   R¹⁵ and R¹⁶ are each independently —C₁₋₆ alkyl; or alternatively R¹⁵     and R¹⁶ together with the carbon atom to which they are both     attached form C₃₋₈ cycloalkyl; and -   Q is phenyl optionally substituted with from 1 to 3 substituents     each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃,     —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a); and is     additionally and optionally mono-substituted with methylenedioxy     attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; -   each R^(a) is independently —H or —C₁₋₄ alkyl -   or a pharmaceutically acceptable salt thereof.

In a sub-class of this class, Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl.

A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (V), wherein R¹⁵ and R¹⁶ are both methyl; or alternatively R¹⁵ and R¹⁶ together with the carbon atom to which they are both attached form cyclohexyl;

-   and all other variables are as defined in the class; -   or a pharmaceutically acceptable salt thereof.

It is to be understood that additional embodiments of the present invention include, but are not limited to, compounds of Formula I wherein each of two or three or more of R¹, R², R³, R⁴, R^(a), R^(b), R^(c), R^(d), R^(k) and R^(m) is independently defined in accordance with its definition in one of the embodiments or an aspect thereof as set forth above, or in accordance with its definition in one of the foregoing classes set forth above or a sub-class or feature thereof. Any and all possible combinations of these variables in Formula I are additional embodiments within the scope of the present invention.

An aspect of the present invention is a compound selected from the group consisting of

-   4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-1-(methylamino)ethyl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylmorpholin-3-yl)pyrimidine-4-carboxamide; -   2-[1-benzoyl-4-(N,N-dimethylglycyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-benzoyl-4-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methylpiperidin-2-yl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[4-methyl-1-(pyridin-2-ylcarbonyl)piperazin-2-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-4-(pyridin-2-ylcarbonyl)piperazin-2-yl]pyrimidine-4-carboxamide; -   2-(1-ethylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-isopropyl-1-methylpiperazin-2-yl)pyrimdine-4-carboxamide; -   2-[1-(acetylamino)cyclohexyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(morpholin-4-ylacetyl)piperidin-2-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(pyrrolidin-1-ylmethyl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methylpyrrolidin-2-yl)pyrimidine-4-carboxamide; -   2-[1-(N,N-dimethylglycyl)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[(pyridin-2-lcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; -   2-[1-(dimethylamino)-2-phenylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-{1-[(2,4-dimethyl-1,3-thiazol-5-yl)carbonyl]piperidin-2-yl}—N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[1-(3-chlorobenzoyl)-4-methylpiperazin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-4-(methylsulfonyl)piperazin-2-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-isopropyl-4-methylpiperazin-2-yl)pyrimdine-4-carboxamide; -   N-(3-bromo-4-fluorobenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[1-(dimethylamino)cyclohexyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-[(pyridin-2-ylcarbonyl)amino]cyclohexyl}pyrimidine-4-carboxamide; -   2-(4-benzyl-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(2,3-dimethoxybenzyl)-5,6-dihydroxy-2-[4-(1-piperidin-1-ylethyl)phenyl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(2-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl)pyrimidine-4-carboxamide; -   N-(2,3-dimethoxybenzyl)-2-[1-(N,N-dimethylglycyl)piperidin-2-yl]-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[1-(anilinocarbonyl)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[(2S,4R)-1-benzoyl-4-(benzyloxy)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)piperidin-2-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-(morpholin-4-ylacetyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-phenyl-1-[(pyridin-2-lcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; -   2-(1-benzoylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-benzylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-benzoylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-isonicotinoylpiperidin-2-yl)pyrimidine-4-carboxamide; -   N-(2,3-dimethoxybenzyl)-5,6dihydroxy-2-(1-isonicotinoylpiperidin-2-yl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(methylsulfonyl)piperidin-2-yl]pyrimidine-4-carboxamide; -   2-(1-benzoyl-1,2,3,4-tetrahydroquinolin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-{1-[(N,N-dimethylglycyl)amino]-2-phenylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(2,3-dimethoxybenzyl)-5,6-dihydroxy-2-[4-(piperidin-1-ylmethyl)phenyl]pyrimidine-4-carboxamide; -   2-{4-[(diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-4-ylmethyl)piperidin-2-yl]pyrimidine-4-carboxamide; -   2-(1-benzoylpyrrolidin-2-yl)-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   tert-butyl     2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)morpholine-4-carboxylate; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-3-ylcarbonyl)piperidin-2-yl]pyrimidine-4-carboxamide; -   2-[2-N,N-dimethylglycyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide;

Another aspect of the present invention is a compound selected from the group consisting of

-   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methylpiperidin-2-yl)pyrimidine-4-carboxamide; -   2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylmorpholin-3-yl)pyrimidine-4-carboxamide; -   2-[(dimethylamino)(phenyl)methyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimiidine-4-carboxamide; -   2-{4-[(diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-benzyl-5,6-dihydroxy-2-(3-phenylpropyl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-yl]pyrimidine-4-carboxamide; -   and pharmaceutically acceptable salts thereof.

Another aspect of the present invention is a compound selected from the group consisting of

-   benzyl     1-[4-({[4-fluoro-2-(methylsulfonyl)benzyl]amino}carbonyl)-5,6-dihydroxypyrimidin-2-yl]-1-methylethylcarbamate; -   2-(1-amino-1-methylethyl)-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-benzoyl-2,3-dihydro-1H-indol-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(2-benzoyl-1,2,3,4-tetrahydroisoquinolin-3-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-amino-2-phenylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(4-benzylmorpholin-3-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-[(1-methyl-1H-imidazol-2-yl)carbonyl]piperidin-2-yl}pyrimidine-4-carboxamide; -   N-(2,3-dimethoxybenzyl)-5,6-dihydroxy-2-[4-(morpholin-4-ylmethyl)phenyl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(morpholin-4-ylmethyl)pyrimidine-4-carboxamide; -   N-(4-Fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-{4-[({[(2-chlorophenyl)sulfonyl]amino}carbonyl)amino]thien-3-yl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4     carboxamide; -   N⁴-(4-fluorobenzyl)-5,6-dihydroxy-N²-(pyridin-2-ylmethyl)pyrimidine-2,4-dicarboxamide; -   2-Benzyl-N-(4-fluorobenzyl)-5-hydroxy-6-(2-morpholin-1-ylethoxy)pyrimidine-4-carboxamide; -   and pharmaceutically acceptable salts thereof. -   N-(2-chlorobenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(2-chlorobenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(5-chloro-2-methylbenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[(pyrazin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; -   2-[1-(diethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimdine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-morpholin-4-ylethyl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-piperidin-1-ylethyl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-pyrrolidin-1-ylethyl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[methyl(pyridin-4-ylmethyl)amino]ethyl}pyrimidine-4-carboxamide; -   2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxy-N-[2-(methylthio)benzyl]pyrimidine-4-carboxamide; -   N¹,N¹-diethyl-N˜2˜-[1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-1-methylethyl]ethanediamide; -   2-[1-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-{[(1-methyl-1H-imidazol-2-yl)carbonyl]amino}ethyl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-1-(4-oxopiperidin-1-yl)ethyl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[methyl(pyridin-2-ylmethyl)amino]ethyl}pyrimidine-4-carboxamide; -   N-[1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-1-methylethyl]-4-methylmorpholine-2-carboxamide; -   2-{1-[acetyl(methyl)amino]-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[1-(acetylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-{1-[4-(dimethylamino)piperidin-1-yl]-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(2,3-dimethoxybenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]-N-(4fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(7-methyl-7-azabicyclo[2.2.1]hept-1-yl)pyrimidine-4-carboxamide; -   2-(7-acetyl-7-azabicyclo[2.2.1]hept-1-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(2-acetyl-2-azabicyclo[2.1.1]hex-1-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(2-methyl-2-azabicyclo[2.1.1]hex-1-yl)pyrimidine-4-carboxamide; -   tert-butyl     (2S,4R)-4-(benzyloxy)-2-(4-{[(4-fluorobenzyl)amino]carbonyl)-5,6-dihydroxypyrimidin-2-yl)piperidine-1-carboxylate; -   2-[(2S,4R)-4-(benzyloxy)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[(2S,4R)-4-(benzyloxy)-1-methylpiperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(2S,4R)-4-hydroxy-1-methylpiperidin-2-yl]pyrimidine     carboxamide; -   2-[1-acetyl-4-(benzyloxy)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-ethyl-4-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[4-methyl-1-(pyrazin-2-ylcarbonyl)piperazin-2-yl]pyrimidine-4-carboxamide; -   tert-butyl     3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)thiomorpholine-4-carboxylate; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-thiomorpholin-3-ylpyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylthiomorpholin-3-yl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[4-(pyridin-2-ylcarbonyl)thiomorpholin-3-yl]pyrimidine-4-carboxamide; -   2-(4-acetylthiomorpholin-3-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   tert-butyl     1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-2-methoxyethylcarbamate; -   2-[1-(dimethylamino)-2-methoxyethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[1-(acetylamino)-2-methoxyethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-amino-2-methoxyethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-[(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-2-[1-(formylamino)-2-methoxyethyl]-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-methoxy-1-(methylamino)ethyl]pyrimidine-4-carboxamide; -   2-{1-[acetyl(methyl)amino]-2-methoxyethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-[methyl(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(4R)-3-(pyridin-2-ylcarbonyl-1,3-thiazolidin-4-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(4R)-1,3-thiazolidin-4-yl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(4R)-3-methyl-1,3-thiazolidinyl]pyrimidine-4-carboxamide; -   2-(3-acetyl-1,3-thiazolidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(3-methyl-1,3-thiazolidin-2-yl)pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1,2,4-trimethylpiperazin-2-yl)pyrimidine-4-carboxamide; -   2-[2,4-dimethyl-1-(pyrazin-2-ylcarbonyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-acetyl-2,4-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   tert-butyl     1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-2-methoxy-1-methylethylcarbamate; -   2-(1-amino-2-methoxy-1-methylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[1-(acetylamino)-2-methoxy-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[1-(dimethylamino)-2-methoxy-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-methoxy-1-methyl-1-(methylamino)ethyl]pyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-methyl-1-[(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; -   2-(1,2-dimethylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-{1-[acetyl(methyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-methyl-1-[methyl(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; -   2-{1-[(cyclohexylmethyl)(methyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-{1-[(cyclohexylmethyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-{1-[(cyclohexylmethyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(4-acetyl-1,2-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-(1-acetyl-2-methylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-methyl-1-(pyrazin-2-ylcarbonyl)piperidin-2-yl]pyrimidine-4-carboxamide; -   N-(2,3-dimethoxybenzyl)-2-(1,2-dimethylpiperidin-2-yl)-5,6-dihydroxypyrimidine-4-carboxamide; -   N-(4-fluorobenzyl)-5,6-hydroxy-2-[2-methyl-1-(pyridin-2-ylcarbonyl)piperidin-2-yl]pyrimidine-4-carboxamide; -   2-{1-[(2,4-dimethyl-1,3-thiazol-5-yl)carbonyl]-2-methylpiperidin-2-yl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   2-[(2S)-1-acetyl-2-methylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; -   and pharmaceutically acceptable salts thereof.

Other embodiments of the present invention include the following:

(a) A pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.

(b) A pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula (I) and a pharmaceutically acceptable carrier.

(c) The pharmaceutical composition of (a) or (b), further comprising a therapeutically effective amount of an HIV infection/AIDS treatment agent selected from the group consisting of HIV/AIDS antiviral agents, immunomodulators, and anti-infective agents.

(d) The pharmaceutical composition of (c), wherein the HIV infection/AIDS treatment agent is an antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HIV reverse transcriptase inhibitors.

(e) A combination useful for inhibiting HIV integrase, for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound of Formula (I) and a therapeutically effective amount of an HIV infection/AIDS treatment agent selected from the group consisting of HIV/AIDS antiviral agents, immunomodulators, and anti-infective agents.

(f) The combination of (e), wherein the HIV infection/AIDS treatment agent is an antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.

(g) A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).

(h) A method of preventing or treating infection by HIV in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).

(i) The method of (h), wherein the compound of Formula (I) is administered in combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HIV reverse transcriptase inhibitors.

(j) A method of preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).

(k) The method of (j), wherein the compound is administered in combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HIV reverse transcriptase inhibitors

(l) A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).

(m) A method of preventing or treating infection by HIV in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).

(n) A method of preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).

The present invention also includes a compound of the present invention (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) inhibiting HIV protease, (b) preventing or treating infection by HIV, or (c) preventing, treating or delaying the onset of AIDS. In these uses, the compounds of the present invention can optionally be employed in combination with one or more HIV/AIDS treatment agents selected from HIV/AIDS antiviral agents, anti-infective agents, and immunomodulators.

Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt.

As used herein, the term “C₁₋₆ alkyl” (or “C₁-C₆ alkyl”) means linear or branched chain alkyl groups having from 1 to 6 carbon atoms and includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. “C₁₋₄ alkyl” means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.

The term “C₀” as employed in expressions such as “C₀₋₆ alkyl” means a direct covalent bond. For example, when R¹ in Compound I is —C₀₋₆ alkyl-O—C₀₋₆ alkyl-R^(k), then R¹ is —O—R^(k) when both alkyl groups are C₀ alkyl. Similarly, when an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond. For example, when R⁴ is

wherein p is an integer equal to zero, 1 or 2, then R⁴ has the following structure when p is zero:

The term “—C₁₋₆ alkyl-” refers to a C₁ to C₆ linear or branched alkyl group as just defined which is bivalent. It can alternatively be referred to as “C₁₋₆ alkylene” or “C₁₋₆ alkanediyl”. A class of alkylenes of particular interest with respect to the invention is —(CH₂)₁₋₆—, and subclasses of particular interest include —(CH₂)₁₋₄—, —(CH₂)₁₋₃—, —(CH₂)₁₋₂—, and —CH₂—.

The term “C₂₋₅ alkenyl” (or “C₂-C₅ alkenyl”) means linear or branched chain alkenyl groups having from 2 to 5 carbon atoms and includes all of the pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 1-propenyl, 2-propenyl, and ethenyl (or vinyl). Similar terms such as “C₂₋₃ alkenyl” have an analogous meaning.

The term “—C₂₋₅ alkenyl-” refers to a C₂ to C₅ linear or branched alkenyl group as just defined which is bivalent. It can alternatively be referred to as “C₂₋₅ alkenylene” or “C₂₋₅ alkenediyl”.

The term “C₂₋₅ alkynyl” (or “C₂-C₅ alkynyl”) means linear or branched chain alkynyl groups having from 2 to 5 carbon atoms and includes all of the pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-butynyl, 1-propynyl, 2-propynyl, and ethynyl (or acetylenyl). Similar terms such as “C₂₋₃ alkynyl” have an analogous meaning.

The term “—C₂₋₅ alkynyl-” refers to a C₂ to C₅ linear or branched alkenyl group as just defined which is bivalent. It can alternatively be referred to as “C₂₋₅ alkynylene” or “C₂₋₅ alkynediyl”.

The term “C₃₋₈ cycloalkyl” (or “C₃-C₈ cycloalkyl”) means a cyclic ring of an alkane having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl). The terms “C₃₋₇ cycloalkyl”, “C₃₋₆ cycloalkyl”, “C₅₋₇ cycloalkyl” and the like have analogous meanings.

The term “C₃₋₇ azacycloalkyl” (or “C₃-C₇ azacycloalkyl”) means a saturated cyclic ring consisting of one nitrogen and from three to seven carbon atoms (i.e., azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl).

The term “halogen” (or “halo”) refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).

The term “C₁₋₆ haloalkyl” (which may alternatively be referred to as “C₁-C₆ haloalkyl” or “halogenated C₁-C₆ alkyl”) means a C₁ to C₆ linear or branched alkyl group as defined above with one or more halogen substituents. The term “C₁₋₄ haloalkyl” has an analogous meaning. The term “C₁₋₆ fluoroalkyl” has an analogous meaning except that the halogen substituents are restricted to fluoro. Suitable fluoroalkyls include the series (CH₂)₀₋₄CF₃ (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).

The term “carbocycle” (and variations thereof such as “carbocyclic” or “carbocyclyl”) as used herein refers to (i) a C₃ to C₈ monocyclic, saturated or unsaturated ring, (ii) a C₇ to C₁₂ bicyclic ring system, or (iii) a C₁₁ to C₁₆ tricyclic ring system, wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated. The carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound. The fused bicyclic carbocycles are a subset of the carbocycles; i.e., the term “fused bicyclic carbocycle” generally refers to a C₇ to C₁₀ bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system. Fused tricyclic carbocycles have an analogous meaning. A subset of the fused bicyclic carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include the following:

The term “aryl” refers to aromatic mono- and poly-carbocyclic ring systems, wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, and biphenylenyl.

The term “heterocycle” (and variations thereof such as “heterocyclic” or “heterocyclyl”) broadly refers to (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring, (ii) a 7- to 12-membered bicyclic ring system, or (iii) an 11 to 16-membered tricyclic ring system; wherein each ring in (ii) or (iii) is independent of or fused to, or bridged with, or spiro to the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring, bicyclic ring system, or tricyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocylic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally be oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized. The heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure. When the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.

Saturated heterocyclics form a subset of the heterocycles; i.e., the term “saturated heterocyclic” generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated. The term “saturated heterocyclic ring” refers to a 4- to 8-membered saturated monocyclic ring which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl).

Heteroaromatics form another subset of the heterocycles; i.e., the term “heteroaromatic” (alternatively “heteroaryl”) generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system. The term “heteroaromatic ring” refers a 5- or 6-membered monocyclic aromatic ring which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples of heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.

Representative examples of bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, 2,3-dihydrobenzofuranyl, 7-azabicyclo[2.2.1]heptyl (e.g.,

), 1,4-dioxa-8-azaspiro[4.5]decyl (e.g.,

), azabicyclo[2.1.1]hexyl, (e.g.,

), 2,3-dihydrobenzo-1,4-dioxinyl (i.e.,

), and benzo-1,3-dioxolyl (i.e.,

). In certain contexts herein,

is alternatively referred to as phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms.

Representative examples of tricyclic heterocycles include phenothiazinyl, carbazolyl, beta-carbolinyl, tetrahydro-beta-carbolinyl, acridinyl, phenazinyl, and phenoxazinyl.

Unless expressly stated to the contrary, an “unsaturated” ring is a partially or fully unsaturated ring. For example, an “unsaturated monocyclic C₆ carbocycle” refers to cyclohexene, cyclohexadiene, and benzene.

Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heterocycle described as containing from “1 to 4 heteroatoms” means the heterocycle can contain 1, 2, 3 or 4 heteroatoms.

When any variable (e.g., R^(a), R^(b), R^(c), R^(k), etc.) occurs more than one time in any constituent or in Formula I or in any other formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

The term “substituted” (e.g., as in “aryl which is optionally substituted with one or more substituents . . . ”) includes mono- and poly-substitution by a named substituent to the extent such single and multiple substitution (including multiple substitution at the same site) is chemically allowed.

Substituted ring systems, which systems are themselves substituents bonded to a non-substituent atom, include, but are not limited to, moieties in which the atom bearing the ring substituent and the atom bonded to the non-substitutent atom are the same. For example, the substituent represented by

is a substituted cyclopropyl ring, wherein the cyclopropyl ring substituent is an amino group.

The compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as mixtures of stereoisomers or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.

The dihydroxypyrimidine compounds of the present invention (i.e., compounds of Formula I wherein R²=H) may also occur as tautomers thereof. Tautomers include, but are not limited to:

It is understood that the present invention includes all tautomers of the dihydroxy compounds embraced by Formula I, both singly and in mixtures.

The compounds of the present inventions are useful in the inhibition of HIV integrase, the prevention or treatment of infection by human immunodeficiency virus (HIV) and the prevention, treatment or the delay in the onset of consequent pathological conditions such as AIDS. Preventing AIDS, treating AIDS, delaying the onset of AIDS, or preventing or treating infection by HIV is defined as including, but not limited to, treatment of a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.

The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV integrase, e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these purposes.

Compounds representative of the present invention have been tested for inhibition in an assay for the strand transfer activity of integrase. The assay is conducted in accordance with Wolfe, A. L. et al., J. Virol. 1996, 70: 1424-1432, for recombinant integrase, except that: (i) the assay uses preassembled integrase strand transfer complexes; (ii) the strand transfer reaction is performed in the presence of inhibitor in 2.5 mM MgCl₂ using 0.5 to 5 nM of a 3′ FITC labeled target DNA substrate as described in WO 02/30930, the disclosure of which is hereby incorporated by reference, and (iii) strand transfer products are detected using an alkaline phosphatase conjugated anti-FITC antibody and a chemiluminescent alkaline phosphatase substrate. Representative compounds (e.g., the compounds set forth in Tables 1-25 below) tested in the integrase assay demonstrated IC₅₀'s of about 5 micromolar or less.

Further description on conducting the assay using preassembled complexes is found in Hazuda et al., J. Virol. 1997, 71: 7005-7011; Hazuda et al., Drug Design and Discovery 1997, 15: 17-24; and Hazuda et al., Science 2000, 287: 646-650.

Certain compounds representative of the present invention have also been tested in an assay for inhibition of acute HIV infection of T-lymphoid cells, conducted in accordance with Vacca, J. P. et al., Proc. Natl. Acad. Sci. USA 1994, 91: 4096. These compounds demonstrated IC₉₅'s of about 10 micromolar or less.

The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term “pharmaceutically acceptable salt” refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. When the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (—COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.

For the purpose of preventing or treating HIV infection or preventing, treating or delaying the onset of AIDS, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing a therapeutically effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.

The term “administration” and variants thereof (e.g., “administering” a compound) in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment. When a compound of the invention or a prodrug thereof is provided in combination with one or more other active agents (e.g., antiviral agents useful for treating HIV infection or AIDS), “administration” and its variants are each understood to include concurrent and sequential provision of the compound or prodrug and other agents.

As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combining the specified ingredients in the specified amounts.

By “pharmaceutically acceptable” is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.

The term “subject” (alternatively referred to herein as “patient”) as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

The term “therapeutically effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated. When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound.

The pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets or capsules, nasal sprays, sterile injectible preparations, for example, as sterile injectible aqueous or oleagenous suspensions or suppositories. These compositions can be prepared by methods and contain excipients which are well known in the art. Suitable methods and ingredients are described in Remington's Pharmaceutical Sciences, 18^(th) edition, edited by A. R. Gennaro, Mack Publishing Co., 1990, which is herein incorporated by reference in its entirety.

The compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight in divided doses. One preferred dosage range is 0.01 to 500 mg/kg body weight orally in divided doses. Another preferred dosage range is 0.1 to 100 mg/kg body weight orally in divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

As noted above, the present invention is also directed to use of the HIV integrase inhibitor compounds of the present invention with one or more agents useful in the treatment of HIV infection or AIDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more of the HIV/AIDS antivirals, imunomodulators, antiinfectives, or vaccines useful for treating HIV infection or AIDS. Suitable antiviral agents include those listed in the following Table: ANTIVIRALS Manufacturer (Tradename and/or Drug Name Location) Indication (Activity) abacavir Glaxo Welcome HIV infection, AIDS, ARC GW 1592 (ZIAGEN ®) (nRTI) 1592U89 abacavir + GlaxoSmithKline HIV infection, AIDS, ARC (nnRTI) lamivudine + (TRIZIVIR ®) zidovudine acemannan Carrington Labs ARC (Irving, TX) ACH 126443 Achillion Pharm. HIV infections, AIDS, ARC (nucleoside reverse transcriptase inhibitor) acyclovir Burroughs Wellcome HIV infection, AIDS, ARC, in combination with AZT AD-439 Tanox Biosystems HIV infection, AIDS, ARC AD-519 Tanox Biosystems HIV infection, AIDS, ARC adefovir dipivoxil Gilead HIV infection, AIDS, ARC GS 840 (RTI) AL-721 Ethigen ARC, PGL, HIV positive, (Los Angeles, CA) AIDS alpha interferon Glaxo Wellcome Kaposi's sarcoma, HIV, in combination w/Retrovir AMD3100 AnorMed HIV infection, AIDS, ARC (CXCR4 antagonist) amprenavir Glaxo Wellcome HIV infection, AIDS, 141 W94 (AGENERASE ®) ARC (PI) GW 141 VX478 (Vertex) ansamycin Adria Laboratories ARC LM 427 (Dublin, OH) Erbamont (Stamford, CT) antibody which neutralizes Advanced Biotherapy AIDS, ARC pH labile alpha aberrant Concepts (Rockville, Interferon MD) AR177 Aronex Pharm HIV infection, AIDS, ARC atazanavir (BMS 232632) Bristol-Myers-Squibb HIV infection, AIDS, ARC (ZRIVADA ®) (PI) beta-fluoro-ddA Nat'l Cancer Institute AIDS-associated diseases BMS-232623 Bristol-Myers Squibb/ HIV infection, AIDS, (CGP-73547) Novartis ARC (PI) BMS-234475 Bristol-Myers Squibb/ HIV infection, AIDS, (CGP-61755) Novartis ARC (PI) capravirine Pfizer HIV infection, AIDS, (AG-1549, S-1153) ARC (nnRTI) CI-1012 Warner-Lambert HIV-1 infection cidofovir Gilead Science CMV retinitis, herpes, papillomavirus curdlan sulfate AJI Pharma USA HIV infection cytomegalovirus immune MedImmune CMV retinitis globin cytovene Syntex sight threatening CMV ganciclovir peripheral CMV retinitis delavirdine Pharmacia-Upjohn HIV infection, AIDS, (RESCRIPTOR ®) ARC (nnRTI) dextran Sulfate Ueno Fine Chem. Ind. AIDS, ARC, HIV Ltd. (Osaka, Japan) positive asymptomatic ddC Hoffman-La Roche HIV infection, AIDS, ARC (zalcitabine, (HIVID ®) (nRTI) dideoxycytidine) ddI Bristol-Myers Squibb HIV infection, AIDS, ARC; Dideoxyinosine (VIDEX ®) combination with AZT/d4T (nRTI) DPC 681 & DPC 684 DuPont HIV infection, AIDS, ARC (PI) DPC 961 & DPC 083 DuPont HIV infection AIDS, ARC (nnRTRI) emvirine Triangle Pharmaceuticals HIV infection, AIDS, ARC (COACTINON ®) (non-nucleoside reverse transcriptase inhibitor) EL10 Elan Corp, PLC HIV infection (Gainesville, GA) efavirenz DuPont HIV infection, AIDS, (DMP 266) (SUSTIVA ®) ARC (nnRTI) Merck (STOCRIN ®) famciclovir Smith Kline herpes zoster, herpes simplex emtricitabine Triangle Pharmaceuticals HIV infection, AIDS, ARC FTC (COVIRACIL ®) (nRTI) Emory University emvirine Triangle Pharmaceuticals HIV infection, AIDS, ARC (COACTINON ®) (non-nucleoside reverse transcriptase inhibitor) HBY097 Hoechst Marion Roussel HIV infection, AIDS, ARC (nnRTI) hypericin VIMRx Pharm. HIV infection, AIDS, ARC recombinant human Triton Biosciences AIDS, Kaposi's sarcoma, interferon beta (Almeda, CA) ARC interferon alfa-n3 Interferon Sciences ARC, AIDS indinavir Merck (CRIXIVAN ®) HIV infection, AIDS, ARC, asymptomatic HIV positive, also in combination with AZT/ddI/ddC (PI) ISIS 2922 ISIS Pharmaceuticals CMV retinitis JE2147/AG1776 Agouron HIV infection, AIDS, ARC (PI) KNI-272 Nat'l Cancer Institute HIV-assoc. diseases lamivudine, 3TC Glaxo Wellcome HIV infection, AIDS, (EPIVIR ®) ARC; also with AZT (nRTI) lobucavir Bristol-Myers Squibb CMV infection lopinavir (ABT-378) Abbott HIV infection, AIDS, ARC (PI) lopinavir + ritonavir Abbott (KALETRA ®) HIV infection, AIDS, ARC (ABT-378/r) (PI) mozenavir AVID (Camden, NJ) HIV infection, AIDS, ARC (DMP-450) (PI) nelfinavir Agouron HIV infection, AIDS, (VIRACEPT ®) ARC (PI) nevirapine Boeheringer HIV infection, AIDS, Ingleheim ARC (nnRTI) (VIRAMUNE ®) novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH) pentafusaide Trimeris HIV infection, AIDS, ARC T-20 (fusion inhibitor) peptide T Peninsula Labs AIDS octapeptide (Belmont, CA) sequence PRO 542 Progenics HIV infection, AIDS, ARC (attachment inhibitor) PRO 140 Progenics HIV infection, AIDS, ARC (CCR5 co-receptor inhibitor) trisodium Astra Pharm. Products, CMV retinitis, HIV infection, phosphonoformate Inc other CMV infections PNU-140690 Pharmacia Upjohn HIV infection, AIDS, ARC (PI) probucol Vyrex HIV infection, AIDS RBC-CD4 Sheffield Med. Tech HIV infection, AIDS, (Houston TX) ARC ritonavir Abbott HIV infection, AIDS, (ABT-538) (RITONAVIR ®) ARC (PI) saquinavir Hoffmann-LaRoche HIV infection, AIDS, (FORTOVASE ®) ARC (PI) stavudine; d4T Bristol-Myers Squibb HIV infection, AIDS, ARC didehydrodeoxy- (ZERIT ®) (nRTI) thymidine T-1249 Trimeris HIV infection, AIDS, ARC (fusion inhibitor) TAK-779 Takeda HIV infection, AIDS, ARC (injectable CCR5 receptor antagonist) tenofovir Gilead (VIREAD ®) HIV infection, AIDS, ARC (nRTI) tipranavir (PNU-140690) Boehringer Ingelheim HIV infection, AIDS, ARC (PI) TMC-120 & TMC-125 Tibotec HIV infections, AIDS, ARC (nnRTI) TMC-126 Tibotec HIV infection, AIDS, ARC (PI) valaciclovir Glaxo Wellcome genital HSV & CMV infections virazole Viratek/ICN (Costa asymptomatic HIV positive, ribavirin Mesa, CA) LAS, ARC zidovudine; AZT Glaxo Wellcome HIV infection, AIDS, ARC, (RETROVIR ®) Kaposi's sarcoma in combination with other therapies (nRTI) PI = protease inhibitor nnRTI = non-nucleoside reverse transcriptase inhibitor nRTI = nucleoside reverse transcriptase inhibitor

A compound of the present invention can also be administered in combination with another HIV integrase inhibitor such as a compound described in WO 99/62513, WO 99/62520, or WO 99/62897. A compound of the present invention can also be administered in combination with a CCR5 receptor antagonist, such as a compound described in WO 99/04794, WO 99/09984, WO 99/38514, WO 00/59497, WO 00/59498, WO 00/59502, WO 00/59503, WO 00/76511, WO 00/76512, WO 00/76513, WO 00/76514, WO 00/76792, or WO 00/76793. The compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more HIV/AIDS antivirals, immunomodulators, antiinfectives, or vaccines useful for treating HIV infection or AIDS disclosed in the Table in WO 01/38332, which is herein incorporated by reference in its entirety.

It will be understood that the scope of combinations of the compounds of this invention with HIV/AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above-referenced Table in WO 01/38332, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS. The HIV/AIDS antivirals and other agents will typically be employed in these combinations in their conventional dosage ranges and regimens as reported in the art, including the dosages described in the Physicians' Desk Reference, 54^(th) edition, Medical Economics Company, 2000. The dosage ranges for a compound of the invention in these combinations are the same as those set forth above.

Abbreviations used in the instant specification, particularly the Schemes and Examples, include the following:

-   -   AIDS=acquired immunodeficiency syndrome     -   ARC=AIDS related complex     -   BOC or Boc=t-butyloxycarbonyl     -   Bn=benzyl     -   Bz=benzoyl     -   CBZ or Cbz=carbobenzoxy (alternatively, benzyloxycarbonyl)     -   DMAD=dimethylacetylenedicarboxylate     -   DMF=N,N-dimethylformamide     -   Et=ethyl     -   FIA-MS=flow injection analysis mass spectrometry     -   HIV=human immunodeficiency virus     -   BPLC=high performance liquid chromatography     -   Me=methyl     -   NMP=N-methyl pyrrolidinone     -   NMR=nuclear magnetic resonance     -   Ph=phenyl     -   TFA=trifluoroacetic acid     -   THF=tetrahydrofuran

The compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials and reagents. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above.

The compounds of the present invention can be prepared by coupling suitable alkyl 2-substituted-5,6 dihydroxypyrimidine-4-carboxylates (or the corresponding carboxylic acids or acid derivatives such as acid halides) with the appropriate amines, as represented by General Scheme below. In the scheme, P¹ and P² are H or protective groups, typically esters (e.g., benzoate or pivalate) that are normally removed under the conditions employed to convert the —COOR{circumflex over ( )} ester to the amide. The ester protective groups are typically used to purify the 2-substituted-5,6 dihydroxypyrimidine-4-carboxylates after their synthesis when the unprotected product cannot be crystallized from the reaction crude and/or for synthetic reasons.

Methods for coupling carboxylic acid derivatives with amines to form carboxamides are well known in the art. Suitable methods are described, for example, in Jerry March, Advanced Organic Chemistry, 3rd edition, John Wiley & Sons, 1985, pp. 370-376. Amines of formula 1-1 can be prepared using the methods described in Richard Larock, Comprehensive Organic Transformations, VCH Publishers Inc, 1989, pp 385-438, or routine variations thereof. Methyl-2-sustituted-5,6-dihydroxypyrimidine-4-carboxylate of formula 1-2 can be prepared using methods described in Culbertson et al., J Heterocycl. Chem. 1979, 16 (7): 1423-24. The procedures and schemes below illustrate and expand upon the chemistry portrayed in the General Scheme.

Scheme A depicts the synthesis of 2-substituted-5,6-dihydroxypyrimidine-4-carboxamide (2-3). The methyl-5,6-dihydroxypyrimidine-4-carboxylate 2-2 can be obtained by reacting the appropriate amidoxime 2-1 with dimethylacetylenedicarboxylate, followed by cyclization at high temperature in appropriate solvent. The methyl ester 2-2 can be reacted with the amine in solvents like DMF, methanol, ethanol, toluene, NMP, at the appropriate temperature to give the final compound 2-3. Amidoximes 2-1 can be prepared from the corresponding nitrites by chemistry described herein (see Example 5, Step 4 or Example 6, Step 1). Nitriles can be prepared from carboxylic acids by various procedures, including, for example, conversion to carboxamides by the procedure of Pozdnev, Tetrahedron Lett. 1989, 30: 5193), and dehydration by the procedure of Waldmann, Tetrahedron 1994, 50: 11865) (see Example 5, Step 3). Compound 2-2 can be recovered by precipitation and filtration from the cooled reaction mixture. Scheme A is exemplified in Example 1 below.

Part 1 of Scheme B depicts a general synthesis of compounds bearing a nucleophilic group (e.g., an amine) in the 2-substituent. After bromination of a —CH₂Br (or —CH₂Cl) group using standard chemistry, the bromo (or chloro) derivative 3-1 can be treated with a nucleophile (“Nu”; e.g., an amine, thiol, or alcoholate) and, without isolation of the nucleophile-substituted ester intermediate 3-2, then with the amine 1-1 to give the final product 3-3. Part 1 of Scheme B is exemplified in Example 2 below. Part 2 of Scheme B shows a variation of Part 1, wherein the site of nucleophilic substitution is —CHBr— (or —CHCl—). Scheme B, Part 2 is exemplified in Example 3 below.

Scheme C shows a method for preparing compounds of the present invention that contain an alkylated aliphatic amine in the substituent at the 2 position. Nitrogen alkylation is achieved via a reductive amination. There are two equivalent synthetic strategies within the scope of Scheme C: reductive alkylation on the pyrimidine methyl ester followed by synthesis of the carboxamide or, alternatively, synthesis of the carboxamide followed by reductive amination. A deprotection step can be employed as neeeded. Example 4 below illustrates the application of Scheme C for preparing a compound with an acyclic aliphatic amine in the 2-position, wherein the CBZ-protected pyrimidine derivative was converted to the corresponding benzylic amide. Example 5 below describes the preparation of a compound with a cyclic amne in the 2 position in which Scheme C was used in the final two steps. Example 6 below illustrates the application of Scheme C to the preparation of a compound with a pyrrolidine in the 2-position. Example 7 describes the alkylation of a compound with a piperazine in the 2-position.

Scheme D presents an alternative approach to the preparation of compounds bearing a cyclic aliphatic tertiary amine as 2-substituents of the pyrimidine core, wherein the alkylation of the secondary amine with an alkyl halide is followed by synthesis of the benzylic amide with concomitant deprotection of the benzoate ester. Scheme D is exemplified in Example 8 below.

Scheme E shows the preparation of compounds of the present invention of formula 6-2 by reaction of aldehydes or ketones 6-1 with suitable amines under reductive alkylation conditions. Scheme E is exemplified in Example 9 below.

Scheme F shows a procedure for preparing compounds of the present invention which are unsubstituted in the 2 position. The pyrimidine monocarboxylic acid 7-1 can be decarboxylated in acid solution to the 2-unsubstitued pyrimidine 7-2, which can be further elaborated to the amide 7-3. Scheme F is exemplifed in Example 10 below.

Synthesis of compounds of general formula 8-3 can be achieved as depicted in Scheme G. The synthetic strategy is based on the reaction of a pyrimidine bearing an aminoaromatic system in the 2 position (8-1) with an isocyanate in the presence of a base and the resulting urea 8-2 can then be converted into the final amide 8-3. Scheme G is exemplifed in Example 11 below.

The preparation of compounds that feature a carboxamide at the 2 position of the pyrimidine core can be achieved as shown in Scheme H. Reaction of 4-ethyl-2-methyl-5,6-dihydroxypyrimidine-2,4 dicarboxylate (9-1) with a suitable amine affords regioselectively the 4-carboxamide (9-2), which can subsequently be converted into the 2,4-dicarboxamide derivative (9-3) by further reaction with an amine. Scheme H is exemplifed in Example 12 below.

Compounds of the present invention with general formula 10-3 containing an acylated nitrogen or sulfonylated nitrogen in the substituent at the 2-position, can be prepared following Scheme I. Acylation or sulfonylation of the nitrogen in the 2-substituent of the pyrimidine core provides compound 10-2, which can be elaborated into the final amide 10-3. Scheme I is exemplified in Examples 13 and 14 below.

Compounds of the present invention bearing an alkoxy substituent on the 6 position of the pyrimidine core can be synthesized as shown in Scheme J. The synthetic pathway is based on the reaction of pyrimidine 11-1, suitably protected on the 5-hydroxyl group, with an alkylating agent (such as an halide or a sulphate). Intermediate 11-2 can be further elaborated into the amide 11-3 following the usual chemistry. Scheme J is exemplified in Example 15 below.

Compounds of the present invention with general formula 14-1 containing a tertiary amine at the 2-position of the pyrimidine core can be prepared according to general procedure describe in scheme K. The N,N dimethyl amine present at the two position of C-4 can be replace with another amine by mixing and heating the substrate and regent in appropriate solvent to afford the desired product 14-1. Scheme K is exemplified in Example 16 reported below.

In the processes for preparing compounds of the present invention set forth in the foregoing schemes and exemplified in the examples below, functional groups in various moieties and substituents may be sensitive or reactive under the reaction conditions employed and/or in the presence of the reagents employed. Such sensitivity/reactivity can interfere with the progress of the desired reaction to reduce the yield of the desired product, or possibly even preclude its formation. Accordingly, it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. Protection can be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973 and in T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups can be removed at a convenient subsequent stage using methods known in the art. For example, in preparing the compounds of the invention it is sometimes necessary to protect one or more amino groups (e.g., amino groups present in substituents at the 2-position of the pyrimidine ring) with, for example, a Boc or Cbz group; or to protect hydroxy (e.g., the 5,6-dihydroxy groups on the pyrimidine ring) with, for example, a benzoyl, benzyl, or pivaloyl group. The Boc group can be removed by acid treatment (e.g., TFA) either before or after formation of the final amide at C-4 of the pyrimidine nucleus. The Cbz and benzyl groups are typically removed by catalytic hydrogenation or under strong acid conditions, either prior to or following formation of the final amide. The benzoyl or pivaloyl group can be removed concurrently with the formation of the final amide. Examples 4 and 6 below illustrate the use of a Cbz protective group and of Boc and benzoyl protective groups in the preparation of compounds of the invention.

The following examples serve only to illustrate the invention and its practice. The examples are not to be construed as limitations on the scope or spirit of the invention.

EXAMPLE 1 N-(4-fluorobenzyl)-5,6-dihydroxy-2-thien-2-ylpyrimidine-4-carboxamide

Step 1: Methyl 5,6-dihydroxy-2-thien-2-ylpyrimidine-4-carboxylate (A-2).

N′-hydroxythiophene-2-carboximidamide (A-1) (amidoxine synthesis is exemplified below—see compounds C-8 and C-14)was suspended in chloroform and refluxed overnight in the presence of 1.0 eq. of dimethylacetylenedicarboxylate. After cooling to room temperature, volatiles were evaporated and the residue was refluxed in xylene for 3 hr. The mixture was cooled to room temperature to allow the formation of a precipitate. The title product (A-2) was collected by filtration and washed with diethyl ether several times.

H¹ NMR (DMSO-d₆, 300 MHz) δ 13.0 (bs, 1 H), 8.08 (d, J=3.2 Hz, 1 H), 7.85 (d, J=4.4 Hz, 1 H), 7.25 (dd, J=4.9 Hz, J=3.9 Hz, 1 H), 3.93 (s, 3 H).

Step 2: N-(4-fluorobenzyl)-5,6-dihydroxy-2-thien-2-ylpyrimidine-4-carboxamide (A-3).

Methyl 5,6-ihydroxy-2-thien-2-ylpyrimidine-4-carboxylate (A-2) was dissolved in DMF and 2.0 eq. of 4-fluorobenzylamine were added to the stirred solution. Reaction mixture was left overnight at 90° C. After cooling to room temperature 1 N HCl was added and a solid precipitated from the mixture. This solid was collected by filtration, washed with ethyl ether and dried under vacuum to afford the compound (A-3).

¹H NMR (DMSO-d₆, 300 MHz) δ 13.0 (s, 1 H), 12.5 (s, 1H), 9.18 (bs, 1 H), 8.03 (d, J=3.0 Hz, 1 H), 7.81 (d, J=4.8 Hz, 1 H), 7.39 (dd, J=5.7 Hz, J=8.4 Hz, 2 H), 7.19-7.2 (m, 3 H), 4.51 (d, J=6.3 Hz, 2 H). MS m/z 346 (M+H)⁺.

EXAMPLE 2 2-{4-[(Diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide

Step 1: Methyl 5,6-bis(benzoyloxy)-2-(4-methylphenyl)pyrimidine-4-carboxylate (B-2).

A mixture of dihydroxypyrimidine methylcarboxylate (B-1) (prepared from 4-methylbenzonitrile by procedures similar to those set forth in Scheme A), 4 eq. of benzoylchloride and 8 eq. of dry pyridine was stirred in dry dichloromethane at room temperature over night. The reaction mixture was diluted with EtOAc and the organic layer was washed twice with 1N HCl, once with brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The solid residue was triturated with diethyl ether to give product (B-2).

¹H-NMR (CDCl₃, 400 MHz) δ 8.38 (d, J=8.2 Hz, 2 H), 8.14 (d, J=7.44 Hz, 2 H), 8.10 (d, J=7.44 Hz, 2 H), 7.62 (m, 2 H), 7.45 (m, 4 H), 7.3 (d, J=8.06 Hz, 2 H), 3.93 (s, 3 H), 2.44 (s, 3 H). Step 2: Methyl 5,6-bis(benzoyloxy)-2-[4-(bromomethyl)phenyl]pyrimidine-4-carboxylate (B-3).

A suspension of methyl ester (B-2), an equimolar amount of N-bromosuccinimide and 5% of dibenzoylhydroperoxide in carbon tetrachloride was heated at 95° C. The reaction mixture was refluxed for 2 hrs, then allowed to cool at room temperature. Succinimide was filtered off and volatiles were removed in vacuo to give the desired product (B-3) as a white solid after treatment with petroleum ether.

¹H-NMR (CDCl₃, 400 MHz) δ 8.47 (d, J=8.25 Hz, 2 H), 8.14 (d, J=7.56 Hz, 2 H), 8.10 (d, J=7.50 Hz, 2 H), 7.63 (m, 2 H), 7.53 (d, J=8.23 Hz, 2 H), 7.46 (m, 4 H), 4.56 (s, 2 H), 3.94 (s, 3 H).

Step 3: 2-{4-[(Diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (B-4).

A mixture of the benzylic bromide (B-3) and diethylamine (4 eq.) in THF was allowed to stir at room temperature overnight. The volatiles were then removed in vacuo, the residue was taken up in DMF and after the addition of a slight excess of 2,3-dimethoxybenzylamine the reaction mixture was stirred at 90° C. over night. IN HCl was then added to the reaction mixture and the crude product was purified by preparative HPLC (C18, CH₃CN/H₂O, 0.1% trifluoroacetic acid) to obtain title compound (B-4) as the trifluoroacetate salt.

¹H-NMR (DMSO-d₆, 400 MHz) δ 13.01 (bs, 1 H), 12.57 (s, 1 H), 9.53 (bs, 1 H), 9.36 (bs, 1 H), 8.34 (d, J=8.32 Hz, 2 H), 7.63 (d, J=8.27 Hz, 2 H), 7.08-6.96 (m, 2 H), 6.80 (m, 1 H), 4.52 (d, J=6.36 Hz, 2 H), 4.37 (d, J=4.35 Hz, 2 H), 3.82 (s, 3 H), 3.80 (s,3 H), 3.08 (m, 4 H), 1.22 (t, J=7.20 Hz, 6 H). MS m/z 467 (M+H)⁺.

EXAMPLE 3 2-[(Dimethylamino)(phenyl)methyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide

Step 1: Methyl-5,6-bis(benzoyloxy)-2-benzylpyrimidine-4-carboxylate (B-6).

To a stirred solution of methyl-2-benzyl-5,6-dihydroxypyrimidine-4-carboxylate (B-5) (1.0 eq.) (prepared from phenylacetonitrile by procedures similar to those set forth in Scheme A) in anhydrous pyridine, benzoyl chloride (5.0 eq.) was added dropwise with external cooling and the reaction was stirred overnight at room temperature. The mixture was poured into 1N HCl and extracted with EtOAc. The organic phase was washed with a saturated solution of NaHCO₃ and with brine, dried (Na₂SO₄), filtered and concentrated under vacuum. The residue was purified by flash column chromatography (SiO₂, 80/20 v/v petroleum ether/ ethyl acetate as eluent) to give the title compound (B-6) as a colorless oil.

¹H NMR (CDCl₃) δ 8.07 (t, J=9.0 Hz, 4 H), 7.62-7.57 (m, 2 H), 7.48-7.40 (m, 6 H), 7.31 (t, J=8.9 Hz, 2 H), 7.28 (d, J=8.9 Hz, 1 H), 4.41 (s, 2 H), 3.91 (s, 3 H). Step 2: Methyl-5,6-bis(benzoyloxy)-2-[bromo(phenyl)methyl]pyrimidine-4-carboxylate (B-7).

A solution of methyl-5,6-bis(benzoyloxy)-2-benzylpyrimidine-4-carboxylate (B-6) (1.0 eq.) in carbon tetrachloride was heated up to 90° C. under nitrogen; N-bromosuccinimide (1.0 eq.) and benzoyl peroxide (0.1 eq.) were added as dry powder and mixture was refluxed for 3 h. After cooling, succinimide was removed by filtration and the filtrate was concentrated and purified by flash column chromatography (SiO₂, 85/15 v/v petroleum ether/ ethyl acetate as eluent) to give the title product (B-7).

¹H NMR (CDCl₃) δ 8.11 (d, J=8.6 Hz, 2 H), 8.05 (d, J=8.6 Hz, 2 H), 7.79 (d, J=8.9 Hz, 2 H), 7.56-7.49 (m, 2 H), 7.50-7.30 (m, 7 H), 6.30 (s, 1 H), 3.90 (s, 3 H).

Step 3: 2-[(Dimethylamino)(phenyl)methyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (B-8).

Methyl-5,6-bis(benzoyloxy)-2-[bromo(phenyl)methyl]pyrimidine-4-carboxylate (B-7) was added to 2.0 M solution of dimethylamine in THF. After stirring the mixture for 10 min at room temperature, volatiles were evaporated by bubbling N₂ through the solution and 4 eq. of 4-fluorobenzylamine in DMF were added. Reaction mixture was stirred at 90° C. for 1 h. After cooling to room temperature, title compound (B-8) was obtained by RP-HPLC (C18, acetonitrile /water containing 0.1% of trifluoroacetic acid as eluant) as its trifluoroacetate salt.

¹H NMR (DMSO-d₆, 600 MHz) δ 13.42 (bs, 1 H), 12.34 (s, 1 H), 10.06 (bs, 1 H), 9.64 (t, J=5.9 Hz, 1 H), 7.52 (s, 5 H), 7.43 (dd, J=8.4 Hz, J=5.6 Hz, 2 H), 7.23 (t, J=8.8 Hz, 2 H), 5.28 (s, 1 H), 4.67 (dd, J=15.4 Hz, J=6.6 Hz, 1 H), 4.59 (dd, J=15.5 Hz, J=6.0 Hz, 1 H), 3.02 (s, 3 H), 2.06 (s, 3 H). ¹³C NMR (DMSO-d₆, 600 MHz) δ 168.25, 161.32 (d, J=242.9 Hz), 148.41, 144.29, 134.30, 130.89, 130.61, 129.40, 129.24, 129.00 (d, J=8.2 Hz), 125.95, 115.56 (d, J=21.4 Hz), 68.90, 43.30, 41.20, 40.80. MS m/z 397 (M+H)⁺.

EXAMPLE 4 2-[1-(Dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide

Step 1: Benzyl 1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-1-methylethyl carbamate (C-2).

A methanol solution of methyl 2-(1-{[(benzyloxy)carbonyl]amino}-1-methylethyl)-5,6-dihydroxypyrimidine-4-carboxylate (C-1) (prepared from N-[(benzyloxy)carbonyl]-2-methylalanine by procedures similar to those set forth in Scheme A) was treated with 2 eq. of 4-fluorobenzylamine and refluxed overnight. After evaporation of the solvent, the residue was poured into EtOAc and extracted with 1N HCl and brine. The organic phase was dried over Na₂SO₄, filtered and concentrated under vacuum. The solid residue was triturated with diethyl ether to give the product (C-2).

¹H NMR (DMSO-d₆, 400 MHz) δ 12.4 (bs, 1 H), 12.3 (bs, 1 H), 9.2 (bs, 1 H) 7.5-7.25 (m, 7 H), 7.16 (t, J=8.8 Hz, 2 H), 4.97 (s, 2 H), 4.48 (d, J=6.4 Hz, 2 H), 1.51 (s, 6 H). Step 2: 2-(1-Amino-1-methylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide(C-3).

To a solution of benzyl 1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-1-methylethylcarbamate (C-2) in methanol 10% Pd/C (10% by weight) was added. The flask was evacuated, then filled with hydrogen and stirred under an hydrogen atmosphere at room temperature for 1 h. The catalyst was filtered off, washed with methanol, the filtrate was evaporated to dryness and the residue was triturated with Et₂O to obtain (C-3) as a pale yellow solid.

¹H NMR (DMSO-₆, 400 MHz) δ 7.36 (t, J=8.2 Hz, 2 H), 7.16 (t, J=8.8 Hz, 2 H), 4.46 (d, J=6.2 Hz, 2 H), 1.43 (s, 6 H).

Step 3: 2-[1-(Dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (C-4).

To a stirred solution of (C-3) in methanol about 11 eq. of acetic acid were added and subsequently NaBH₃CN (8 eq.) and formaldehyde (37% solution, 2.5 eq.). The mixture was stirred at room temperature for 5 days, concentrated by rotary evaporation and subjected to RP-HPLC (C18, water/acetonitrile with 0.1% of trifluoroacetic acid as eluant). Collection and liophilization of appropriate fractions afforded the product (C-4) as its trifluoroacetate salt. The white powder was dissolved in 1N HCl and lyophilized again to be converted into the corresponding hydrochloride salt.

¹H NMR (DMSO-d₆, 300 MHz) δ 12.4 (s, 1 H) 10.2 (bs, 2 H), 7.41 (dd, J=8.3 Hz, J=6.9 Hz, 2 H), 7.16 (t, J=8.3 Hz, 2 H), 4.50 (d, J=5.9 Hz, 2 H), 2.73 (s, 6 H), 1.60 (s, 6H). MS m/z 349 (M+H)⁺.

EXAMPLE 5 N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylmorpholin-3-yl)-pyrimidine-4-carboxamide

Step 1: 4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid (C-5).

To a vigorously stirred solution of 3-morpholinecarboxylic acid and triethylamine (1.11 eq.) in MeOH at 50° C. was added di-t-butyl dicarbonate (2 eq.). Stirring was continued at 50° C. for 5 min and at room temperature overnight. The reaction mixture was then concentrated to obtain an oily residue and suspended between EtOAc and saturated NaHCO₃. The organic layer was extracted with saturated NaHCO₃ and H₂O. The combined aqueous layers were brought to pH=2.0 with 3 M HCl and immediately extracted with EtOAc. The combined organic layers were washed with dilute HCl, dried, filtered and evaporated to give C-5 as a pale yellow oil, a 1:1 mixture of rotamers by NMR.

δ ¹H NMR (400 MHz, DMSO-d6) 12.93 (bs, 1 H), 4.32 (s, 0.5 H), 4.29 (s, 0.5 H), 4.2-4.1 (m, 1 H), 3.83-3.74 (m,1 H), 3.58-3.52 (m, 2 H), 3.36-3.31 (m, 1 H), 3.16 (t, J=11.4 Hz, 0.5 H), 3.00 (t, J=11.4 Hz, 0.5 H), 1.40 (s, 4.5 H), 1.36 (s, 4.5 H). MS m/z 232 (M+H)⁺. Step 2: tert-Butyl 3-(aminocarbonyl)morpholine-4-carboxylate-(C-6).

To a stirred solution of compound C-5 (1 eq.), pyridine (0.6 eq.) and di-t-butyl dicarbonate (1.3 eq.) in dioxane, NH₄HCO₃ (1.26 eq.) was added and the mixture was stirred at room temperature for 20 hours. Mixture was concentrated, taken up in EtOAc and washed with water and brine. Organics were dried over Na₂SO₄ and evaporated giving C-6 as an oil which crystallized at room temperature.

¹H-NMR (DMSO-d₆, 300 MHz) δ 7.35 (bs, 1 H), 7.06 (bs, 1 H), 4.15 (bs, 2 H), 3.76 (bs, 1 H), 3.57-3.51 (m, 2H), 3.28 (m, 1 H), 3.18 (m, 1 H), 1.36 (s, 9 H). MS m/z 231 (M+H)⁺. Step 3: tert-Butyl 3-cyanomorpholine-4-carboxylate-(C-7).

A solution of C-6 (1 eq.) and triethylamine (2.1 eq.) in CH₂Cl₂ was cooled to 0° C. and trifluoroacetic anhydride (1.1 eq.) added dropwise under nitrogen. Stirring was continued 3.5 hours more at room temperature and volatiles removed in vacuo. Residues taken in EtOAc were washed with water, brine and dried over Na₂SO₄. Evaporation gave the title compound as a brown solid.

¹H NMR (DMSO-d₆, 400 MHz) δ 5.04 (d, J=2.7 Hz, 1 H), 3.96 (d, J=12.2 Hz, 1 H), 3.86 (dd, J=11.5, 2.6 Hz, 1 H), 3.69 (d, J=12.4 Hz, 1 H), 3.56 (dd, J=12.2, 3.2 Hz, 1 H), 3.40 (td, J=11.9, 2.89 Hz, 1 H), 2.97 (m, 1 H), 1.43 (s, 9 H). MS m/z 213 (M+H)⁺. Step 4: tert-Butyl 3-[(Z)-amino(hydroxyimino)methyl]morpholine-4-carboxylate-(C-8).

A solution of C-7 (1 eq.), hydroxylamine hydrochloride (1.4 eq.) and triethylamine (1.7 eq.) in EtOH was refluxed under nitrogen for 5 hours. Mixture was concentrated and residues taken up in EtOAc and washed with water and brine. Combined organics were dried over Na₂SO₄ and evaporated giving C-8 as yellow solid.

¹H NMR (DMSO-d₆, 400 MHz) δ 9.16 (bs, 1 H), 5.32 (bs, 2 H), 4.30 (bs, 1 H), 4.08 (d, J=11.6 H, 1 H), 3.75 (d, J=6.8 Hz, 1 H), 3.50-3.33 (m, 4 H), 1.38 (s, 9 H) MS: m/z 246 (M+H)⁺. Step 5: Dimethyl-2-({2-amino-2-[4-(tert-butoxycarbonyl)morpholin-3-yl]ethenyl}oxy)but-2-enedioate-(C-9).

A solution of C-8 (1 eq.) and dimethylacetylenedicarboxylate (1.2 eq.) in CHCl₃ was refluxed for 1 hour under nitrogen and solution concentrated. Residue was purified by flash chromatography on silica gel, eluents petroleum ether/EtOAc 7:3->1:1, to give the desired product as a mixture of two isomers E/Z (76:14).

¹H NMR (DMSO-d₆, 400 MHz, 300K) δ 6.60 and 6.20 (2 bs, 2 H), 5.58 and 5.41 (2s, 1 H), 4.36 (bs, 1 H), 4.04 (bs, 1 H), 3.8 (bs, 1 H), 3.76 and 3.72 (2 s, 3 H), 3.63 and 3.58 (2 s, 3 H), 3.53 (td, J=13.6, 3.7 Hz, 1 H), 3.44 (t, J=10.4 Hz, 1 H), 3.31 (m, 2 H), (s, 9 H). MS m/z 388 (M+H)⁺. Step 6: tert-Butyl-3-[4,5-dihydroxy-6-(methoxycarbonyl)pyrimidin-2-yl]morpholinecarboxylate-(C-10).

The adducts C-9 were refluxed in xylenes for 24 hours. Then the reaction was cooled and concentrated in vacuo. Ethyl ether was added until precipitation of a solid that was filtered, washed with ethyl ether and dried to give the pyrimidine C-10 as an orange solid.

¹H NMR (DMSO-d₆, 400 MHz, 340 K) δ 4.62 (s, 1H), 4.15 (d, J=12 Hz, 1H), 3.84 (bs,1H), 3.82 (s, 3H), 3.70 (dd, J=12.3, 4 Hz, 1H), 3.61 (dd, J=12.2, 3.8 Hz, 1H), 3.56 (t, J=13 Hz, 1H), 3.43 (td, J=11.5, 3.4 Hz, 1H), 1.35 (s, 9H). MS m/z 356 (M+H)⁺. Step 7: Methyl 5,6-dihydroxy-2-morpholin-3-ylpyrimidine-4-carboxylate (C-11).

The methyl ester A was treated with a mixture of TFA:dichloromethane:H₂O (65:35:10) at room temperature for 15 minutes. The reaction mixture was concentrated and the residue was taken up in Et₂O and evaporated several times in order to remove excess trifluoroacetic acid. A solid residue was obtained after filtration.

¹H NMR (DMSO-d₆, 400 MHz, 300K) δ 13.24 (bs, 1 H), 10.54 (bs, 1H), 9.54 (bs, 2H), 4.34 (d, J=6.9 Hz, 1 H), 4.24 (dd, J=12.2, 3.2 Hz, 1H), 3.93 (d, J=11.2 Hz, 1H), 3.84 (s, 3H), 3.75 (t, J=10.3 Hz, 1H), 3.58 (t, J=10.5 Hz, 1H), 3.32 (d, J=12.8 Hz, 1H), 3.20 (td, J=11, 3.7 Hz, 1H). MS: m/z 256 (M+H)⁺. Step 8: N-(4-fluorobenzyl)-5,6-dihydroxy-2-morpholin-3-ylpyrimidine-4-carboxamide (C-12).

The methyl ester C-11 in dry MeOH was treated with 4-fluorobenzyl amine (2.0 eq.) at 90° C. for 1 hour. The reaction mixture was concentrated and the residue triturated with Et₂O. A solid residue was obtained. Title compound was isolated by RP-HPLC as its trifluoroacetate salt (C18 column, eluants water/acetonitrile containing 0.1% TFA).

¹H NMR (DMSO-d₆+TFA, 400 MHz, 300 K) δ 9.63 (bs, 1 H), 9.4 (t, J=6.07 Hz, 1 H), 9.2 (bs, 1 H), 7.39 (dd, J=8.31, J=5.76 Hz, 2 H), 7.18 (t, J=8.84 Hz, 2 H), 4.59 (dd, J=15.53, J=6.80 Hz, 1 H), 4.53 (dd, J=15.36, J=6.24 Hz, 1 H), 4.37 (bs, 1 H), 4.24 (dd, J=12.41, J=3.24 Hz, 1 H), 3.99 (d, J=12.04 Hz, 1 H), 3.74-3.62 (m, 2 H), 3.41 (d, J=13.09 Hz, 1 H), 3.40 (bs, 1 H). MS m/z 349 (M+H)⁺.

Step 9: N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylmorpholin-3-yl)-pyrimidine-4-carboxamide (C-13).

To a solution of C-12 (1 eq.) in MeOH were added 37% HCOH (6 eq.), NaBH₃CN (5.2 eq.) and AcONa (5.8 eq.). Mixture was stirred at room temperature under nitrogen for 12 hours, then concentrated and title compound C-13 was obtained by RP-HPLC purification on a C18 column (eluants water/acetonitrile containing 0.1% TFA) as its trifluoacetate salt.

¹H NMR (DMSO-d₆+TFA, 400 MHz, 330 K) δ 9.2 (bt, 1 H), 7.40 (dd, J=8.38, J=5.75 Hz, 2 H), 7.16 (t, J=8.84 Hz, 2 H), 4.57 (d, J=6.34 Hz, 2 H), 4.27 (dd, J=10.03, J=3.55 Hz, 1 H), 4.22 (dd, J=12.82, J=3.22 Hz, 1 H), 4.10 (d, J=13.73 Hz, 1 H), 3.77 (t, J=11.84 Hz, 1 H), 3.65-3.60 (m, 2 H), 3.41 (td, J=12.54, J=3.67 Hz, 1 H), 2.87 (s, 3 H). MS m/z 363 (M+H)⁺.

EXAMPLE 6 N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methylpyrrolidin-2-yl)pyrimidine-4-carboxamide

Step 1: Tert-butyl-2-[amino(hydroxyimino)methyl]pyrrolidine-1-carboxylate (C-14).

A solution of hydroxylamine hydrochloride (1.0 eq.) in MeOH was added at 0° C. to a solution of KOH (1.0 eq.) in MeOH. The resulting reaction mixture was filtered and added to a solution of tert-butyl-2-cyanopyrrolidine-1-carboxylate (1.0 eq.) in methanol and stirred at 40° C. for 2 h. The solvent was removed in vacuo and the residue treated with water, the solid was filtered and washed with a mixture of Et₂O: Petroleum Ether 1:1 to afford the title compound C-14 as a white solid.

¹H-NMR (DMSO-d₆, 400 MHz) δ 8.92 (s, 1 H), 5.35 (s,1 H), 5.15 (s, 1 H), 4.25 (bs, 0.5 H), 4.10 (s, 0.5 H), 3.40-3.30 (m, 1 H), 2.10-1-70 (m, 4 H), 1.40 (s, 4.5 H),1.35 (s, 4.5 H), one signal is obscured by water. Step 2: Methyl 5-(benzoyloxy)-2-[1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-6-hydroxypyrimidine-4-carboxylate (C-15)

A solution of C-14 (1.0 eq.) and dimethyl acetylenedicarboxylate (1.05 eq.) in CHCl₃ was refluxed for 3 h. The reaction mixture was concentrated and the crude product was used directly in the next step without further purification. The crude product was dissolved in xylene and refluxed for 24 h. The solvent was removed in vacuo and the crude was dissolved in pyridine. Benzoic anhydride was added (1.5 eq.). The reaction mixture was stirred at room temperature until the starting material was consumed as determined by MS analysis. The reaction mixture concentrated, the resulting oil was diluted with ethyl acetate and washed with 1N HCl solution, saturated NaHCO₃ solution, brine. The crude oil obtained after organic solvent evaporation was purified by flash chromatography to obtain C-15 as a yellow solid.

¹H-NMR (CDCl₃, 400 MHz) δ 12.08 (bs, 1 H), 8.18 (d, J=7.6 Hz, 2 H), 7.64 (t, J=7.6 Hz, 1 H), 7.50 (t, J=7.6 Hz, 2 H), 4.80-4.60 (m, 1 H), 3.82 (s, 3 H), 3.60-3.50 (m, 1 H), 3.40-3.20 (m, 1 H), 2.50-2.10 (m, 2 H), 2.00-1.70 (m, 2 H), 1.50 (s, 9 H). MS m/z 444 (M+H)⁺. Step 3: Methyl 5-(benzoyloxy)-6-hydroxy-2-pyrrolidin-2-ylpyrimidine-4-carboxylate (C-16)

Methyl 5-(benzoyloxy)-2-[1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-6-hydroxypyridine-4-carboxylate C-15 was treated with TFA:CH₂Cl₂ (3:7) at 0° C. The solution was warmed to room temperature and the progress of the reaction was monitored by MS analysis. After 1h the reaction was complete and the solvent was removed under reduced pressure using a rotatory evaporator. The product C-16 was precipitated with Et₂O and collected by filtration.

¹H NMR (CDCl₃, 400 MHz) δ 8.14 (d, J=7.5 Hz, 2 H), 7.67 (t, J=7.6 Hz, 1 H), 7.50 (dd, J=7.6, 7.6 Hz, 2 H), 4.99 (dd, J=14.9, J=7.3 Hz, 1 H), 3.78 (s, 3 H), 3.60-3.40 (m, 2 H), 2.60-2.45 (m, 1 H), 2.40-2.30 (m, 1 H), 2.20-2.10 (m, 2 H). MS m/z 344 (M+H)⁺. Step 4: N-(4-fluorobenzyl)-5,6-dihydroxy-2-pyrrolidin-2-ylpyrimidine-4-carboxamide (C-17)

A solution of methyl 5-(benzoyloxy)-6-hydroxy-2-pyrrolidin-2-ylpyrimidine-4-carboxylate (C-16) (1.0 eq.) in MeOH was treated with 4-fluorobenzylamine (3.0 eq.). The solution was stirred at reflux until the starting material was consumed as determined by MS analysis. The reaction was concentrated and the product (C-17) was precipitated with MeOH and collected by filtration.

¹H NMR (DMSO-d₆, 400 MHz) δ 9.55 (bs, 1 H), 7.35 (dd, J=13.7, J=7.8 Hz, 2 H), 7.16 (dd, J=17.5, J=8.8 Hz, 2 H), 4.60-4.40 (m, 2 H), 4.06 (dd, J=14.0, J=6.9 Hz, 1 H), 3.15-3.10 (m, 1 H), 3.00-2.90 (m, 1 H), 2.20-2.10 (m, 1 H), 1.90-1.70 (m, 3 H). MS m/z 333 (M+H)⁺.

Step 5: N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methylpyrrolidin-2-yl)pyrimidine-4-carboxamide (C-18)

To a stirred solution of N-(4-fluorobenzyl)-5,6-dihydroxy-2-pyrrolidin-2-ylpyrimidine-4-carboxamide (C-17) (1.0 eq.) in MeOH, Et₃N (1.0 eq.) was added followed by the addition of AcONa (1.6 eq.), AcOH glacial (1.6 eq.), 37% HCOH (2.0 eq.) and NaBH(AcO)₃ (1.4 eq.). The mixture was stirred at room temperature until the reactants were consumed as determined by MS analysis. The reaction mixture was quenched by adding aqueous NaHCO₃, and the product extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure using a rotatory evaporator. A portion of the mixture was purified by RP-HPLC (C18, water/acetonitrile with 0.1% of trifluoroacetic acid as eluant) to give the title compound C-18 as its trifluoroacetate salt.

¹H NMR δ (DMSO-d₆, 400 MHz) δ 13.20 (bs, 1 H), 12.50 (bs, 1 H), 10.0-9.70, (m, 1 H), 9.63 (bs, 1 H), 7.35 (dd, J=13.8 Hz, J=8.2 Hz, 2 H), 7.18 (dd, J=17.5 Hz, J=8.8 Hz, 2 H), 4.54 (m, 2 H), 4.40 (dd, J=15.7 Hz, J=7.7 Hz, 1 H), 3.82-3.70 (m, 1 H), 3.40-3.20 (m, 1 H), 2.94 (s, 3 H), 2.60-2.50 (m, 1 H), 2.20-1.80 (m, 3 H). MS m/z 347 (M+H)⁺.

EXAMPLE 7 2-(1,4-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide

Step 1: Preparation of Compound C-20

Compound C-19 (which was prepared from 1-[(benzyloxy)carbonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid (Bigge et al, Tetrahedron Lett. 1989, 30: 5193) using procedures similar to those set forth in Scheme A) was deprotected with TFA/dichloromethane 1:1. After 1.5 h the solution was evaporated to obtain the crude product C-20. Step 2: Preparation of Compound C-21

To the crude C-20 dissolved in MeOH, NaCNBH₃ (1.4 eq.), AcONa (1.6 eq.) and HCHO 37% (2 eq.) were added. After 1 h the mixture was evaporated to obtain crude C-21. Step 3: Preparation of Compound C-22

Crude C-21 dissolved in MeOH and hydrogenated at atmospheric pressure on 10% Pd/C overnight. After filtration and evaporation of the filtrate crude C-22 was obtained. Step 4: Preparation of Compound C-23

Crude C-22 was dissolved in MeOH and NaCNBH₃ (1.4 eq.), AcONa (1.6 eq.) and HCHO 37% (2 eq.) were added. After 2.5 h the mixture was evaporated to obtain crude product C-23.

Step 5: 2-(1,4-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide C-24

Crude C-23 was dissolved in NMP (6 ml/mmol) and 4-fluorobenzylamine (3 eq.) added. The mixture was stirred at 90° C. overnight. Part of the crude material was purified by preparative HPLC (C18, gradient of CH₃CN/H₂O+0.01% TFA) to obtain the title product (C-24) as its trifluoroacetate salt.

¹H NMR (DMSO d₆+TFA, 300 K, 400 MHz) δ 12.5 (bs, 1 H), 9.30 (t, J=6.4 H, 1 H), 7.38 (dd, J=5.8, 8.8 Hz, 2 H), 7.17 (t, J=8.8 H, 2 H), 4.58-4.4 (m, 2 H), 3.66 (bs, 1 H), 3.55-3.35 (m, 3 H), 3.20 (d, J=13.3 Hz, 1 H), 3.03, (t, J=11.7 Hz, 1 H), 2.79 (s, 3 H), 2.85-2.70 (m, 1 H), 2.33 (bs, 3 H). MS m/z 376 (M+H)⁺.

EXAMPLE 4A 2-[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6-dihydroxypyrimidine-4-carboxamide

Step 1: tert-Butyl 4-(aminocarbonyl)tetrahydro-2H-pyran-4-yl-carbamate (C-25)

To a stirred solution of the commercially available 4[(tert-butoxycarbonyl)amino]tetrahydro-2H-pyran-4-carboxylic acid in dioxane, pyridine (0.6 eq.), di-butyl dicarbonate (1.3 eq) and ammonium bicarbonate (1.26 eq) were added and the mixture was stirred at room temperature for 20 hours. Dioxane was concentrated and the residue dissolved in ethyl acetate and washed with HCl 1N, saturated aqueous NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and evaporated in vacuo to obtain the solid compound (C-25).

¹H NMR (CDCl₃, 300 MHz, 300 K) δ 6.82 (bs,1H), 5.37 (bs, 1H), 4.80 (bs, 1H), 3.88 (t, J=4.4 Hz, 1H), 3.84 (t, J=4.4 Hz, 1H), 3.72-3.64 (m, 2H), 2.30-2.21 (m, 2H), 1.98-1.94 (m, 2H), 1.48 (s, 9H). MS: m/z 245 (M+H)⁺. Step 2: tert-Butyl 4-cyanotetrahydro-2H-pyran-4-yl-carbamate (C-26)

A solution of tert-butyl 4-(aminocarbonyl)tetrahydro-2H-pyran-4-yl-carbamate (C-25) and triethylamine (2.1 eq.) in dichloromethane was cooled to 0° C. and trifluoroacetic anhydride (1.1 eq.) was added dropwise under nitrogen. Stirring was continued for 1 hour allowing the mixture to reach room temperature. Volatiles were removed in vacuo and residue was taken up in ethyl acetate, washed with HCl 1N, brine and dried over Na₂SO₄. Evaporation gave a crude which was purified by flash chromatography on silica gel (eluent:petroleum ether:ethyl acetate=7:3) to give the title compound (C-26), colorless oil, as a 8:2 mixture of two rotamers by ¹H NMR.

¹H NMR (CDCl₃, 300 MHz, 300 K) δ 4.71 (bs, 1H), 3.96 (t, J=3.5 Hz, 1H), 3.93 (t, J=4.1 Hz, 1H ), 3.79-3.76 (m, 2H), 2.37-2.34 (m, 2H), 1.89-1.82 (m, 2H), 1.50 (s, 7H), 1.47 (s, 2H). MS: m/z 227 (M+H)⁺. Step 3: tert-Butyl-4-[amino(hydroxyimino)methyl]tetrahydro-2H-pyran-4-yl-carbamate (C-27)

A solution of free hydroxylamine in ethanol was obtained by dissolving separately hydroxylamine hydrochloride (1.1 eq) and potassium hydroxide (1.1 eq) in ethanol. The two solutions were mixed together, the potassium chloride filtered off and the resulting ethanolic solution was used to treat a solution of tert-butyl-4-cyanotetrahydro-2H-pyran-4-yl-carbamate (C-26) in ethanol at 45° C. for 5 hours. Mixture was concentrated to obtain the title compound (C-27) as a crude solid that was used in the next step without further purification.

MS: m/z 260 (M+H)⁺. Step 4: Dimethyl-2-{[(amino{4-[(tert-butoxycarbonyl)amino]tetrahydro-2H-pyran-4-yl}methylidene)amino]oxy}but-2-enedioate (C-28)

A solution of tert-butyl-4-[amino(hydroxyimino)methyl]tetrahydro-2H-pyran-4-yl-carbamate (C-27) and dimethylacetylendicarboxylate (1.2 eq.) in chloroform was refluxed for 1 hour under nitrogen and the solution was concentrated. Residue was purified by flash chromatography on silica gel (eluent:petroleum ether:ethyl acetate=7:3) to give the desired product (C-28) as a mixture of isomers in ratio 7:3.

¹H-NMR (CDCl₃, 300 MHz, 300 K) δ 5.91 (bs, 1H), 5.83 (s, 0.7H), 5.75 (s, 0.3H), 5.67 (bs, 1H), 4.67 (s, 0.7H), 4.63 (s, 0.3H), 3.93 (s, 2.1H), 3.86 (s,0.9H), 3.84-3.63 (m, 4H), 3.76 (s, 0.9H), 3.73 (s, 2.1H), 2.32-2.17 (m, 2H), 2.14-1.98 (m, 2H), 1.47 (s, 9H). MS: m/z 402 (M+H)⁺. Step 5: Methyl 2-{4-[(tert-butoxycarbonyl)amino]-tetrahydro-2H-pyran-4-yl}-5,6-dihydroxypyrimidine-4-carboxylate (C-29)

A solution of dimethyl-2-{[(amino{4-[(tert-butoxycarbonyl)amino]tetrahydro-2H-pyran-4-yl}methylidene)amino]oxy}but-2-enedioate (C-28) in o-xylene was refluxed for 6 hours. Then the reaction was cooled down and concentrated. Ethyl ether was added until precipitation of a solid that was filtered, washed with other ethyl ether and dried to give the title compound (C-29)as a brown solid.

MS: m/z 370 (M+H)⁺.

The reaction mother liquor was concentrated and used for the next step. Step 6: Methyl 5-(benzoyloxy)-2-{4-[(tert-butoxycarbonyl)amino]tetrahydro-2H-pyran-4-yl}-6-hydroxypyrimidine-4-carboxylate (C-30)

The concentrated mother liquor containing methyl 2-{4-[(tert-butoxycarbonyl)amino]-tetrahydro-2H-pyran-4-yl}-5,6-dihydroxypyrimidine-4-carboxylate (C-29), dissolved in dry pyridine was treated with benzoic anhydride (2 eq.) overnight at room temperature.

The mixture was evaporated, taken up in ethyl acetate and washed with HCl 1N and brine. Organics were dried over Na₂SO₄, filtered and evaporated the resulting crude oil was purified by flash chromatography on silica gel (eluent:ethyl acetate:petroleum ether=7:3) to obtain methyl 5-(benzoyloxy)-2-{4-[(tert-butoxycarbonyl)amino]tetrahydro-2H-pyran-4-yl}-6-hydroxypyrimidine-4-carboxylate (C-30).

¹H NMR (DMSO-d₆, 300 MHz, 300 K) δ 13.20 (bs, 1H), 8.09 (d, J=7.3 Hz, 2H), 7.79 (t, J=7.5 Hz, 1H), 7.63 (t, J=8.01 Hz, 2H), 3.76 (s, 3H), 3.75-3.60 (m, 4H), 2.22-2.15 (m, 2H), 2.00-1.87 (m, 2H), 1.34 (bs, 9H). MS: m/z 474 (M+H)⁺. Step 7: tert-Butyl-4-[4-({[4-fluoro-2-(methylsulfonyl)benzyl]amino}carbonyl)-5,6-dihydroxypyrimidin-2-yl]tetrahydro-2H-pyran-4-yl-carbamate (C-31)

Methyl-5-(benzoyloxy)-2-{4[(tert-butoxycarbonyl)amino]tetrahydro-2H-pyran-4-yl}-6-hydroxypyrimidine-4-carboxylate (C-30) in dry MeOH was treated with 4-fluoro-2-(methylsulfonyl)benzylamine (2.5 eq.) at reflux for 2 hours. Solvent was removed in vacuo and the residue was taken up in ethyl acetate, washed with HCl 1N, brine, dried over Na₂SO₄. The filtrate was concentrated in vacuo and triturated with ethyl ether to obtain the crude title compound (C-31).

MS: m/z 541 (M+H)⁺. Step 8: 2-(4-Aminotetrahydro-2H-pyran-4-yl)-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6-dihydroxypyrimidine-4-carboxamide trifluoroacetate (C-32)

A solution of tert-butyl-4-[4-({[4-fluoro-2-(methylsulfonyl)benzyl]amino}carbonyl)-5,6-dihydroxypyrimidin-2-yl]tetrahydro-2H-pyran-4-yl-carbamate (C-31) in dichloromethane was treated with an excess of trifluoroacetic acid for 3 hours at room temperature. The acid in excess was removed in vacuo to obtain the crude title compound (C-32)as a pale yellow solid, after trituration with ethyl ether.

MS: m/z 441 (M+H)⁺.

Step 9: 2-[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6-dihydroxypyrimidine-4-carboxamide (C-33)

A solution of 2-(4-aminotetrahydro-2H-pyran-4-yl)-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6-dihydroxypyrimidine-4-carboxamide trifluoroacetate (C-32) in MeOH was treated with triethylamine (1 eq.), sodium acetate (1.6 eq.), formaldehyde 37% w/w aq. soln. (3 eq.), and sodium cyanoborohydride (1.43 eq.). The mixture was left stirring at room temperature for 1h. Trifluoroacetic acid (3 eq) and sodium cyanoborohydride (0.5 eq) were added, left stirring overnight. The reaction mixture was concentrated and the title compound (C-33)as trifluoro acetate salt was obtained by preparative HPLC purification (C₁₈, eluting with water and acetonitrile containing 0.1% trifluoroacetic acid in gradient).

¹H NMR (DMSO-d₆+TFA, 300 MHz, 300 K) δ 10.90 (bs, 1H), 9.42 (bt, 1H), 7.76 (d, J=8.5 Hz, 1H), 7.61 (d, J=5.6 Hz, 2H), 4.90 (d, J=6.3 Hz, 2H), 3.93 (d, J=6.3 Hz, 2H), 3.44 (s, 3H), 3.21-3.06 (m, 4H), 2.72 (s, 6H), 1.90-1.82 (m, 2H). MS: m/z 469(M+H)⁺.

EXAMPLE 6A N-(4-fluorobenzyl)-5,6-dihydroxy-2-(7-methyl-7-azabicyclo[2.2.1]hept-1-yl)pyrimidine-4-carboxamide

Step1: 7-[(benzyloxy)carbonyl]-7-azabicyclo[2.2.1]heptane-1-carboxylic acid (C-35)

7-benzyl 1-tert-butyl 7-azabicyclo[2.2.1]heptane-1,7-dicarboxylate (C-34)(synthesized following the procedure reported in J. O. C, 1996, 61, 6313-6325) was stirred in TFA/DCM/H₂O (95/5/5, 0.3 M) for 10 minutes. Evaporation of the solvent afforded the titled compound (C-35).

¹H-NMR (DMSOd₆, 300K, 300 MHz) δ: 12.5 (bs, 1H), 7.45-7.30 (m, 5H), 5.06 (s, 2H), 4.27 (t, J=4.6 Hz, 1H), 2.00-1.92 (m, 2H), 1.76-1.65 (m, 4H), 1.55-1.43 (m, 2H). MS (EI+) m/z 276 (M+H)⁺. Step 2: benzyl 1-(aminocarbonyl)-7-azabicyclo[2.2.1]heptane-7-carboxylate (C-36)

A stirred solution of 7-[(benzyloxy)carbonyl]-7-azabicyclo[2.2.1]heptane-1-carboxylic acid (C-35) in dioxane was treated with pyridine (0.8 eq.) and Boc₂O (1.5 eq.), then ammonium bicarbonate (1.46 eq.) was added and the mixture was stirred at room temperature for 15 hours. Dioxane was concentrated and the residue was taken up in ethyl acetate, washed with HCl 1N and brine and dried over Na₂SO₄ to give, after filtration and concentration, the titled compound (C-36).

¹H-NMR (DMSOd₆, 300K, 300 MHz) δ 7.42-7.28 (m, 5H), 7.18 (bs, 1H), 7.00 (bs, 1H), 5.05 (s, 2H), 4.28 (t, J=4.5 Hz, 1H), 2.00-1.90 (m, 2H), 1.77-1.60 (m, 4H), 1.52-1.40 (m, 2H). MS (EI+) m/z 275 (M+H)⁺. Step 3: benzyl 1-cyano-7-azabicyclo[2.2.1]heptane-7-carboxylate (C-37)

Benzyl 1-(aminocarbonyl)-7-azabicyclo[2.2.1]heptane-7-carboxylate (C-36) in dichloromethane was treated at 0° C. with Et₃N (2.1 eq.) and trifluoroacetic anhydride (1.1 eq.) was added dropwise. The reaction mixture was stirred at 0° C. for 30 minutes. Then, it was diluted with dichloromethane, washed with saturated NaHCO₃ solution, H₂O, brine and dried over Na₂SO₄. Filtration and evaporation afforded the titled compound (C-37).

¹H-NMR (DMSOd₆, 300K, 300 MHz) δ 7.42-7.30 (m, 5H), 5.14 (s, 2H), 4.32 (t, J=5.0 Hz, 1H), 2.2-1.98 (m, 4H), 1.90-1.70 (m, 2H), 1.62-1.45 (m, 2H). MS (EI+) m/z 257 (M+H)⁺. Step 4: dimethyl-2-{[(amino{7-[(benzyloxy)carbonyl]-7-azabicyclo[2.2.1]hept-1-yl}methylidene)amino]oxy}but-2-enedioate (C-38).

Triethyl amine (1.5 eq.), hydroxylamine hydrochloride (1.3 eq.) were added to a solution of benzyl 1-cyano-7-azabicyclo[2.2.1]heptane-7-carboxylate (C-37) in absolute methanol. The mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, the residue was dissolved in chloroform and treated with dimethylacetylene dicarboxylate (2 eq.) for 14 hours at 60° C. The reaction mixture was then concentrated and the resulting crude oil was purified by flash chromatography (petroleum ether/EtOAc 1:1) to give the titled compound (C-38) as a mixture of isomers.

¹H-NMR (DMSOd₆, 300K, 300 MHz δ: 7.41-7.25 (m, 5H), 6.57 (bs, 1.3 H), 6.17 (bs,0.7 H), 5.66 (s,0.65 H), 5.61 (s, 0.35 H), 5.04 (s, 2H), 4.35-4.30 (m, 1H), 3.79 (s, 1.95H), 3.75 (s, 1.05H), 3.63 (s,1.05H), 3.60 (s,1.95H), 2.15-1.92 (m, 2H), 1.80-1.45 (m, 6H). MS (EI+) m/z 432 (M+H)⁺. Step 5: benzyl 1-[5-(benzoyloxy)-4-hydroxy-6-(methoxycarbonyl)pyrimidin-2-yl]-7-azabicyclo[2.2.1]heptane-7-carboxylate (C-39)

Dimethyl-2-{[(amino{7-[(benzyloxy)carbonyl]-7-azabicyclo[2.2.1]hept-1-yl}methylidene)amino]oxy}but-2-enedioate (C-38) was dissolved ortho-xylene and refluxed for 14 hours. Solvent was evaporated after cooling at room temperature and the resulting crude oil was dissolved in pyridine, treated with benzoic anhydride (2 eq.). The reaction mixture was stirred at room temperature for 3 hours. Reaction mixture was concentrated and the residue was taken up in ethyl acetate and washed with HCl 1N and saturated NaHCO₃ solution. The organic phase was dried over Na₂SO₄, filtered and after concentration and purification by flash chromatography the titled compound was obtained.

¹H-NMR (DMSOd₆, 300K, 300 MHz) δ 13.38 (s, 1H), 8.09 (d, J=7.5 Hz, 2H), 7.80 (t, J=7.5 Hz, 1H), 7.64 (t, J=7.5 Hz, 2H), 7.40-7.22 (m, 5H), 5.00 (s, 2H), 4.40 (t, J=4.3 Hz, 1H), 3.76 (s, 3H), 2.32-1.117 (m, 2H), 1.95-1.79 (m, 4H), 1.66-1.51 (m, 2H). MS (EI+) m/z 504 (M+H)⁺.

Step 6: N-(4-fluorobenzyl)-5,6-dihydroxy-2-(7-methyl-7-azabicyclo[2.2.1]hept-1-yl)pyrimidine-4-carboxamide (C-40)

Benzyl 1-[5-(benzoyloxy)-4-hydroxy-6-(methoxycarbonyl) pyrimidin-2-yl]-7-azabicyclo[2.2.1]heptane-7-carboxylate (C-39) in methanol was hydrogenated under H₂ atmosphere in presence of Pd/C 10% (10% w/w) at room temperature for 2 hours. After filtration and evaporation, the crude was dissolved in MeOH and p-fluorobenzylamine (3.5 eq.) added. After being refluxed overnight, the residue was washed with Et₂O/EP. The solid was dissolved in MeOH and NaCNBH₃ (1.4 eq.), AcONa (1.6 eq.), HCHO 37% (1 eq.) were added. The reaction mixture was stirred at room temperature overnight. The product was purified by preparative HPLC (C18, gradient CH₃CN/H₂O+0.01% TFA) to obatine the title compound (C-40) as trifluoro acetate salt.

¹H-NMR (DMSOd₆, 300K, 400 MHz) δ 12.9 (bs, 1H), 12.2 (s, 1H), 10.95 (bs, 1H), 9.66 (bs, 1H), 7.47-7.40 (m, 2H), 7.21-7.12 (m, 2H), 4.50 (d, J=6.0 Hz, 2H), 4.17 (bs, 1H), 2.67 (s, 3H), 2.45-2.1 (m, 6H), 1.95-1.80 (m, 2H). MS (EI+) m/z 373 (M+H)⁺.

EXAMPLE 7B N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1,2,4-trimethylpiperazin-2-yl)pyrimidine-4-carboxamide

Step 1: 1-benzyl 4-tert-butyl 2-cyano-2-methylpiperazine-1,4-dicarboxylate (C-41).

To a cooled (−75° C.) solution of LDA 2M in heptane/THF (1.5 eq) in THF, a solution of 1-[(benzyloxy)carbonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid (Bigge et al, Tetrahedron Lett. 1989, 30: 5193) in THF was added dropwise at −75° C. After being stirred for 1 hour at −75° C., MeI (1.5 eq) was added. After 2 hours at −75° C. the reaction mixture was left warming to r.t., evaporated, diluted with AcOEt, washed with NaHCO₃, water, brine and dried over Na₂SO₄. The crude was purified by flash chromatography on silica gel (petroleum ether/AcOEt, 85:15) to obtain the title compound (C-41).

¹H NMR (DMSOd₆, 340K, 300 MHz) δ 7.45-7.30 (m, 5H), 5.19 (AA′ system, J=13 Hz, 2H), 4.05 (d, J=14 Hz, 1H), 3.87-3.78 (m, 1H), 3.66 (d, J=14 Hz, 1H), 3.62-3.35 (m, 3H), 1.66 (s, 3H), 1.45 (s, 9H). MS (EI+) m/z 360 (M+H)⁺. Step 2: 1-benzyl 4-tert-butyl 2-[(Z)-amino({[(1E)-3-methoxy-1-(methoxycarbonyl)-3-oxoprop-1-enyl]oxy}imino)methyl]-2-methylpiperazine-1,4-dicarboxylate (C-42).

A solution of 1-benzyl 4-tert-butyl 2-cyano-2-methylpiperazine-1,4-dicarboxylate (C-41) in EtOH was added to a solution of Et₃N (3.2 eq) and NH₂OH HCl (3 eq) in EtOH. The mixture was stirred 2 hr at 40° C. After evaporation of the solvent, the residue was diluted with AcOEt, washed with water, dried over Na₂SO₄, filtered and concentrated. The residue was further dissolved in chloroform and dimethylacetylenedicarboxylate (1.5 eq) added to the stirred solution. Reaction was refluxed over night. The mixture was evaporated and the residue was purified by flash chromatography on silica gel (petroleum ether/AcOEt, 65:35) affording (C-42).

¹H NMR (DMSOd₆, 340K, 300 MHz). Two sets of signals were observed due to the presence of the geometric isomers: δ 7.48-7.25 (m, 5H), 6.31, 6.01 (bs, 2H), 5.63, 5.55 (s, 1H), 5.12-5.02 (m, 2), 3.85-3.60 (m, 9H, at 3.79, 3.76 (s), at 3.66, 3.61 (s)), 3.60-3.45 (m, 2H), 3.45-3.31 (m, 1H), 1.51, 1.45 (s, 3H), 1.41 (s, 9H). MS (EI+) m/z 535 (M+H)⁺. Step3: 1-benzyl 4-tert-butyl 2-[5-(benzoyloxy)-4-hydroxy-6-(methoxycarbonyl) pyrimidin-2-yl]-2-methylpiperazine-1,4-dicarboxylate (C-43).

1-benzyl 4-tert-butyl 2-[(Z)-amino({[(1E)-3-methoxy-1-(methoxycarbonyl)-3-oxoprop-1-enyl]oxy}imino)methyl]-2-methylpiperazine-1,4-dicarboxylate (C-42) was dissolved in xylene and stirred at 155° C. for 8 h. After evaporation of the solvent, the residue was dissolved in pyridine and benzoic anhydride (1.5 eq) was added. The reaction mixture was stirred at room temperature over night, then pyridine was evaporated. The residue was diluted with AcOEt, the organic phase washed with HCl 1N, dried (Na₂SO₄) and evaporated. The product (C-43) was purified by flash chromatography (eluent:petroleum ether/AcOEt 70/30).

¹H-NMR (DMSOd₆, 340K, 400 MHz) δ 12.96 (bs, 1H), 8.11-8.04 (m, 2H), 7.79-7.73 (m, 1H), 7.66-7.58 (m, 2H), 7.37-7.22 (m, 5H), 5.03 (s, 2H), 4.00-3.91 (m, 1H), 3.80-3.52 (m, 7H, at 3.75 (s)), 3.47-3.40 (m, 1H), 1.65 (s, 3H), 1.35 (s, 9H). MS (EI+) m/z 607 (M+H)⁺. Step 4: Methyl 5-(benzoyloxy)-2-[4-(tert-butoxycarbonyl)-2-methylpiperazin-2-yl]-6-hydroxypyrimidine-4-carboxylate (C-44).

1-benzyl 4-tert-butyl 2-[5-(benzoyloxy)-4-hydroxy-6-(methoxycarbonyl)pyrimidin-2-yl]-2-methylpiperazine-1,4-dicarboxylate (C-43) was dissolved in AcOEt and hydrogenated at 1 atm on 10% (w/w) Pd/C over night. After filtration of the catalyst, solvent was evaporated to give the crude title compound (C-44).

¹H-NMR (DMSOd6+TFA, 340K, 400 MHz) δ: 8.11-8.04 (m, 2H), 7.81-7.74 (m, 1H), 7.66-7.58 (m, 2H), 4.22 (d, J=14.4 Hz, 1H), 3.80 (s, 3H), 3.75-3.67 (m, 2H), 3.63-3.44 (m, 2H), 3.32-3.24 (m, 1H) 1.68 (s, 3H), 1.38 (s, 9H). MS (EI+) m/z 473 (M+H)⁺. Step 5: methyl 2-[4-(tert-butoxycarbonyl)-1,2-dimethylpiperazin-2-yl]-5,6-dihydroxypyrimidine-4-carboxylate (C-45).

Crude material methyl 5-(benzoyloxy)-2-[4-(tert-butoxycarbonyl)-2-methylpiperazin-2-yl]-6-hydroxypyrimidine-4-carboxylate (C-44) obtained in step 1 was dissolved in MeOH, and NaCNBH₃ (2.8 eq), AcONa (3.2 eq) and HCHO (37% in H₂O, 4eq) were added. The reaction mixture was stirred at room temperature. After 30′, the solvent was evaporated and the crude solid (C-45) obtained washed with Et₂O.

MS (EI+) m/z 383 (M+H)⁺. Step 6: tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-3,4-dimethylpiperazine-1-carboxylate (C-46).

Crude material obtained methyl 2-[4-(tert-butoxycarbonyl)-1,2-dimethylpiperazin-2-yl]-5,6-dihydroxypyrimidine-4-carboxylate (C-45) was dissolved in MeOH and p-fluorobenzylamine (5.0 eq) was added. The mixture was refluxed till the consumption of the starting material was completed; then solvent was evaporated and the crude solid (C-46) obtained washed with Et₂O.

MS (EI+) m/z 476 (M+H)⁺. Step 7: 2-(1,2-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (C-47).

Crude material tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimdin-2-yl)-3,4-dimethylpiperazine-1-carboxylate (C-46) was stirred in DCM/TFA (1:1) for 1 hour. Evaporation of the solvent afforded the crude title compound (C47).

MS (EI+) m/z 376 (M+H)⁺.

Step 8: N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1,2,4trimethylpiperazin-2-yl)pyrimidine-4-carboxamide hydrochloride (C-48) (6).

Crude material obtained in step 2-(1,2-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (C-47) was dissolved MeOH and Et₃N (2.2 eq) was added. Then NaCNBH3 (2.8 eq), AcONa (3.2 eq) and HCHO (37% in H₂O, 4 eq) were added. The reaction mixture was stirred at room temperature over night.

The reaction mixture was evaporated and the residue purified by preparative HPLC (C18, gradient of CH₃CN/H₂O+0.01% TFA) to give the title product (C-48) as trifluoroacetate salt.

¹H-NMR (CD₃CN+TFA, 280K, 600 MHz) δ: 7.50-7.38 (m, 2H), 7.13-7.07 (m, 2H), 4.66-4.51 (m, 2H), 4.00-3.72 (m, 4.3H), 3.60-3.56 (t, J=12.7 Hz, 0.7 H), 3.49-3.44 (t, J=15.5 Hz, 1 H), 3.04 (s, 2H), 2.91 (s, 1H), 2.73 (s, 1H), 2.69 (s b, 2H), 2.05 (s,1H) 1.95 (2H obscured by solvent). MS (EI+) m/z 390 (M+H)⁺.

EXAMPLE 8 N-(4-Fluorobenzyl)-5,6-dihydroxy-2-(1-methylpiperidin-2-yl)pyrimidine-4-carboxamide (D-2)

Methyl 5-(benzoyloxy)-6-hydroxy-2-piperidin-2-ylpyrimidine-4-carboxylate (D-1)(prepared from 1-[(benzyloxy)carbonyl)]piperidine-2-carboxylic acid by procedures similar to those set forth in Scheme A) was dissolved in the minimal amount of chloroform. To the stirred solution were added tetrahydrofuran, triethylamine (5 eq.) and methyl iodide (3 eq.), and the reaction was stirred at 40° C. After 30 min, triethylamine (3 eq.) and methyl iodide (2 eq.) were added and mixture was stirred for 30 min at 40° C. After evaporation of volatiles, the residue was taken up into N-methylpyrrolidinone and treated with 3 eq. of 4-fluorobenzylamine at 95° C. for 15 min. The title product (D-2) was isolated as its trifluroacetate salt by RP-HPLC (C18, water/acetonitrile with 0.1% of trifluoroacetic acid as eluant).

¹H NMR (DMSO d₆, 400 MHz) δ 13.1 (bs, 1 H), 12.2 (s, 1 H), 9.45 (bs, 1 H), 9.34 (t, J=6.4 Hz, 1 H), 7.37 (dd, J=5.6 Hz, J=8.4 Hz, 2 H), 7.18 (t, J=8.8 Hz, 2 H), 4.57 (d, J=6.4 Hz, 2 H), 4.05 (bs, 1 H), 3.61 (bd, J=12.4 Hz, 1 H), 3.52-3.50 (m, 1 H), 2.78 (bs, 3 H), 2.16 (d, J=13.6 Hz, 1 H), 1.92-1.80 (m, 2 H), 1.65-1.46 (m, 3 H). MS m/z 361 (M+H)⁺.

EXAMPLE 9 N-(4-Fluorobenzyl)-5,6-dihydroxy-2-(morpholin-4-ylmethyl)pyrimidine-4-carboxamide

Step 1: 2-(Diethoxymethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (E-2).

To a solution of methyl 2-(diethoxymethyl)-5,6-dihydroxypyrimidine-4-carboxylate E-1 (prepared from diethoxyacetonitrile by procedures similar to those set forth in Scheme A) (1.0 eq.) in dry MeOH was added 4-F-benzylamine (3 eq.), stirring at reflux overnight. Solvent was removed in vacuo and the solid residue washed with Et₂O and dried. This material dissolved in CHCl₃ was washed with 2N HCl, brine and dried over Na₂SO₄. Evaporation of solvents gave E-2 as a brown powder.

¹H NMR (300 MHz, DMSO-d₆) δ 12.62 (bs, 1 H), 12.51 (bs, 1 H), 9.22 (t, J=6.2 Hz, 1 H), 7.36 (dd, J=8.5, 5.7 Hz, 2 H), 7.14 (t, J=8.9 Hz, 2H), 5.12 (s, 1 H), 4.45 (d, J=6.3 Hz, 2 H), 3.71-3.41 (m, 4 H), 1.15 (t, J=7.0 Hz, 6 H). MS m/z 366 (M+H)⁺. Step 2: N-(4-Fluorobenzyl)-2-formyl-5,6-dihydroxypyrimidine-4-carboxamide (E-3).

A solution of E-2 in 100% formic acid was stirred at 50° C. for 1.5 hours. Volatiles were removed in vacuo and solid residue triturated with Et₂O obtaining after drying E-3 as a white solid.

¹H NMR (300 MHz, DMSO) δ 13.19 (bs, 2 H), 9.62 (t, J=6.3 Hz, 1 H), 9.41 (s, 1 H), 7.40 (dd, J=8.5, 5.7 Hz, 2 H), 7.17 (t, J=8.8 Hz, 2 H), 4.49 (d, J=6.4 Hz, 2 H). MS m/z 292 (M+H)⁺.

Step 3: N-(4-Fluorobenzyl)-5,6-dihydroxy-2-(morpholin-4-ylmethyl)pyrimidine-4-carboxamide (E4).

To a solution of E-3 in dry dichloroethane was added morpholine (1 eq.), stirring at room temperature for 30 minutes. NaB(OAc)₃H (1.4 eq.) was added and the reaction stirred at room temperature one more hour. Volatiles were removed in vacuo and solid residue purified by RP-HPLC on a C18 column, eluents water/acetonitrile+0.1% TFA, to give E-4 as its trifluoroacetate salt.

¹H NMR (300 MHz, DMSO-d6, 330 K) δ 9.05 (bt, 1 H), 7.38 (dd, J=8.5, 5.6 Hz, 2 H), 7.15 (t, J=8.8 Hz, 2 H), 4.51 (d, J=6.3 Hz, 2 H), 3.85 (bs, 2 H), 3.74 (t, J=4.6 Hz, 4 H), 2.98 (bs, 4 H). MS m/z 363 (M+H)⁺.

EXAMPLE 10 N-(4-Fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide

Step 1: 4,5-Dihydroxy-6-(methoxycarbonyl)pyrimidine-2-carboxylic acid (F-2).

2-Ethoxycarbonyl-4,5-dihydroxy-6-(methoxycarbonyl)pyrimidine (F-1) [obtained from ethyl amino(hydroxyimino)ethanoate (Branco et al., Tetrahedron 1992, 40: 6335) by procedures similar to those set forth in Scheme A] was suspended in dioxane/THF 2:1 and 1N NaOH was added. After 20 min the mixture was acidified with 1N HCl, concentrated and filtered to give F-2.

¹H NMR (DMSO-d₆, 300 K, 400 MHz) δ 13.10 (bs, 1 H), 11.11 (bs, 1 H), 3.82 (s, 3 H). MS m/z 213 (M−H)⁻. Step 2: Methyl 5,6-dihydroxypyrimidine-4-carboxylate (F-3).

A solution of F-2 in HCl 1N was stirred for 6 hours at 90° C. The reaction mixture was filtered and the solid washed with HCl 1N. Evaporation of the filtrate afforded F-3 as a solid.

¹H NMR (DMSO d₆, 300 K, 400 MHz) δ 7.75 (s, 1 H), 3.82 (s, 3 H).

Step 3: N-(4-Fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (F-4).

F-3 was dissolved in DMF and 4-fluorobenzylamine (3 eq.) was added. After 2 hours at 90° C. the mixture was evaporated. The title product F-4 was purified by preparative HPLC (C18, 5 μm, gradient of CH₃CN/H₂O+0.01% TFA).

¹H NMR (DMSO d₆, 300 K, 400 MHz) δ 12.72 (bs, 1 H), 12.54 (bs, 1H), 9.48 (bs, 1 H), 7.77 (s, 1 H), 7.36 (t, J=8.0 Hz, 2 H), 7.14 (t, J=8.8 Hz, 2 H), 4.43 (d, J=6.3 Hz, 2 H). MS m/z 262 (M−H)⁻.

EXAMPLE 11 2-{4-[({[(2-chlorophenyl)sulfonyl]amino}carbonyl)amino]thien-3-yl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4 carboxamide

Step 1: Methyl 2-{4-[({[(2-chlorophenyl)sulfonyl]amino}carbonyl)amino]-thien-3-yl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4 carboxylate (G-2).

A solution of methyl 2-(4-aminothien-3-yl)5,6-dihydroxypyrimidine-4-carboxylate trifluoroacetate (1 eq.) G-1 (obtained from the deprotection of the corresponding Boc protected compound) and 2-chlorobenzensulfonylisocyanate (1.02 eq.) in pyridine was stirred at room temperature for 12 h. Pyridine was removed by concentration under reduced pressure. 1N HCl was added to the residue and the resulting solid was collected by filtration. The solid was triturated with H₂O and then Et₂O to give the title compound.

¹H NMR (400 MHz, DMSO) δ 13.17 (bs, 1 H), 11.70 (bs, 1 H), 10.91 (bs, 1 H), 10.80 (bs, 1 H), 8.35 (d, J=3.35 Hz, 1 H), 8.11 (d, J=7.33 Hz, 1 H), 7.77 (m, 2 H), 7.63-7.57 (m, 1 H), 7.58 (d, J=3.35 Hz, 1 H), 3.88 (s, 3 H). MS m/z 485 (M+H)⁺.

Step 2: 2-{4-[({[(2-chlorophenyl)sulfonyl]amino}carbonyl)amino]thien-3-yl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4 carboxamide (G-3).

A solution of G-2 (1 eq.) and 2,3-dimethoxybenzylamine (1 eq.) in DMF was stirred at 50° C. for 12 h. DMF was removed by concentration under reduced pressure. 1N HCl was added to the residue. After filtration a solid was obtained which was triturated with water and then Et₂O. The title product G-3 was obtained by HPLC purification (Nucleosil, gradient: MeCN/H₂O 30%-90% in 10 min) to give the title compound as a solid.

¹H NMR (400 MHz, DMSO) δ 13.03 (bs, 1 H), 12.65 (bs, 1 H), 11.60 (bs, 1 H), 9.47 (bs, 1 H), 9.20 (bs, 1 H), 8.11 (d, J=7.88 Hz, 1 H), 8.05 (m, 1 H), 7.68 (m, 2 H), 7.59 (m, 2 H), 7.07 (app. t, J=7.94 Hz, 1 H), 6.96 (m, 2 H), 4.57 (s, 1 H), 4.56 (s, 1 H), 3.80 (s, 6 H). MS m/z 620 (M+H)⁺.

EXAMPLE 12 N⁴-(4-fluorobenzyl)-5,6-dihydroxy-N²-(pyridin-2-ylmethyl)pyrimidine-2,4-dicarboxamide

2-Ethoxycarbonyl-4,5-dihydroxy-6-(methoxycarbonyl)pyrimidine (F-1) was dissolved in DMF and 4-fluorobenzylamine (2.1 eq.) added. After stirring for 5 h at 90° C., a further addition of 4-fluorobenzylamine (0.61 eq.) was done and the mixture was stirred at the same temperature overnight. To this mixture, containing N-(4-fluorobenzyl)-2-ethoxycarbonyl-5,6-dihydroxy-pyrimidine-4-carboxamide (H-2), 2-picolylamine (3 eq.) was added and the reaction was stirred at 90° C. for 3 h. The product was purified by preparative RP-HPLC (gradient of CH₃CN/H₂O+0.01% TFA), to give the title compound (H-3) as its trifluoroacetate salt

¹H NMR (DMSO-d₆, 300K, 400 MHz) δ 12.90 (bs, 1 H), 12.74 (bs, 1 H), 9.81 (t, J=6.7 Hz, 1 H), 9.74 (t, J=6.7 Hz, 1 H), 8.54 (d, J=4.8 Hz, 1 H), 7.82 (t, J=6.9 Hz, 1 H), 7.40-7.30 (m, 4 H), 7.18 (t, J=8.8 Hz, 2 H), 4.61 (d, J=6.4 Hz, 2 H), 4.56 (d, J=6.4 Hz, 2 H). MS m/z 398 (M+H)⁺.

EXAMPLE 13 2-(1-benzoyl-2,3-dihydro-1H-indol-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide

Step 1: Preparation of Compound I-2

Compound I-1 (prepared from indoline-2-carboxylic acid by protection of the nitrogen and following procedures similar to those set forth in Scheme A) was dissolved in MeOH/EtOAc (1:4) and hydrogenated at atmospheric pressure on 10% Pd/C overnight, crude product I-2 was obtained after filtration and evaporation. Step 2: Preparation of Compound I-3

Crude product I-2 was dissolved in THF, followed by pyridine (8 eq.), and PhCOCl (4 eq.). Crude product I-3 was obtained after being stirred at room temperature overnight and solvent evaporation.

Step 3: 2-(1-benzoyl-2,3-dihydro-1H-indol-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (I-4).

The crude I-3 dissolved in DMF and 4-fluorobenzylamine (4 eq.) added. The mixture was stirred at 90° C. for 4 hours. The title product I-4 was purified by preparative RP-HPLC (C18, gradient of CH₃CN/H₂O+0.01% TFA).

¹H NMR (DMSO d₆, 340 K, 300 MHz) δ 12.63 (bs, 1 H), 11.92 (bs, 1 H), 8.26 (bs, 1 H), 7.45-6.96 (m, 13 H), 5.38 (dd, J=4.5 Hz, J=10.0 Hz, 1H), 4.48-4.36 (m, 2H), 3.60 (dd, J=10.2 Hz, J=16.4 Hz, 1 H), 3.19 (dd, J=16.4 Hz, J=4.4 Hz, 1 H). MS m/z 485 (M+H)⁺.

EXAMPLE 14 N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-yl]pyrimidine-4-carboxamide

Step 1: Preparation of Compound I-6

The benzoyl protected pyrimidine I-5 [prepared from tetrahydroquinoline-2-carboxylic acid (Robl et al, Tetrahedron Letters, 1995, 36, 1593) by protection of the nitrogen and following procedures similar to those set forth in Scheme A] was dissolved in EtOAc and hydrogenated at atmospheric pressure on 10% Pd/C at room temperature overnight. I-6 was obtained after filtration and evaporation of the organic solvent. Step 2: Preparation of Compound I-7

The residue was dissolved in dichloromethane and picolinic acid (1.1 eq.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.3 eq.), hydroxybenzotriazole (1.3 eq.), and diethylisopropylamine (1.3 eq.) were added. Further additions of the reactants were made until complete consumption of the starting material. Mixture was evaporated to give crude I-7.

Step 3: N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-yl]pyrimidine-4-carboxamide (I-8)

The crude I-7 product was dissolved in MeOH and 4-fluorobenzylamine (3 eq.) was added The reaction mixture was refluxed overnight. The product was purified by preparative RP-HPLC (C18 gradient of CH₃CN/H₂O+0.01% TFA), to give I-8 as its trifluoroacetate salt.

¹H-NMR (DMSO-d₆, 400 MHz, 340 K) δ 12.65 (bs, 1 H), 11.81 (bs, 1 H), 8.37 (d, J=4.4 Hz, 1 H), 7.92 (bt, 1 H), 7.82 (t, J=7.0 Hz, 1 H), 7.54 (d, J=7.6 Hz, 1 H), 7.38 (t, J=5.4 Hz, 1 H), 7.27 (t, J=5.4 Hz, 2 H), 7.14-7.10 (m, 3 H), 6.91 (t, J=6.7, 1 H), 6.70-6.50 (m, 2 H), 5.45 (t, J=7.2 Hz, 1 H), 4.45-4.35 (m, 2 H), 2.70-2.80 (m, 2 H), 2.05 (bs, 1 H), one proton obscured by DMSO MS m/z 500 (M+H⁺).

EXAMPLE 15 2-Benzyl-N-(4-fluorobenzyl)-5-hydroxy-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide

Step 1: Methyl 2-benzyl-5-[(tert-butoxycarbonyl)oxy]-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxylate (N-2)

To a stirred solution of methyl 2-benzyl-5-[(tert-butoxycarbonyl)oxy]-6-hydroxypyrimidine-4-carboxylate (N-1) (prepared from B-5 in Example 3, Step 1 by protection of the 5-hydroxyl group with pivaloyl chloride using a procedure similar to those set forth in Example 6, Step 2) in THF, CsCO₃ (2 eq.) and 4-(2-chloroethyl)morpholine (1.5 eq.) hydrochloride were added and mixture reacted at 60° C. for 1 h. Further addition of 4-(2-chloroethyl)morpholine (1 eq.) allowed the complete consumption of starting material after 2 h. The mixture was then allowed to cool to room temperature, poured into EtOAc, extracted with brine, dried (Na₂SO₄), filtered and concentrated.

Step 2: 2-Benzyl-N-(4-fluorobenzyl)-5-hydroxy-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide (N-3)

The oily residue containing N-2 was taken into DMF and treated with 3 eq. of 4-fluorobenzylamine at 90° C. for 1 h. The title compound (N-3) was isolated as its trifluoroacetate salt by RP-HPLC (C18, water/acetonitrile with 0.1% of TFA as eluant).

¹H NMR (DMSO-d₆, 400 MHz) δ 12.15 (bs, 1 H), 9.95 (bs, 1 H), 9.75 (t, J=6.4 Hz, 1 H), 7.38 (dd, J=8.5 Hz, J=5.7 Hz, 2 H), 7.34-7.27 (m, 4 H), 7.23-7.14 (m, 3 H), 4.67 (bs, 2 H), 4.49 (d, J=6.4 Hz, 2 H), 4.07 (s, 2 H), 4.00-3.90 (m, 2 H), 3.70-3.40 (m, 6 H), 3.25-3.10 (m, 2 H). MS m/z 467 (M+H⁺).

EXAMPLE 16 N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-morpholin-4-ylethyl)pyrimidine-4-carboxamide

Step 1:

To a stirred solution of 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide hydrochloride (prepared as described in example 4) in NMP an excess of morpholine (10 eq.) was added and mixture was stirred over night at 100° C. After cooling to room temperature, title product was isolated by RP HPLC (MeCN/H₂O containing 0.1% TFA as eluant).

¹H NMR (DMSO-d₆) δ 12.33 (bs, 1 H), 9.41 (t, J=6.0 Hz, 1H), 7.39 (dd, J=8.6 Hz, J=5.5 Hz, 2 H), 7.19 (t, J=9.1 Hz, 2 H), 4.56 (d, J=6.0 Hz, 2H), 3.88 (bs, 2 H), 3.29 (bs, 2 H), 1.68 (s, 6 H). MS m/z (M⁺+1) 391

Tables 1 to 25 below list compounds of the present invention which have been prepared. The Tables provide the structure and name of each compound, the mass of its molecular ion plus 1 (M⁺) or molecular ion minus 1 (M⁻) as determined via FIA-MS, and the synthetic scheme employed to prepare the compound. When the compound was prepared as a salt, the identity of the salt is included with the compound name. The synthetic scheme identified as “A*” in the Tables is identical to Scheme A above, except for an additional deprotection step to remove Boc, Cbz, or benzyl present from the substituent in the 2-position of the pyrimidine ring. TABLE 1 Exp Structure Name M+ Scheme 1

N-benzyl-5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 328 A 2

N-cyclohexyl-5,6-dihydroxy-2-thien- 2-ylpyrimidine-4-carboxamide 320 A 3

5,6-dihydroxy-N-(pyridin-2- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide (HCl salt) 329 A 4

5,6-dihydroxy-2-thien-2-yl-N-[2- (trifluoromethyl)benzyl]pyrimidine- 4-carboxamide 396 A 5

5,6-dihydroxy-2-thien-2-yl-N-[3- (trifluoromethyl)benzyl]pyrimidine- 4-carboxamide 396 A 6

5,6-dihydroxy-N-(4-methoxybenzyl)- 2-thien-2-ylpyrimidine-4- carboxamide 358 A 7

N-(2-bromobenzyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 407 A 8

5,6-dihydroxy-N-(pyridin-4- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide (HCl salt) 329 A 9

5,6-dihydroxy-N-(2-methoxybenzyl)- 2-thien-2-ylpyrimidine-4- carboxamide 358 A 10

N-(2,6-dimethoxybenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 388 A 11

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 388 A 12

5,6-dihydroxy-N-(2-methylbenzyl)- 2-thien-2-ylpyrimidine-4- carboxamide 342 A 13

N-(2,4-dichloro-6-methylbenzyl)- 5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 411 A 14

N-(2-fluorobenzyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 346 A 15

5,6-dihydroxy-2-thien-2-yl-N-[4- (trifluoromethyl)benzyl]pyrimidine- 4-carboxamide 396 A 16

N-(1,1′-biphenyl-2-ylmethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 404 A 17

5,6-dihydroxy-N-[4-(1,2,3- thiadiazol-4-yl)benzyl]-2-thien-2- ylpyrimidine-4-carboxamide 412 A 18

N-(2,5-dichlorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 397 A 19

N-(2-chloro-4-fluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 380 A 20

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 376 A 21

N-(2,3-dichlorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 397 A 22

5,6-dihydroxy-2-thien-2-yl-N-[2- (trifluoromethoxy)benzyl]pyrimidine- 4-carboxamide 412 A 23

5,6-dihydroxy-N-[2- (methylthio)benzyl]-2-thien-2- ylpyrimidine-4-carboxamide 374 A 24

5,6-dihydroxy-N-(3-phenylprop-2- ynyl)-2-thien-2-ylpyrimidine-4- carboxamide 352 A 25

5,6-dihydroxy-N-prop-2-ynyl-2- thien-2-ylpyrimidine-4-carboxamide 276 A 26

5,6-dihydroxy-N-(2-hydroxyphenyl)- 2-thien-2-ylpyrimidine-4- carboxamide 330 A 27

N-(1-benzofuran-2-ylmethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 368 A 28

N-(3-chloro-4-fluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 380 A 29

N-(3,5-dichlorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 397 A 30

N-(2,5-dimethoxybenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 388 A 31

N-(2,3-dihydro-1-benzofuran-5- ylmethyl)-5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 370 A 32

N-(2-chloro-6-phenoxybenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 454 A 33

N-(1,2-diphenylethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 418 A 34

N-(1,1′-biphenyl-3-ylmethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 404 A 35

N-(2,3-dimethylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 356 A 36

N-(2-chloro-6-methylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 376 A 37

5,6-dihydroxy-N-(pyridin-3- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide (HCl salt) 329 A 38

5,6-dihydroxy-2-thien-2-yl-N-[3- (trifluoromethoxy)benzyl]pyrimidine- 4-carboxamide 412 A 39

N-[3-fluoro-5-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-thien- 2-ylpyrimidine carboxamide 414 A 40

N-[2-fluoro-5-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-thien- 2-ylpyrimidine carboxamide 414 A 41

N-(3,5-difluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 364 A 42

N-(4-chloro-2-fluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 380 A 43

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-thien-2-ylpyrimidine-4- carboxamide 358 A 44

N-[4-fluoro-2-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-thien- 2-ylpyrimidine-carboxamide 414 A 45

N-(3-chlorobenzyl)-5,6-dihydroxy- 2-thien-2-ylpyrimidine-4- carboxamide 362 A 46

N-(2-chlorobenzyl)-5,6-dihydroxy- 2-thien-2-ylpyrimidine-4- carboxamide 362 A 47

5,6-dihydroxy-N-(1-phenylpropyl)- thien-2-ylpyrimidine-4- carboxamide 356 A 48

N-[4-fluoro-3-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-thien- 2-ylpyrimidine-4-carboxamide 414 A 49

benzyl 2-{4-[(benzylamino)- carbonyl]-5,6-dihydroxy- pyrimidin-2-yl}thien-3- ylcarbamate 477 A 50

N-(2,3-dihydro-1H-inden-2-yl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 354 A 51

N-(3-fluorobenzyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 346 A 52

5,6-dihydroxy-N-(4-hydroxy-3- methoxybenzyl)-2-thien-2- ylpyrimidine-4-carboxamide 374 A 53

N-(3,4-dichlorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine carboxamide 397 A 54

N-(4-fluorobenzyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 346 A 55

5,6-dihydroxy-N-(3-nitrobenzyl)-2- thien-2-ylpyrimidine-4-carboxamide 373 A 56

N-(2,4-dichlorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine carboxamide 397 A 57

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 364 A 58

5,6-dihydroxy-2-thien-2-yl-N- (2,4,6-trimethoxybenzyl)pyrimidine- 4-carboxamide 418 A 59

5,6-dihydroxy-N-(1- naphthylmethyl)-2-thien-2- ylpyrimidine-4-carboxamide 378 A 60

N-(3,4-dimethoxybenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine- 4-carboxamide 388 A 61

N-(2,6-difluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine- 4-carboxamide 364 A 62

N-(2,5-difluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine- 4-carboxamide 364 A 63

N-(4-chlorobenzyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 362 A 64

N-(2.4-difluorobenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine- 4-carboxamide 364 A 65

5,6-dihydroxy-2-thien-2-yl-N-(3,4,5- trimethoxybenzyl)pyrimidine- 4-carboxamide 418 A 66

N-(3,5-dimethoxybenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine- 4-carboxamide 388 A 67

5,6-dihydroxy-N-(4-methylbenzyl)- 2-thien-2-ylpyrimidine-4- carboxamide 342 A 68

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-thien-2-ylpyrimidine-4- carboxamide 372 A 69

5,6-dihydroxy-2-thien-2-yl-N- (thien-2-ylmethyl)pyrimidine-4- 4-carboxamide 334 A 70

N-benzyl-2-[3-({[(2-chloro- benzyl)amino]carbonyl} amino)thien- 2-yl]-5,6-dihydroxypyrimidine-4- carboxamide

08 (M−1

A 71

N-(2,3-dihydro-1H-inden-1-yl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 354 A 72

N-[1-(3-furyl)ethyl]-5,6-dihydroxy- 2-thien-2-ylpyrimidine-4- carboxamide 332 A 73

N-(1,3-benzodioxol-5-yhnethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 372 A 74

5,6-dihydroxy-N-[1-(5-oxo-4,5- dihydro-1H-1,2,4-triazol-3-yl)ethyl]- 2-thien-2-ylpyrimidine-4- carboxamide 349 A 75

5,6-dihydroxy-N-(1,3-thiazol-5- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide 335 A 76

5,6-dihydroxy-N-(2-methoxybenzyl) 2-(5-nitrothien-2-yl)pyrimidine-4- carboxamide 403 A 77

N-benzyl-5,6-dihydroxy-2-(5- nitrothien-2-yl)pyrimidine-4- carboxamide 373 A 78

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(5-nitrothien-2- yl)pyrimidine-4-carboxamide 421 A 79

N-benzyl-5,6-dihydroxy-2-(5- methylthien-2-yl)pyrimidine-4- carboxamide 342 A 80

N-(2,4-dimethoxybenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 388 A 81

N-[3,5-bis(trifluoromethyl)benzyl]- 5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 464 A 82

5,6-dihydroxy-N-(1H-indol-3- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide 367 A 83

N-[1-(2-furyl)ethyl]-5,6-dihydroxy- 2-thien-2-ylpyrimidine-4- carboxamide 332 A 84

5,6-dihydroxy-N-(isoxazol-3- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide 319 A 85

5,6-dihydroxy-N-[(4-methyl-1,2,5- oxadiazol-3-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide 334 A 86

5,6-dihydroxy-N-(quinolin-3- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide 379 A 87

N-(1-benzothien-3-blmethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine carboxamide 384 A 88

5,6-dihydroxy-N-(1H-indol-2- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide 367 A 89

5,6-dihydroxy-N-(1,3-thiazol-2- ylmethyl)-2-thien-2-ylpyrimidine-4- carboxamide 335 A 90

5,6-dihydroxy-N-(imidazo[1,2- a]pyridin-2-ylmethyl)-2-thien-2- ylpyrimidine-4-carboxamide 368 A 91

N-[(1,3-dimethyl-1H-pyrazol-4- yl)methyl]-5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 346 A 92

N-(1-benzothien-2-ylmethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 384 A 93

5,6-dihydroxy-N-[(5-phenyl-1,3,4- oxadiazol-2-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide 396 A 94

N-(3-chloro-2-methylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 376 A 95

N-(5-chloro-2-methylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 376 A 96

N-(4-chloro-2-methylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 376 A 97

N-(2,5-dimethylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 356 A 98

N-(2,4-dimethylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 356 A 99

N-(3,4-dimethylbenzyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 356 A 100

N-[(1R)-2,3-dihydro-1H-inden-1-yl]- 5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 354 A 101

N-(2-furylmethyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 318 A 102

5,6-dihydroxy-N-(1-phenylethyl)-2- thien-2-ylpyrimidine-4-carboxamide 342 A 103

5,6-dihydroxy-N-[(1S)-1- phenylethyl]-2-thien-2-ylpyrimidine- 4-carboxamide 342 A 104

5,6-dihydroxy-N-[(1R)-1- phenylethyl]-2-thien-2-ylpyrimidine- 4-carboxamide 342 A 105

methyl 4-({[(5,6-dihydroxy-2-thien- 2-ylpyrimidin-4- yl)carbonyl]amino}methyl)benzoate 386 A 106

N-(3-bromobenzyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 407 A 107

N-(4-bromobenzyl)-5,6-dihydroxy-2- thien-2-ylpyrimidine-4-carboxamide 407 A 108

5,6-dihydroxy-N-[4- (methylsulfonyl)benzyl]-2-thien-2- ylpyrimidine-4-carboxamide 406 A 109

5,6-dihydroxy-N-(1,2,3,4- tetrahydronaphthalen-1-yl)-2-thien- 2-ylpyrimidine-4-carboxamide 368 A 110

N-[(1S)-2,3-dihydio-1H-inden-1-yl]- 5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 354 A 111

5,6-dihydroxy-2-thien-2-yl-N-{[6- (trifluoromethyl)pyridin-3- yl]methyl}pyrimidine-4- carboxamide (HCl salt) 397 A 112

N-[(1,5-dimethyl-1H-pyrazol-4- yl)methyl]-5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 346 A 113

5,6-dihydroxy-N-[(3-methylisoxazol- 5-yl)methyl]-2-thien-2-ylpyrimidine- 4-carboxamide 333 A 114

N-(2,3-dimethoxybenzyl)-5-hydroxy- 6-methoxy-2-thien-2-ylpyrimidine-4- carboxamide 402 A 115

N-(1,3-benzodioxol-5-ylmethyl)-5- hydroxy-6-methoxy-2-thien-2- ylpyrimidine-4-carboxamide 386 A 116

N-(4-fluorobenzyl)-5-hydroxy-6- methoxy-2-thien-2-ylpyrimidine-4- carboxamide 360 A 117

N-(2,4-difluorobenzyl)-5-hydroxy-6- methoxy-2-thien-2-ylpyrimidine-4- carboxamide 378 A 118

4-({[(5,6-dihydroxy-2-thien-2- ylpyrimidin-4-yl)carbonyl]- amino}methyl)benzoic acid 372 A 119

N-[3-(3-acetylphenyl)prop-2-ynyl]- 5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 394 A 120

5,6-dihydroxy-N-phenyl-2-thien-2- ylpyrimidine-4-carboxamide 314 A 121

5,6-dihydroxy-N-(3-methylbenzyl)- 2-thien-2-ylpyrimidine-4- carboxamide 342 A 122

5,6-dihydroxy-N-[(2-methyl-1,3- thiazal-4-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (HCl salt) 349 A 123

5,6-dihydroxy-N-[(4-pbenyl-1,3- thiazol-2-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (HCl salt) 411 A 124

5,6-dihydroxy-N-[(5-methyl-1H- 1,2,4-triazol-3-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (HCl salt) 333 A 125

5,6-dihydroxy-N-[(4-methyl-1,3- thiazol-2-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (HCl salt) 349 A 126

5,6-dihydroxy-N-(6,7,8,9-tetrahydro- 5H-benzo[7]annulen-7-ylmethyl)-2- thien-2-ylpyrimidine-4-carboxamide 396 A 127

5,6-dihydroxy-N-[(1-methyl-1H- pyrazol-4-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (TFA salt) 332 A 128

5,6-dihydroxy-N-[(2-phenyl-1,3- thiazol-4-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (TFA salt) 411 A 129

5,6-dihydroxy-N-(1H-imidazol-2- ylethyl)-2-thien-2-ylpyrimidine-4- carboxamide (TFA salt) 318 A 130

tert-butyl 3-({[(5,6-dihydroxy-2- thien-2-ylpyrimidin-4-yl)carbonyl]- amino}methyl)benzylcarbamate 457 A 131

tert-butyl [3-({[(5,6-dihydroxy-2- thien-2-ylpyrimidin-4-yl)carbonyl]- amino} methyl)phenyl]acetate 442 A 132

5,6-dihydroxy-N-[2-(1H-indol-3- yl)benzyl]-2-thien-2-ylpyrimidine-4- carboxamide 443 A 133

N-[3-(aminomethyl)benzyl]-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide (TFA salt) 357 A 134

N-[2-(aminomethyl)benzyl]-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 357 A 135

5,6-dihydroxy-N-[2-(1H-indol-3- ylmethyl)benzyl]-2-thien-2- ylpyrimidine-4-carboxamide 457 A 136

tert-butyl 3-[2-({[(5,6-dihydroxy-2- thien-2-ylpyrimidin-4-yl)carbonyl]- amino}methyl)benzyl]- 1H-indole-1-carboxylate 557 A 137

5,6-dihydroxy-N-[3-(1H-indol-3- ylmethyl)benzyl]-2-thien-2- ylpyrimidine-4-carboxamide 457 A 138

tert-butyl 3-[3-({[(5,6-dihydroxy-2- thien-2-ylpyrimidin-4- yl)carbonyl]amino}methyl)benzyl]- 1H-indole-1-carboxylate 557 A 139

5,6-dihydroxy-N-[4-(1H-indol-3- ylmethyl)benzyl]-2-thien-2- ylpyrimidine-4-carboxamide 457 A 140

5,6-dihydroxy-N-[3-(1H-indol-3- yl)benzyl]-2-thien-2-ylpyrimidine-4- carboxamide 443 A 141

2-[3-({[(2-chlorobenzyl)amino]- carbonyl}amino)thien-2-yl]-5,6- dihydroxypyrimidine-4-carboxamide 420 A 142

N-(2-chlorobenzyl)-2-[3-({[(2- chlorobenzyl)amino]carbonyl}- amino)thien-2-yl]-5,6-dihydroxy- pyrimidine-4-carboxamide

642 (M-1

A 143

5,6-dihydroxy-N-methyl-N-(1- naphthylmethyl)-2-thien-2- ylpyrimidine-4-carboxamide 392 A 144

5,6-dihydroxy-N-[(1R)-1-(1- naphthyl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 392 A 145

5,6-dihydroxy-N-[(1S)-1-(1- naphthyl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 392 A 146

5,6-dihydroxy-N-[(1R)-2-hydroxy-1- phenylethyl]-2-thien-2-ylpyrimidine- 4-carboxamide 358 A 147

5,6-dihydroxy-N-[2-(2- methoxyphenyl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 372 A 148

5,6-dihydroxy-N-[2-(4- nitrophenyl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 387 A 149

5,6-dihydroxy-N-[2-(1H-indol-3- yl)ethyl]-2-thien-2-ylpyrimidine-4- carboxamide 381 A 150

5,6-dihydroxy-N-[2-(5-methoxy-1H- indol-3-yl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 411 A 151

5,6-dihydroxy-N-[3-(2- oxopyrrolidin-1-yl)propyl]-2-thien- ylpyrimidine-4-carboxamide 363 A 152

5,6-dihydroxy-N-[(1R)-1-(4- methoxyphenyl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 372 A 153

N-(1,3-benzodioxol-4-ylmethyl)-5,6- dihydroxy-2-thien-2-ylpyrimidine-4- carboxamide 372 A 154

N-(2-benzylphenyl)-5,6-dihydroxy- 2-thien-2-ylpyrimidine-4- carboxamide 404 A 155

N-(4-benzylphenyl)-5,6-dihydroxy- 2-thien-2-ylpyrimidine-4- carboxamide 404 A 156

N-(2,3-dihydro-1,4-benzodioxin-2- ylmethyl)-5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 386 A 157

5,6-dihydroxy-N-[(1-pyrimidin-2- ylpiperidin-3-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (TFA salt) 413 A 158

5,6-dihydroxy-N-[(4-phenyl- morpholin-2-yl)methyl]-2-thien-2- ylpyrimidine-4-carboxamide (TFA salt) 413 A 159

5,6-dihydroxy-N-(2-phenyl- cyclopropyl)-2-thien-2- ylpyrimidine-4-carboxamide 354 A 160

5,6-dihydroxy-N-[2-(2-phenyl-1H- indol-3-yl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 457 A 161

N-[(1S)-1-benzyl-2-hydroxyethyl]- 5,6-dihydroxy-2-thien-2- ylpyrimidine-4-carboxamide 372 A 162

5,6-dihydroxy-N-[(1R)-1-(3- methoxyphenyl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 372 A 163

5,6-dihydroxy-N-[(1S)-1-(3- methoxyphenyl)ethyl]-2-thien-2- ylpyrimidine-4-carboxamide 372 A 164

5,6-dihydroxy-N-[(1S)-2-hydroxy-1- phenylethyl]-2-thien-2-ylpyrimidine- 4-carboxamide 358 A 165

5,6-dihydroxy-N-[(1R,2S)-2- hydroxy-2,3-dihydro-1H-inden-1-yl]2-thien-2-ylpyrimidine-4- carboxamide 370 A 166

tert-butyl 2-({2-[4-(aminocarbonyl)- 5,6-dihydroxypyrimidin-2-yl]thien-3- yl}amino)-2-oxo-1- phenylethylcarbamate 486 A 167

2-(3-{[amino(phenyl)acetyl]- amino}thien-2-yl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 386 A 168

2-(3-{[amino(phenyl)acetyl]- amino}thien-2-yl)-N-benzyl-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 476 A

TABLE 2 1

N-(3-chlorobenzyl)-2-{4-[({[(2- chlorophenyl)sulfonyl]amino}- carbonyl)amino]thien-3-yl}-5,6- dihydroxypyrimidine-4-carboxamide 594 G 2

N-benzyl-5,6-dihydroxy-2-thien-3- ylpyrimidine-4-carboxamide 328 A 3

2-[4-({[(2,3-dichlorobenzyl)- amino]carbonyl} amino)thien- 3-yl]-5,6-dihydroxy-N- methylpyrimidine-4-carboxamide 468 G 4

2-{4-[({[(2-chlorophenyl)- sulfonyl]amino} carbonyl)- amino]thien-3-yl}-N-(2,3- dimethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 620 G 5

N-benzyl-2-(4- {[(benzylamino)carbonyl]amino}-3- thienyl)-5,6-dihydroxy-4- pyrimidinecarboxamide 476 G 6

2-{4-[({[(2- chlorophenyl)sulfonyl]amino}- carbonyl)amino]thien-3-yl}-5,6- dihydroxy-N-(2-phenylethyl)- pyrimidine-4-carboxamide 574 G 7

2-{4-[({[(2-chlorophenyl)- sulfonyl]amino} carbonyl)- amino]thien-3-yl}-5,6- dihydroxy-N-methylpyrimidine-4- carboxamide 484 G 8

N-benzyl-5,6-dihydroxy-2-[4- ({[(thien-2-ylmethyl)amino]- carbonyl}amino)thien-3-yl]- pyrimidine-4-carboxamide 482 G 9

5,6-dihydroxy-N-methyl-2-[4- ({[(phenylsulfonyl)amino]carbonyl}amino)thien-3-yl]pyrimidine-4- carboxamide 450 G

TABLE 3 1

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 365 A 2

N-(4-fluorobenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4- carboxamide 347 A 3

N-(3,4-dichlorobenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 397 A 4

N-(2-ethoxybenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4- carboxamide 373 A 5

N-(3-fluorobenzyl)-5,6- dihydroxy-2-(1,3-tbiazol-2- yl)pyrimidine-4- carboxamide 347 A 6

N-(2,4-difluorobenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 365 A 7

5,6-dihydroxy-N-(1- naphthylmethyl)-2-(1,3-thiazol- 2-yl)pyrimidine-4-carboxamide 379 A 8

N-(2-chlorobenzyl)-5,6- dihydroxy-2-(1,3- thiazol-2-yl)pyrimidine-4- carboxamide 363 A 9

5,6-dihydroxy-N-(2-methoxy- benzyl)-2-(1,3-thiazol-2-yl) pyrimidine-4-carboxamide 363 A 10

N-(4-chlorobenzyl)-5,6- dihydroxy-2-(1,3- thiazol-2-yl)pyrimidine-4- carboxamide 363 A 11

N-(3-chloro-2-methylbenzyl)- 5,6-dihydroxy-2-(1,3- thiazol-2-yl) pyrimidine-4-carboxamide 377 A 12

N-(2,5-difluorobenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 365 A 13

N-[4-fluoro-3- (trifluoromethyl)benzyl]-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 415 A 14

N-[3-fluoro-5- (trifluoromethyl)benzyl]-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 415 A 15

N-(3,4-dimethoxybenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 389 A 16

5,6-dihydroxy-2-(1,3-thiazol- 2-yl)-N-[2-(trifluoromethyl) benzyl]pyrimidine- 4-carboxamide 397 A 17

N-(3,5-difluorobenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 365 A 18

5,6-dihydroxy-N-(3-methoxy- benzyl)-2-(1,3-thiazol-2- yl)pyrimidine-4- carboxamide 359 A 19

N-(3,4-dimethylbenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 357 A 20

N-benzyl-5,6-dihydroxy-2-(1,3- thiazol-2-yl)pyrimidine-4- carboxamide 329 A 21

N-(1-benzothien-3-ylmethyl)- 5,6-dihydroxy-2-(1,3- thiazol-2-yl)pyrimidine-4- carboxamide 385 A 22

N-(2,3-dihydro-1H-inden-1-yl)- 5,6-dihydroxy-2-(1,3- thiazol-2-yl)pyrimidine- 4-carboxamide 355 A 23

N-(2,3-dihydro-1H-inden-2-yl)- 5,6-dihydroxy-2-(1,3- thiazol-2-yl)pyrimidine- 4-carboxamide 355 A 24

5,6-dihydroxy-N-(4-methoxy- benzyl)-2-(1,3-thiazol-2-yl) pyrimidine-4- carboxamide 359 A 25

N-(3-chloro-4-methylbenzyl)- 5,6-dihydroxy-2-(1,3- thiazol-2-yl)pyrimidine-4- carboxamide 377 A 26

N-[4-fluoro-2- (trifluoromethyl)benzyl]-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 415 A 27

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 389 A 28

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-(1,3- thiazol-2-yl) pyrimidine-4-carboxamide 373 A 29

5,6-dihydroxy-2-(1,3-thiazol-2- yl)-N-(2,4,6- trimethoxybenzyl)pyrimidine- 4-carboxamide 419 A 30

N-(2,4-dimethoxybenzyl)-5,6- dihydroxy-2-(1,3-thiazol-2- yl)pyrimidine-4-carboxamide 389 A 31

N-benzyl-5,6-dihydroxy-2-(6- methoxy-1,3-benzothiazol-2- yl)pyrimidine-4-carboxamide 409 A

TABLE 4 1

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (2-methyl-1,3-thiazol-4- yl)pyrimidine-4-carboxamide 361 A 2

N-(2,4-difluorobenzyl)-5,6- dihydroxy-2-(2-methyl-1,3-thiazol-4- yl)pyrimidine-4-carboxamide 379 A 3

N-benzyl-5,6-dihydroxy-2-(2- methyl-1,3-thiazol-4-yl)pyrimidine- 4-carboxamide 343 A 4

N-(1,3-benzodioxol-5-ylmethyl)-5,6- dihydroxy-2-(2-methyl-1,3-thiazol-4- yl)pyrimidine-4-carboxamide 387 A 5

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(2-methyl-1,3-thiazol-4- yl)pyrimidine-4-carboxamide 403 A

TABLE 5 1

N-benzyl-5,6-dihydroxy-2-(2- methylphenyl)pyrimidine-4- carboxamide 336 A 2

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-(2-methylphenyl)pyrimidine-4- carboxamide 380 A 3

N-[4-fluoro-3- (trifluoromethyl)benzyl]-5,6- dihydroxy-2-(2- methylphenyl)pyrimidine-4- carboxamide 422 A 4

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(2-methylphenyl)pyrimidine-4- carboxamide 354 A 5

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(2- methylphenyl)pyrimidine-4- carboxamide 396 A 6

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(2-methylphenyl)- pyrimidine-4-carboxamide 384 A 7

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-(2-methylphenyl)pyrimidine-4- carboxamide 366 A 8

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-(2-methylphenyl)- pyrimidine-4-carboxamide 372 A 9

N-(2,4-difluorobenzyl)-5,6- dihydroxy-2-(2-methylphenyl)- pyrimidine-4-carboxamide 372 A 10

N-benzyl-5,6-dihydroxy-2- phenylpyrimidine-4-carboxamide 322 A 11

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-{2-[(pyridin-2- ylcarbonyl)amino]phenyl}pyrimidine- 4-carboxamide 502 I 12

N-(4-fluoro-2-(trifluoro- methyl)benzyl]-5,6-dihydroxy- 2-(2-methylphenyl)pyrimidine- 4-carboxamide 422 A 13

N-(2,3-dihydro-1H-inden-2-yl)-5,6- dihydroxy-2-phenylpyrimidine-4- carboxamide 348 A 14

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-phenylpyrimidine-4- carboxamide 382 A 15

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[2-(isonicotinoyl- amino) phenyl]pyrimidine-4- carboxamide (HCL salt) 502 I 16

N-benzyl-2-[2-({[(2,3- dichlorobenzyl)amino]carbonyl}- amino)phenyl]-5,6- dihydroxypyrimidine-4-carboxamide 538 G 17

benzyl 4-{[(2-{4- [(benzylamino)carbonyl]-5,6- dihydroxypyrimidin-2- yl}phenyl)amino]carbonyl}- piperidine-1-carboxylate 582 I 18

N-benzyl-5,6-dihydroxy-2-[2-(1- naphthylmethoxy)phenyl]pyrimidine- 4-carboxamide 478 A 19

N-benzyl-2-[2-({[(2,5- dichlorobenzyl)amino]carbonyl}- amino]phenyl]-5,6- dihydroxypyrimidine-4-carboxamide 538 G 20

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-{2-[(pyridin-3-yl- carbonyl)amino]phenyl}pyrimidine- 4-carboxamide (TFA salt) 502 I 21

N-{2-[4-(aminocarbonyl)-5,6- dihydroxypyrimidin-2- yl]phenyl}phenylalaninamide (TFA salt) 394  A* 22

tert-butyl 3-({3-[4-(aminocarbonyl)- 5,6-dihydroxypyrimidin-2- yl]phenyl}amino)-3-oxo-1- phenylprop-2-ylcarbamate 494.2 I

TABLE 6 1

N-(3-chloro-4-fluorobenzyl)-5,6- dihydroxy-2-(3-methylphenyl)- pyrimidine-4-carboxamide 388 A 2

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(3-methylphenyl)- pyrimidine-4-carboxamide 384 A 3

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[3-(morpholin-4- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 439 B 4

N-(3-chlorobenzyl)-5,6-dihydroxy- 2-(3-methylphenyl)pyrimidine- 4-carboxamide 370 A 5

2-{-[(diethylamino)methyl]phenyl}N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 425 B 6

N-benzyl-5,6-dihydroxy-2-(3- nitrophenyl)pyrimidine-4- carboxamide 367 A 7

N-(3-chloro-4-methylbenzyl)-2-{3- [(diethylamino)methyl]phenyl}-5,6- dihydroxypyrimidine-4- carboxamide (HCl salt) 455 B 8

N-(3-chloro-4-methylbenzyl)-2-{3- [(diisopropylamino)methyl]phenyl}- 5,6-dihydroxypyrimidine-4- carboxamide (HCl salt) 483 B 9

N-benzyl-5,6-dihydroxy-2-(3- methylphenyl)pyrimidine-4- carboxamide 336 A 10

N-(1,1′-biphenyl-3-ylmethyl)-5,6- dihydroxy-2-(3-methylphenyl)- pyrimidine-4-carboxamide 412 A 11

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{3-[(2-oxopyridin-1(2H)- yl)methyl]phenyl}pyrimidine- 4-carboxamide 447 A 12

5,6-dihydroxy-N-(2-methoxybenzyl)- 2-(3-methylphenyl)pyrimidine-4- carboxamide 366 A 13

N-benzyl-5,6-dihydroxy-2-[3- (pyrrolidin-1-ylmethyl)phenyl]- pyrimidine-4-carboxamide (HCl salt) 405 B 14

2-{3-[(dimethylamino)- methyl]phenyl}-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 397 B 15

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-{3-[(2-oxopyridin- 1(2H)-yl)methyl]phenyl}pyrimidine- 4-carboxamide 477 A 16

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-{3-[(2-oxopyridin- 1(2H)-yl)methyl]phenyl}pyrimidine- 4-carboxamide 465 A 17

N-[4-fluoro-2-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-{3- [(2-oxopyridin-1(2H)-yl)methyl]- phenyl}pyrimidine-4-carboxamide 515 A 18

N-(2,3-dimethylbenzyl)-5,6- dihydroxy-2-(3-methylphenyl)- pyrimidine-4-carboxamide 364 A 19

2-(3-bromophenyl)-N-(2,3-dihydro- 1H-inden-2-yl)-5,6-dihydroxy- pyrimidine-4-carboxamide 426 A 20

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{3-[(4-methylpiperazin-1- yl)methyl]phenyl}pyrimidine- 4-carboxamide (TFA salt) 452 B 21

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[3-(piperidin-1-ylmethyl)- phenyl]pyrimidine-4- carboxamide (TFA salt) 437 B 22

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-{3-[(2-oxopyridin- 1(2H)-yl)methyl]phenyl}pyrimidine- 4-carboxamide 473 A 23

N-(3-chloro-4-methylbenzyl)-2- {3-[(3,5-dimethylpiperazin-1- yl)methyl]phenyl}-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 496 B 24

N-benzyl-5,6-dihydroxy-2-{3- [(2-oxopyridin-1(2H)-yl)methyl]- phenyl}pyrimidine-4-carboxamide 429 A 25

N-(2,4-dimethoxybenzyl)-5,6- dihydroxy-2-{3-[(2-oxopyridin- 1(2H)-yl)methyl]phenyl}pyrimidine- 4-carboxamide 489 A 26

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[3-(pyrrolidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 465 B 27

2-{3-[(diisopropylamino)- methyl]phenyl}-N-(2,3- dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 495 B 28

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-{3-[(2-oxopyridin-1(2H)- yl)methyl]phenyl}pyrimidine- 4-carboxamide 459 A 29

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(3-methylphenyl)- pyrimidine-4-carboxamide 396 A 30

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-{3-[(2-oxopyridin- 1(2H)-yl)methyl]phenyl}- pyrimidine-4-carboxamide 489 A 31

5,6-dihydroxy-2-(3-methylphenyl)- N-(3-phenylprop-2-ynyl)pyrimidine- 4-carboxamide 360 A 32

N-benzyl-2-{3-[(dimethylamino)- methyl]phenyl}-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 379 B 33

N-benzyl-2-[3-({[(3,4- dichlorobenzyl)amino]carbonyl}- amino)phenyl]-5,6-dihydroxy- pyrimidine-4-carboxamide 539 G 34

N-benzyl-5,6-dihydroxy-2-[3- (piperidin-1-ylmethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 419 B 35

N-benzyl-2-{3-[(3,5- dimethylpiperazin-1-yl)methyl]- phenyl}-5,6-dihydroxypyrimidine- 4-carboxamide (TFA salt) 448 B 36

2-{3-[(dimethylamino)methyl]- phenyl}-N-[3-fluoro-4-(trifluoro- methyl)benzyl]-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 465 B 37

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[3-(piperidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 479 B 38

N-(2,3-dimethoxybenzyl)-2-{3- [(dimethylamino)methyl]phenyl}- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 439 B 39

2-{3-[(diethylamino)methyl]phenyl}- N-(2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 467 B 40

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(3-{[(2,4,5- trichlorophenyl)thio]methyl}phenyl)- pyrimidine-4-carboxamide 607 B 41

5,6-dihydroxy-2-(3-nitrophenyl)-N- prop-2-ynylpyrimidine-4- carboxamide 315 A

TABLE 7 1

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(4-methylphenyl)pyrimidine-4- carboxamide 354 A 2

N-(2,4-difluorobenzyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 372 A 3

5,6-dihydroxy-2-(4-methylphenyl)- N-[2-(trifluoromethyl)benzyl]- pyrimidine-4-carboxamide 404 A 4

N-[4-fluoro-2-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-(4- methylphenyl)pyrimidine-4- carboxamide 422 A 5

N-(4-chlorobenzyl)-5,6-dihydroxy- 2-(4-methylphenyl)pyrimidine- 4-carboxamide 370 A 6

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 380 A 7

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-[4-(pyrrolidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TEA salt) 453 B 8

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[4-(pyrrolidin-1-ylmethyl)- phenyl]pyrimidine-4-carboxamide (TEA salt) 423 B 9

N-(3,4-dimethylbenzyl)-5,6- dihydroxy-2-[4-(morpholin-4- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 449 B 10

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-[4-(morpholin-4-ylmethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 465 B 11

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-[4-(morpholin-4- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 469 B 12

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [4-(morpholin-4-ylmethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 439 B 13

N-(3-chlorobenzyl)-5,6-dihydroxy-2- (4-methylphenyl)pyrimidine-4- carboxamide 370 A 14

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 372 A 15

2-{4-[(dimethylamino)methyl]- phenyl}-N-(3,4-dimethylbenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 407 B 16

N-(3-chloro-4-methylbenzyl)-2-{4- [(dimethylamino)methyl]phenyl}- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 427 B 17

N-(3-chloro-4-methylbenzyl)-2-{4- [(diethylamino)methyl]phenyl}-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 455 B 18

2-{4-[(diethylamino)methyl]phenyl}- N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 425 B 19

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-[4-(piperidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 467 B 20

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [4-(piperidin-1-ylmethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 437 B 21

N-(1,1′-biphenyl-3-ylmethyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 412 A 22

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[4-(morpholin-4- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 481 B 23

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-(4-methylphenyl)pyrimidine-4- carboxamide 380 A 24

N-(4-fluoro-3-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-(4-methyl- phenyl)pyrimidine-4-carboxamide 422 A 25

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-(4-methylphenyl)pyrimidine-4- carboxamide 366 A 26

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-{4-[(4-methylpiperazin-1- yl)methyl]phenyl}pyrimidine-4- carboxamide (TFA salt) 478 B 27

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-{4-[(4-methylpiperazin- 1-yl)methyl]phenyl}pyrimidine-4- carboxamide (TFA salt) 482 B 28

N-(4-fluorobenzyl)-5,6-dihydroxy-2- {4-[(4-methylpiperazin-1- yl)methyl]phenyl}pyrimidine-4- carboxamide (TFA salt) 452 B 29

N-(3,4-dimethylbenzyl)-5,6- dihydroxy-2-[4-(piperidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 447 B 30

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-[4-(piperidin-1-ylmethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 463 B 31

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [4-(1-morpholin-4-ylethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 453 B 32

2-{4-[(dimethylamino)methyl]- phenyl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 397 B 33

2-{4-[(diethylamino)methyl]phenyl}- N-(3,4-dimethylbenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 435 B 34

2-{4-[(diethylamino)methyl]phenyl}- N-(2-ethoxybenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 451 B 35

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 384 A 36

5,6-dihydroxy-N-(4-methoxybenzyl)- 2-(4-methylphenyl)pyrimidine-4- carboxamide 366 A 37

N-(2,3-dimethoxybenzyl)-2-{4- [(dimethylamino)methyl]phenyl}- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 439 B 38

N-(3,4-dimethylbenzyl)-5,6- dihydroxy-2-{4-[(4-methylpiperazin- 1-yl)methyl]phenyl}pyrimidine-4- carboxamide (TFA salt) 462 B 39

2-{4-[(dimethylamino)methyl]- phenyl}-N-(2-ethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 423 B 40

N-(4-fluorobenzyl)-5,6-dihydroxy-2- {4-[1-(4-methylpiperazin-1- yl)ethyl]phenyl}pyrimidine-4- carboxamide (TFA salt) 466 B 41

N-(2,3-dimethylbenzyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 364 A 42

N-(2-chloro-4-fluorobenzyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 388 A 43

N-benzyl-5,6-dihydroxy-2-(4- methylphenyl)pyrimidine-4- carboxamide 336 A 44

5,6-dihydroxy-N-(2-methoxybenzyl)- 2-(4-methylphenyl)pyrimidine-4- carboxamide 366 A 45

N-(3,4-dimethylbenzyl)-5,6- dihydroxy-2-[4-(pyrrolidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 433 B 46

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [4-(1-piperidin-1-ylethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 451 B 47

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[4-(1-morpholin-4- ylethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 495 B 48

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-{4-[1-(4-methyl- piperazin-1-yl)ethyl]phenyl}- pyrimidine-4-carboxamide (TFA salt) 508 B 49

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 396 A 50

N-(3-chloro-4-fluorobenzyl)-5,6- dihydroxy-2-(4-methylphenyl)- pyrimidine-4-carboxamide 388 A 51

2-{4-[(diethylamino)methyl]- phenyl}-N-(2,3-dimethoxybenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 467 B 52

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[4-(piperidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 479 B 53

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-[4-(pyrrolidin-1-ylmethyl)phenyl]- pyrimidine-4-carboxamide (TFA salt) 449 B 54

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[4-(1-piperidin-1- ylethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 493 B 55

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-{4-[4-methylpiperazin- 1-yl)methyl]phenyl}pyrimidine-4- carboxamide (TFA salt) 494 B 56

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[4-(pyrrolidin-1- ylmethyl)phenyl]pyrimidine-4- carboxamide (TFA salt) 465 B

TABLE 8 1

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 292 (M−) F 2

N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 262 (M−) F 3

N-[4-fluoro-2-(trifluoromethyl)- benzyl]-5,6-dihydroxypyrimidine- 4-carboxamide 332 F 4

N-(2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 304 (M−) F 5

N-(3,4-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 306 F

TABLE 9 1

N4-(4-fluorobenzyl)-5,6-dihydroxy- N2-(pyridin-2-ylmethyl)pyrimidine- 2,4-dicarboxamide (TFA salt) 396 (M−) H 2

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (piperazin-1-ylcarbonyl)pyrimidine- 4-carboxamide (TFA salt) 376 H 3

N4-(4-fluorobenzyl)-5,6-dihydroxy- N2-(2-morpholin-4-ylethyl)pyrimidine- 2,4-dicarboxamide (TFA salt) 420 H 4

N,N′-dibenzyl-5,6-dihydroxy- pyrimidine-2,4-dicarboxamide 379 H 5

N2-(4-fluorobenzyl)-5,6-dihydroxy- N4-(2-morpholin-4-dicarboxamide (TFA salt) 420 H

TABLE 10 1

2-benzyl-N-(2,4-difluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 372 A 2

2-(benzyloxycarbonylaminomethyl)- N-(2,4-difluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 445 A 3

N-[(4-{[(4-fluorobenzyl)amino]- carbonyl}-5,6-dihydroxypyrimidin-2- yl)methyl]morpholine-4-carboxamide 406 G 4

2-(benzyloxycarbonylaminomethyl)- N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 427 A 5

2-(benzyloxycarbonylaminomethyl)- N-(1-naphthylmethyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 459 A 6

2-benzyl-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 354 A 7

2-benzyl-5,6-dihydroxy-N-(1- naphthylmethyl)pyrimidine- 4-carboxamide 386 A 8

2-benzyl-N-(3-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 354 A 9

2-benzyl-N-(3,4-difluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 372 A 10

2-(1,3-benzodioxol-5-ylmethyl)-N- (3,4-difluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 416 A 11

2-(1,3-benzodioxol-5-ylmethyl)-N- [4-fluoro-2-(trifluoromethyl)benzyl]- 5,6-dihydroxypyrimidine- 4-carboxamide 466 A 12

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (2-phenylethyl)pyrimidine- 4-carboxamide 368 A 13

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (3-phenylpropyl)pyrimidine- 4-carboxamide 382 A 14

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(thien-2-ylmethyl)- pyrimidine-4-carboxamide 402 A 15

N-(4-fluorobenzyl)-5,6-dihydroxy-2- {[(morpholin-4-ylacetyl)- amino]methyl}pyrimidine- 4-carboxamide (TFA salt) 420 I 16

2-[(benzoylamino)methyl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 397 I 17

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (morpholin-4-ylmethyl)pyrimidine- 4-carboxamide (TFA salt) 363 E 18

benzyl 2-(4-{[(4-fluorobenzyl)- amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)ethylcarbamate 441 A 19

2-[2-(benzoylamino)ethyl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 411 I 20

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-methylpyrimidine-4-carboxamide 278 A 21

2-{[(N,N-dimethylglycyl)- amino]methyl}-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 378 I 22

2-(benzyloxycarbonylamino- methyl)-N-(3-methoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 439 A 23

2-(benzyloxycarbonylamino- methyl)-N-(4-chlorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 443 A 24

2-(benzyloxycarbonylamino- methyl)-N-(1,3-benzodioxol-5-yl- methyl)-5,6-dihydroxypyrimidine- 4-carboxamide 453 A 25

2-(benzyloxycarbonylaminomethyl)- N-(3-chloro-4-methylbenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 457 A 26

N,2-dibenzyl-5,6-dihydroxy- pyrimidine-4-carboxamide 336 A 27

2-benzyl-N-(2-ethoxybenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 380 A 28

2-(1,3-benzodioxol-5-ylmethyl)- N-(3-chloro-4-methylbenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 428 A 29

2-(1,3-benzodioxol-5-ylmethyl)- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 398 A 30

2-(1,3-benzodioxol-5-ylmethyl)- N-(2-ethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 424 A 31

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(thien-2-ylmethyl)pyrimidine- 4-carboxamide 360 A 32

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(thien-3- ylmethyl)pyrimidine-4-carboxamide 390 A 33

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(thien-3-ylmethyl)pyrimidine-4- carboxamide 360 A 34

2-butyl-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 320 A 35

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(2-phenylethyl)- pyrimidine-4-carboxamide 398 A 36

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-(2-phenylethyl)pyrimidine-4- carboxamide 394 A 37

N-benzyl-5,6-dihydroxy-2-(3- phenylpropyl)pyrimidine-4- carboxamide 364 A 38

N-benzyl-5,6-dihydroxy-2-(2- phenylethyl)pyrimidine-4- carboxamide 350 A 39

2-(benzyloxycarbonylaminomethyl)- N-(2-ethoxybenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 453 A 40

N-benzyl-5,6-dihydroxy-2- (phenoxymethyl)pyrimidine-4- carboxamide 352 A 41

N,2-bis(1,3-benzodioxol-5- ylmethyl)-5,6-dihydroxypyrimidine- 4-carboxamide 424 A 42

N-(4-chlorobenzyl)-5,6-dihydroxy- 2-(2-phenylethyl)pyrimidine-4- carboxamide 384 A 43

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-(2-phenylethyl)- pyrimidine-4-carboxamide 394 A 44

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-(thien-3-yl- methyl)pyrimidine-4-carboxamide 386 A 45

2-butyl-N-(3-chloro-4-methyl- benzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 350 A 46

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[(4-methylpiperazin-1- yl)methyl]pyrimidine-4- carboxamide (TFA salt) 376 E 47

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(pyrrolidin-1-ylmethyl)pyrimidine- 4-carboxamide (TFA salt) 347 E 48

2-(anilinomethyl)-N-(4-fluoro- benzyl)-5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 369 E 49

2-(3,4-dimethoxybenzyl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 414 A 50

N-benzyl-5,6-dihydroxy-2-(thien- 3-ylmethyl)pyrimidine-4-carboxamide 342 A 51

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-(thien-3-ylmethyl)pyrimidine-4- carboxamide 386 A 52

N-(4-chlorobenzyl)-5,6-dihydroxy- 2-(thien-3-ylmethyl)pyrimidine-4- carboxamide 376 A 53

2-(2,2-dimethoxyethyl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 352 A 54

2-((acetylamino)methyl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 335 I 55

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(3-phenylpropyl)- pyrimidine-4-carboxamide 424 A 56

2-(benzyloxycarbonylaminomethyl)- N-benzyl-5,6-dihydroxypyrimidine- 4-carboxamide 409 A 57

2-(benzyloxycarbonylaminomethyl)- N-(2-methoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 439 A 58

2-(benzyloxycarbonylaminomethyl)- N-(2-trifluoromethylbenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 477 A 59

2-benzyl-N-(2,3-dimethoxybenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 396 A 60

N-(1,3-benzodioxol-5-ylmethyl)-2- benzyl-5,6-dihydroxypyrimidine-4- carboxamide 380 A 61

N-benzyl-2-(3,4-dimethoxybenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 396 A 62

N-(3-chloro-4-methylbenzyl)-2- (3,4-dimethoxybenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 444 A 63

2-(3,4-dimethoxybenzyl)-N-(2- ethoxybenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 440 A 64

N-(1,3-benzodioxol-5-ylmethyl)- 2-(3,4-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 440 A 65

2-(1,3-benzodioxol-5-ylmethyl)- N-benzyl-5,6-dihydroxypyrimidine-4- carboxamide 380 A 66

2-(1,3-benzodioxol-5-ylmethyl)- N-[4-fluoro-3-(trifluoromethyl)- benzyl]-5,6-dihydroxypyrimidine- 4-carboxamide 466 A 67

N-(2,4-dimethoxybenzyl)-5,6- dihydroxy-2-(2-phenylethyl)- pyrimidine-4-carboxamide 410 A 68

5,6-dihydroxy-N-(3-methoxy- benzyl)-2-(2-phenylethyl)- pyrimidine-4-carboxamide 380 A 69

5,6-dihydroxy-N-(3-methoxy- benzyl)-2-(thien-3-ylmethyl)- pyrimidine-4-carboxamide 372 A 70

N-(2,4-dimethoxybenzyl)-5,6- dihydroxy-2-(thien-3-ylmethyl)- pyrimidine-4-carboxamide 402 A 71

N-benzyl-2-butyl-5,6- dihydroxypyrimidine-4- carboxamide 302 A 72

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[(isonicotinoylamino)methyl]- pyrimidine-4-carboxamide (TFA salt) 398 I 73

2-[(dimethylamino)methyl]-N- (4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 321 C 74

2-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-N-(3-methoxybenzyl)- pyrimidine-4-carboxmide 410 A 75

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(phenoxymethyl)- pyrimidine-4-carboxamide 412 A 76

2-(aminomethyl)-N-(4-fluoro- benzyl)-5,6-dihydroxypyrimidine- 4-carboxamide (HCl salt) 293  A* 77

2-(benzyloxycarbonylaminomethyl)- N-(2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 469 A 78

2-(1,3-benzodioxol-5-ylmethyl)- N-(2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 440 A 79

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(2-phenylethyl)- pyrimidine-4-carboxamide 410 A 80

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(thien-3-ymethyl)- pyrimidine-4-carboxamide 402 A 81

2-(aminomethyl)-N-benzyl-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 275 M 82

2-butyl-N-(2,3-dimethoxybenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 362 A 83

N-(2,3-dimethoxybenzyl)-2-(3,4- dimethoxybenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 456 A 84

N-(2,3-dimethoxybenzyl)-2-(2,2- dimethoxyethyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 394 A 85

N-(4-fluorobenzyl)-5,6-dihydroxy-2- ({[(4-methylpiperazin-1-yl)- acetyl]amino}methyl)pyrimidine- 4-carboxamide (TFA salt) 433 I 86

2-benzyl-N-(4-fluorobenzyl)-5- hydroxy-6-(2-morpholin-4-yl- ethoxy)pyrimidine-4-carboxamide (TFA salt) 467 J 87

2-benzyl-6-[2-(dimethylamino)- ethoxy]-N-(4-fluorobenzyl)-5- hydroxypyrimidine-4-carbaxamide (TFA salt) 425 3

TABLE 11 1

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(4-methylmorpholin-2- yl)pyrimidine-4-carboxamide (TFA salt) 363 C 2

2-[4-(N,N-dimethylglycyl)- morpholin-2-yl]-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 434 I 3

2-(diethoxymethyl)-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 366 A 4

N-benzyl-5,6-dihydroxy-2- [methoxy(phenyl)methyl]- pyrimidine-4-carboxamide 366 A 5

5,6-dihydroxy-N-(3-methoxy- benzyl)-2-[methoxy(phenyl)- methyl]-pyrimidine-4-carboxamide 396 A 6

2-[1-(benzyloxy)butyl]-N-(3,4- difluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 444 A 7

2-[1-(benzyloxy)butyl]-N-(3- 4-methylbenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 456 A 8

2-[(benzyloxy)(phenyl)methyl]- N-(2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 502 A 9

2-[(benzyloxy)(phenyl)methyl]- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 460 A 10

2-[(benzyloxy)(phenyl)methyl]- N-(3-chloro-4-methylbenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 490 A 12

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[methoxy(phenyl)- methyl]pyrimidine-4- carboxamide 426 A 13

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[methoxy(phenyl)methyl]- pyrimidine-4-carboxamide 384 A 14

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-[methoxy(phenyl)- methyl]pyrimidine- 4-carboxamide 414 A 15

N-benzyl-5,6-dihydroxy-2-(1- hydroxybutyl)pyrimidine-4- carboxamide 318  A* 16

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(1-hydroxybutyl)- pyrimidine-4-carboxamide 366  A* 17

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1-hydroxybutyl)pyrimidine-4- carboxamide 336  A* 18

2-[1-(benzyloxy)butyl]-5,6- dihydroxy-N-(3-methoxybenzyl)- pyrimidine-4-carboxamide 438 A 19

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-[methoxy- (phenyl)methyl]pyrimidine- 4-carboxamide 410 A 20

2-[1-(benzyloxy)butyl]-N- (2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 468 A 21

2-{(benzyloxy)(phenyl)methyl]- N-[4-fluoro-3-(trifluoromethyl)- benzyl]-5,6-dihydroxypyrimidine- 4-carboxamide 528 A 22

N-(4-chlorobenzyl)-5,6-dihydroxy- 2-[methoxy(phenyl)methyl]- pyrimidine-4-carboxamide 400 A 23

5,6-dihydroxy-N-(2-methoxy- benzyl)-2-[methoxy(phenyl)- methyl]-pyrimidine-4-carboxamide 396 A 24

N-[4-fluoro-3-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2- [methoxy(phenyl)methyl]- pyrimidine-4-carboxamide 452 A 25

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-[methoxy(phenyl)- methyl]pyrimidine-4-carboxamide 402 A 26

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(1-hydroxybutyl)- pyrimidine-4-carboxamide 378  A* 27

5,6-dihydroxy-2-(1-hydroxybutyl)- N-(3-methoxybenzyl)pyrimidine- 4-carboxamide 348  A* 28

tert-butyl 2-(4-{[(4- fluorobenzyl)amino]carbonyl}-5,6- dihydrcxypyrimidin-2- yl)morpholine-4-carboxylate 449 A 29

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-morpholin-2-ylpyrimidine-4- carboxamide (TFA salt) 349  A* 30

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-[methoxy(phenyl)methyl]- pyrimidine-4-carboxamide 410 A 31

benzyl 4-[(benzyloxy)(4-{[(2,3- dimethoxybenzyl)amino]- carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)methyl]piperidine- 1-carboxylate 643 A 32

2-[(benzyloxy)(piperidin-4- yl)methyl]-N-(2,3-dimethoxy- benzyl)-5,6-dihydroxypyrimidine- 4-carboxamide (TFA salt) 509  A*

TABLE 12 1

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-isopropylpyrimidine- 4-carboxamide 336 A 2

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1-phenylethyl)pyrimidine-4- carboxamide 368 A 3

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-(1-phenylethyl)- pyrimidine-4-carboxamide 398 A 4

N-[4-fluoro-2-(trifluoromethyl)- benzyl]-5,6-dihydroxy-2-(1- phenylethyl)pyrimidine-4- carboxamide 436 A 5

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-isopropylpyrimidine- 4-carboxamide 324 A 6

N-benzyl-5,6-dihydroxy-2-(1- phenylethyl)pyriniidine-4- carboxamide 350 A 7

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-(1-phenylethyl)pyrimidine-4- carboxamide 394 A 8

N-(2,4-dimethoxybenzyl)-5,6- dihydroxy-2-(1-phenylethyl)- pyrimidine-4-carboxamide 410 A 9

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-(1- phenylethyl)pyrimidine-4- carboxamide 394 A 10

N-(4-chlorobenzyl)-5,6-dihydroxy- 2-(1-phenylethyl)pyrimidine-4- carboxamide 384 A 11

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-(1-phenylethyl)pyrimidine-4- carboxamide 380 A 12

N-(4-fluorobenzyl)-5,6-dihydroxy-2- isopropylpyrimidine-4-carboxamide 306 A 13

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(1-phenylethyl)- pyrimidine-4-carboxamide 410 A 14

N-[4-fluoro-2- (trifluoromethyl)benzyl]-5,6- dihydroxy-2-isopropylpyrimidine- 4-carboxamide 374 A 15

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-isopropylpyrimidine-4- carboxamide 332 A 16

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-isopropylpyrimidine-4- carboxamide 348 A 17

N-(1,3-benzodioxol-5-ylmethyl)- 5,6-dihydroxy-2-isopropylpyrimidine- 4-carboxamide 332 A 18

N-benzyl-5,6-dihydroxy-2- isopropylpyrimidine-4-carboxamide 288 A 19

N-[4-fluoro-3- (trifluoromethyl)benzyl]-5,6- dihydroxy-2-isopropylpyrimidine-4- carboxamide 374 A 20

N-(2,4-dimethoxybenzyl)-5,6- dihydroxy-2-isopropylpyrimidine-4- carboxamide 348 A

TABLE 13 1

N-benzyl-2-cyclopentyl-5,6- dihydroxypyrimidine-4- carboxamide 314 A 2

N-(3-chloro-4-methylbenzyl)-2- cyclopentyl-5,6- dihydroxypyrimidine-4- carboxamide 362 A 3

2-cyclopentyl-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 332 A 4

2-cyclopentyl-N-(2,3- dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 374 A 5

2-cyclopentyl-N-(2-ethoxybenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 358 A 6

2-cyclopentyl-N-[4-fluoro-2- (trifluoromethyl)benzyl]-5,6- dihydroxypyrimidine-4- carboxamide 400 A 7

2-cyclopentyl-5,6-dihydroxy-N- (2-methoxybenzyl)pyrimidine-4- carboxamide 344 A 8

N-(1,3-benzodioxol-5-ylmethyl)- 2-cyclopentyl-5,6- dihydroxypyrimidine-4- carboxamide 358 A 9

2-cyclopentyl-5,6-dihydroxy-N- (3-methoxybenzyl)pyrimidine-4- carboxamide 344 A 10

2-cyclopentyl-N-(2,4- dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 374 A

TABLE 14 1

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-[morpholin-4- yl(phenyl)methyl]pyrimidine-4-carboxamide (TFA salt) 457 B 2

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[morpholin-4-yl(phenyl)- methyl]pyrimidine-4- carboxamide (TFA salt) 439 B 3

2-[(dimethylamino)(phenyl)- methyl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 397 B 4

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[(2-methyl-2,3-dihydro-1H-indol- 1-yl)(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 485 B 5

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{phenyl[(pyridin-3-yl- methyl)amino]methyl}pyrimidine- 4-carboxamide (TFA salt) 460 B 6

N-(3,5-dichlorobenzyl)-2- [(dimethylamino)(phenyl)methyl]- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 447 B 7

N-(4-fluorobenzyl)-2-[(4- formylpiperazin-1- yl)(phenyl)methyl]-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 466 B 8

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[{[3-(1H-imidazol-1- yl)propyl]amino}(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 477 B 9

N-(4-fluorobenzyl)-2-[[(4- fluorobenzyl)amino](phenyl)- methyl]-5,6-dihydroxypyrimidine- 4-carboxamide (TFA salt) 477 B 10

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[(4-methylpiperazin-1- yl)(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 452 B 11

2-[[(3,4-dimethoxybenzyl)- amino] (phenyl)methyl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 519 B 12

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[(2-methyl-2,3-dihydro-1H- 1-yl)(phenyl)methyl]pyrimidine- 4-carboxamide (TFA salt) 485 B 13

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[[4-(2-methoxyphenyl)piperazin-1- yl](phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 544 B 14

N-(2,4-difluorobenzyl)-2- [(dimethylamino)(phenyl)methyl]- 5,6-dihydroxypyimidine-4- carboxamide (TFA salt) 415 B 15

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{phenyl[(pyridin-4-yl- methyl)amino]methyl}pyrimidine- 4-carboxamide (TFA salt) 460 B 16

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-[phenyl(piperidin-1- yl)methyl]pyrimidine-4- carboxamide (TFA salt) 455 B 17

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[phenyl(piperidin-1- yl)methyl]pyrimidine-4- carboxamide (TFA salt) 437 B 18

2-[(dimethylamino)(phenyl)- methyl]-N-(4-fluorobenzyl)-5,6- dihydroxypyimidine-4- carboxamide 397 B 19

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[{[3-(2-oxopyrrolidin-1- yl)propyl]amino}(phenyl)- methyl]pyrimidine-4- carboxamide (TEA salt) 494 B 20

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[{[2-(1H-indol-3-yl)ethyl]- amino}(phenyl)methyl]pyrimidine- 4-carboxamide (TFA salt) 512 B 21

2-[[benzyl(methyl)amino]- (phenyl)methyl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 473 B 22

2-[1,4-dioxa-8-azaspiro[4.5]- dec-8-yl(phenyl)methyl]-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 495 B 23

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[[(2S)-2-(methoxymethyl)- pyrrolidin-1-yl](phenyl)methyl]- pyrimidine-4-carboxamide (TFA salt) 467 B 24

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{phenyl[(pyridin-2- ylmethyl)amino]methyl}pyrimidine- 4-carboxamide (TFA salt) 460 B 25

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{phenyl[(2-piperidin-1-yl- ethyl)amino]methyl}pyrimidine- 4-carboxamide (TFA salt) 480 B 26

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[[(3-morpholin-4-ylpropyl)- amino](phenyl)methyl]pyrimidine- 4-carboxamide (TFA salt) 496 B 27

N-benzyl-5,6-dihydroxy-2- [morpholin-4-yl(phenyl)methyl]- pyrimidine-4-carboxamide (TFA salt) 421 B 28

2-[(dimethylamino)(phenyl)- methyl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 397 B 29

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[{[(1S)-1-methylpropyl]- amino}(phenyl)methyl]pyrimidine- 4-carboxamide (TFA salt) 425 B 30

N-(3,4-difluorobenzyl)-5,6- dihydroxy-2-[(4-methylpiperazin-1- yl)(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 470 B 31

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-[morpholin-4-yl(phenyl)methyl]- pyrimidine-4-carboxamide (TFA salt) 465 B 32

N-2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[(4-methylpiperazin-1- yl)(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 494 B 33

N-[(1S)-2,3-dihydro-1H-inden-1-yl]- 2-[(dimethylamino)(phenyl)methyl]- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 405 B 34

N-(2-chlorobenzyl)-2- [(dimethylamino)(phenyl)methyl]- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 413 B 35

N-(3,4-difluorobenzyl)-2- [(dimethylamino)(phenyl)methyl]- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 415 B 36

2-[(dimethylamino)(phenyl)- methyl]-5,6-dihydroxy-N-(3- methoxybenzyl)pyrimidine-4- carboxamide (TFA salt) 409 B 37

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[[(2-morpholin-4-ylethyl)- amino](phenyl)methyl]pyrimidine- 4-carboxamide (TFA salt) 482 B 38

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{phenyl[(2-pyrrolidin-1- ylethyl)amino]methyl}pyrimidine- 4-carboxamide (TFA salt) 466 B 39

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[{[(1R)-1-(hydroxymethyl)- propyl]amino}(phenyl)methyl]- pyrimidine-4-carboxamide (TFA salt) 441 B 40

2-[(diethylamino)(phenyl)methyl]- N-(3,4-difluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 443 B 41

2-{(diethylamino)(phenyl)methyl]- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 425 B 42

2-[(4-benzylpiperazin-1- yl)(phenyl)methyl]-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 528 B 43

N-benzyl-2-[(dimethylamino)- (phenyl)methyl]-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 379 B 44

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[[methyl(1-methylpiperidin-4- yl)amino](phenyl)methyl]pyrimidine- 4-carboxamide (TFA salt) 480 B 45

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[(2-methylpyrrolidin-1- yl)(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 437 B 46

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[morpholin-4- yl(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 481 B 47

N-(2-ethoxybenzyl)-5,6-dihydroxy- 2-[phenyl(piperidin-1- yl)methyl]pyrimidine-4- carboxamide (TFA salt) 463 B 48

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-[phenyl(piperidin-1- yl)methyl]pyrimidine-4- carboxamide (TFA salt) 449 B 49

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-[morpholin-4- carboxamide (TFA salt) 451 B 50

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{phenyl[(2S)-2-(pyrrolidin-1- ylmethyl)pyrrolidin-1- yl]methyl}pyrimidine-4- carboxamide (TFA salt) 506 B 51

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-[phenyl(piperidin-1- yl)methyl]pyrimidine-4- carboxamide (TFA salt) 479 B 52

5,6-dihydroxy-N-(3-methoxybenzyl)- 2-[(4-methylpiperazin-1- yl)(phenyl)methyl]pyrimidine-4- carboxamide (TFA salt) 464 B 53

2-[[(4-fluorobenzyl)amino]- (phenyl)methyl]-5,6-dihydroxy-N- (pyridin-2-ylmethyl)pyrimidine-4- carboxamide (TFA salt) 460 B 54

N-(2,3-dimethoxybenzyl)-2- [(dimethylamino)(phenyl)methyl]- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 439 B 55

2-[[(4-fluorobenzyl)amino]- (phenyl)methyl]-5,6-dihydroxy-N- (pyridin-3-ylmethyl)pyrimidine-4- carboxamide (TFA salt) 460 B 56

5,6-dihydroxy-2-{phenyl[(pyridin- 2-ylmethyl)amino]methyl}-N- (pyridin-2-ylmethyl)pyrimidine-4- carboxamide (TFA salt) 443 B 57

2-[(diethylamino)(phenyl)methyl]- N-(2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 467 B

TABLE 15 1

N-(4-fluorobenzyl)-5,6-dihydroxy-2- {1-methyl-1-[(pyridin-2- ylcarbonyl)amino]ethyl}pyrimidine- 4-carboxamide (TFA salt) 426 I 2

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{1-[(pyridin-2-ylcarbonyl)amino]- cyclohexyl}pyrimidine-4- carboxamide (TFA salt) 466 I 3

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{1-methyl-1-[(morpholin-4- ylacetyl)amino]ethyl}pyrimidine- 4-carboxamide (TFA salt) 448 I 4

2-[1-(acetylamino)cyclohexyl]- N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 403 I 5

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-methyl-1-(methylamino)ethyl]- pyrimidine-4-carboxamide 335 C 6

N-(4-fluorobenzyl)-5-hydroxy-6- methoxy-2-{1-methyl-1-[(pyridin-2- ylcarbonyl)amino]ethyl}pyrimidine- 4-carboxamide (TFA salt) 440 I 7

2-[1-(dimethylamino)cyclohexyl]- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine- 4-carboxamide (TFA salt) 389 E 8

benzyl 1-(4-{[(4-fluoro- benzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)-1- methylethylcarbamate 455 A 9

2-(1-aminocyclohexyl)-N-(4-fluoro- benzyl)-5,6-dihydroxypyrimidine- 4-carbaxamide (TFA salt) 361  A* 10

2-[1-(dimethylamino)-1- methylethyl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 349 E 11

N-(3-bromo-4-fluorobenzyl)-2- [1-(dimethylamino)-1-methylethyl]- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 428 E 12

benzyl 1-(4-{[(4-fluorobenzyl)- amino]carbonyl}-5-hydroxy- 6-methoxypyrimidin-2-yl)- 1-methylethylcarbamate 469 J 13

2-(1-amino-1-methylethyl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 321  A* 14

benzyl 1-(4-{[(2,3-dimethoxy- benzyl)amino]carbonyl}- 5,6-dihydroxypyrimidin-2-yl)-1- methylethylcarbamate 497 A 15

2-(1-amino-1-methylethyl)-N-(4- fluorobenzyl)-5-hydroxy-6- methoxypyrimidine-4-carboxamide 335  A* 16

2-[1-(dimethylamino)-1- methylethyl]-N-(4-fluorobenzyl)-5- hydroxy-6-methoxypyrimidine-4- carboxamide 363 A

TABLE 16 1

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1-methyl-2,3-dihydro-1H-indol-2- yl)pyrimidine-4-carboxamide (TFA salt) 395 C 2

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{2-phenyl-1-[(pyridin-2- ylcarbonyl)amino]ethyl}pyrimidine- 4-carboxamide (TFA salt) 488 I 3

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(2-methyl-1,2,3,4-tetrahydro- isoquinolin-3-yl)pyrimidine- 4-carboxamide (TFA salt) 409 C 4

2-(2-benzoyl-1,2,3,4-tetrahydro- isoquinolin-3-yl)-N-(4-fluoro- benzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 499 I 5

2-[1-(N,N-dimethylglycyl)-2,3- dihydro-1H-indol-2-yl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 466 I 6

2-(2,3-dihydro-1H-indol-2-yl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 381  A* 7

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1,2,3,4-tetrahydroisoquinolin-3- yl)pyrimidine-4-carboxamide 395  A* 8

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[2-(morpholin-4-ylacetyl)-1,2,3,4- tetrahydroisoquinolin-3-salt) yl]pyrimidine-4-carboxamide (TFA salt) 522 I 9

2-(1-benzoyl-2,3-dihydro-1H-indol- 2-yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 485 I 10

2-(1-benzyl-2,3-dihydro-1H-indol- 2-yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 471 C 11

2-[1-(dimethylamino)-2- dihydroxypyrimidine-4- carboxamide (TFA salt) 411 C 12

benzyl 2-(4-{[(4-fluorobenzyl)- amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)indoline-1- carboxylate 515 A 13

2-[2-(N,N-dimethylglycyl)-1,2,3,4- tetrahydroisoquinolin-3-yl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 480 I 14

tert-butyl 1-(4-{[(4-fluoro- benzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)-2- phenylethylcarbamate 483 A 15

2-{1-[(N,N-dimethylglycyl)amino]- 2-phenylethyl}-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 468 I 16

2-(1-amino-2-phenylethyl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 383  A*

TABLE 17 1

benzyl 2-(4-{[(4-fluorobenzyl)- amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)piperidine- 1-carboxylate 481 A 2

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(methylsulfonyl)piperidin-2- yl]pyrimidine-4-carboxamide 425 I 3

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{1-[(4-methyl-1,2,3-thiadiazol- 5-yl)carbonyl]piperidin-2- yl}pyrimidine-4-carboxamide (TFA salt) 473 I 4

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(1H-imidazol-4-ylcarbonyl)- piperidin-2-yl]pyrimidine-4- carboxamide (TFA salt) 441 I 5

2-{1-[(2,4-dimethyl-1,3- thiazol-5-yl)carbonyl]piperidin- 2-yl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 486 I 6

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{1-[(1-methyl-1H-imidazol-2- yl)carbonyl]piperidin-2- yl}pyrimidine-4-carboxamide (TFA salt) 455 I 7

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(pyridazin-3-ylcarbonyl)- piperidin-2-yl]pyrimidine- 4-carboxamide 453 I 8

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-{1-[(4-methylmorpholin-2- yl)carbonyl]piperidin-2- yl}pyrimidine-4-carboxamide 474 I 9

2-(1-acetylpiperidin-2-yl)-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 389 I 10

2-(1-benzoylpiperidin-2-yl)-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 451 I 11

2-[1-(anilinocarbonyl)piperidin- 2-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 466 G 12

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(pyridin-2-ylcarbonyl)- piperidin-2-yl]pyrimidine-4- carboxamide (TFA salt) 452 I 13

2-[1-(1H-benzimidazol-5- ylcarbonyl)piperidin-2-yl]-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 491 I 14

2-{1-[(ethylamino)carbonyl]- piperidin-2-yl}-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 418 G 15

N-(4-fluorobenzyl)-2-(1- formylpiperidin-2-yl)-5,6- dihydroxypyrimidine-4- carboxamide 375 I 16

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-piperidin-2-ylpyrimidine- 4-carboxamide 347  A* 17

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(pyridin-4-ylmethyl)piperidin- 2-yl]pyrimidine-4-carboxamide (TFA salt) 438 D 18

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1-isonicotinoylpiperidin-2- yl)pyrimidine-4-carboxamide (TFA salt) 452 I 19

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(morpholin-4-ylacetyl)- piperidin-2-yl]pyrimidine-4- carboxamide (TFA salt) 474 I 20

2-(1-ethylpiperidin-2-yl)-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 375 C 21

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(pyridin-3-ylcarbonyl)- piperidin-2-yl]pyrimidine-4- carboxamide (TFA salt) 452 I 22

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(pyridin-3-ylmethyl)piperidin- 2-yl]pyrimidine-4-carboxamide (TFA salt) 438 D 23

2-(1-benzylpiperidin-2-yl)-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 437 D 24

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(2-oxo-2-phenylethyl)- piperidin-2-yl]pyrimidine-4- carboxamide (TFA salt) 465 D 25

benzyl 2-(4-{[(2,3-dimethoxy- benzyl)amino]carbonyl}- 5,6-dihydroxypyrimidin-2- yl)piperidine-1-carboxylate 523 A 26

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1-isobutylpiperidin-2-yl)- pyrimidine-4-carboxamide (TFA salt) 403 C 27

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1-methylpiperidin-2- yl)pyrimidine-4-carboxamide (TFA salt) 361 D 28

2-[1-(N,N-dimethylglycyl)- piperidin-2-yl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 432 I 29

2-{1-[2-(dimethylamino)- 2-oxoethyl]piperidin-2-yl}-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 432 D 30

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-(1-isonicotinoyl- piperidin-2-yl)pyrimidine- 4-carboxamide (TFA salt) 494 I 31

N-(4-fluorobenzyl)-5,6- dihydroxy-2-[1-(pyridin-2- ylmethyl)piperidin-2-yl]- pyrimidine-4-carboxamide (TFA salt) 438 D 32

2-(1-benzylpiperidin-2-yl)-N- (2,3-dimethoxybenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 479 D 33

N-(2,3-dimethoxybenzyl)-2-[1- (N,N-dimethylglycyl)piperidin-2- yl]-5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 474 I 34

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-piperidin-2- ylpyrimidine-4-carboxamide 389  A*

TABLE 18 1

N-benzyl-2-(1-formylpiperidin-3-yl)- 5,6-dihydroxypyrimidine-4- carboxamide 357 I 2

N-(2,3-dimethoxybenzyl)-2-(1- formylpiperidin-3-yl)-5,6- dihydroxypyrimidine-4- carboxamide 417 I 3

N-(4-fluorobenzyl)-2-(1- formylpiperidin-3-yl)-5,6- dihydroxypyrimidine-4- carboxamide 375 I 4

benzyl 3-(4-{[(4-fluorobenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)piperidine- 1-carboxylate 481 A 5

2-(1-acetylpiperidin-3-yl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 389 I 6

benzyl 3-(4-{[(2-ethoxybenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)piperidine- 1-carboxylate 507 A 7

benzyl 3-{4-[(benzylamino) carbonyl]-5,6-dihydroxypyrimidin- 2-yl}piperidine-1-carboxylate 463 A 8

benzyl 3-(4-{[(3-chloro-4- methylbenzyl)amino]carbonyl}- 5,6-dihydroxypyrimidin-2-yl)- piperidine-1-carboxylate 511 A 9

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(morpholin-4-ylacetyl)- piperidin-3-yl]pyrimidine-4- carboxamide (TFA salt) 474 I 10

2-(1-benzylpiperidin-3-yl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 437 C 11

benzyl 3-(4-{[(2,3-dimethoxy- benzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl) piperidine-1-carboxylate 523 A 12

N-(4-fluorobenzyl)-5,6-dihydroxy-2- piperidin-3-ylpyrimidine-4- carboxamide (TFA salt) 347  A* 13

2-[1-(N,N-dimethylglycyl)piperidin- 3-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 432 I 14

N-benzyl-5,6-dihydroxy-2-piperidin- 3-ylpyrimidine-4-carboxamide (TFA salt) 329  A* 15

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-piperidin-3- ylpyrimidine-4-carboxamide (TFA salt) 389  A*

TABLE 19 1

benzyl 4-(4-{[(4-fluorobenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)piperidine- 1-carboxylate 481 A 2

N-(4-fluorobenzyl)-2-(1- formylpiperidin-4-yl)-5,6- dihydroxypyrimidine-4-carboxamide 375 I 3

N-(3,5-dichlorobenzyl)-2-(1- formylpiperidin-4-yl)-5,6- dihydroxypyrimidine-4-carboxamide 425 I 4

benzyl 4-{4-[(benzylamino) carbonyl]-5,6-dihydroxypyrimidin- 2-yl}piperidine-1-carboxylate 463 A 5

benzyl 4-(4-{[(3-chloro-4- methylbenzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)- piperidine-1-carboxylate 511 A 6

benzyl 4-(4-{[(2-ethoxybenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)piperidine- 1-carboxylate 507 A 7

benzyl 4-(4-{[(2,3-dimethoxy- benzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2- yl)piperidine-1-carboxylate 523 A 8

2-[1-(N,N-dimethylglycyl)piperidin- 4-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 432 I 9

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (1-methylpiperidin-4-yl)pyrimidine- 4-carboxamide (TFA salt) 361 C 10

N-(4-fluorobenzyl)-5,6-dihydroxy-2- piperidin-4-ylpyrimidine-4- carboxamide (TFA salt) 347  A* 11

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-piperidin-4-yl- pyrimidine-4-carboxamide (TFA salt) 389  A* 12

N-benzyl-5,6-dihydroxy-2- piperidin-4-ylpyrimidine-4- carboxamide (TFA salt) 329  A*

TABLE 20 1

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1,2,3,4-tetrahydroquinolin-2- yl)pyrimidine-4-carboxamide (TFA salt) 395  A* 2

benzyl 2-(4-{[(4-fluorobenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)-3,4-dihydro- quinoline-1(2H)-carboxylate 529 A 3

2-(1-benzoyl-1,2,3,4-tetrahydro- quinolin-2-yl)-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 499 I 4

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-(1-methyl-1,2.3,4-tetrahydro- quinolin-2-yl)pyrimidine- 4-carboxamide (TFA salt) 409 C 5

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-[1-(pyridin-2-ylcarbonyl)-1,2,3,4- tetrahydroquinolin-2-yl]pyrimidine- 4-carboxamide (TFA salt) 500 I 6

2-(1-benzyl-1,2,3,4-tetrahydro- quinolin-2-yl)-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 485 C

TABLE 21 1

2-(1-benzoylpiperazin-2-yl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 452  A* 2

2-[1-(2-chlorobenzoyl)-4- methylpiperazin-2-yl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (HCl salt) 500 I 3

2-(4-acetyl-1-methylpiperazin-2-yl)- N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 404 I 4

2-(4-benzoyl-1-methylpiperazin-2- yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 466 I 5

2-{1-(4-chlorobenzoyl)-4- methylpiperazin-2-yl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 500 I 6

2-{4-[(ethylamino)carbonyl]-1- methylpiperazin-2-yl}-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 433 G 7

2-[1-(3-chlorobenzoyl)-4-methyl- piperazin-2-yl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 500 I 8

2-(4-ethyl-1-methylpiperazin-2-yl)- N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 390 C 9

2-(1-benzoyl-4-ethylpiperazin-2-yl)- N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 480 C 10

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [1-methyl-4-(methylsulfonyl) piperazin-2-yl]pyrimidine-4- carboxamide (TFA salt) 440 I 11

2-(1-benzoyl-4-methylpiperazin-2- yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 466 I 12

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (1-methylpiperazin-2-yl)pyrimidine- 4-carboxamide (TFA salt) 362  A* 13

tert-butyl 3-(4-{[(4-fluorobenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)-4-methylpiperazine- 1-carboxylate (TFA salt) 462 C 14

2-(1,4-dimethylpiperazin-2-yl)-N- (4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 376 C 15

tert-butyl 3-(4-{[(4-fluorobenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)piperazine-1- carboxylate (TFA salt) 448  A* 16

2-[1-benzoyl-4-(N,N-dimethyl- glycyl)piperazin-2-yl]-N-(4-fluoro- benzyl)-5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 537 I 17

2-(4-benzyl-1-methylpiperazin-2-yl)- N-(4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 452 C 18

2-(1-benzoyl-4-isopropylpiperazin-2- yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 494 C 19

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (1-isopropyl-4-methylpiperazin-2- yl)pyrimidine-4-carboxamide (TFA aslt) 404 C 20

benzyl 2-(4-{[(4-fluorobenzyl) amino]carbonyl}-5,6-dihydroxy- pyrimidin-2-yl)piperazine- 1-carboxylate (TFA salt) 482  A* 21

2-[4-(anilinocarbonyl)-1-methyl- piperazin-2-yl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide (TFA salt) 481 G 22

1-benzyl 4-tert-butyl 2-(4-{[(4- fluorobenzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)piperazine- 1,4-dicarboxylate 580 (M−) A 23

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [4-methyl-1-(pyridin-2-ylcarbonyl) piperazin-2-yl]pyrimidine-4- carboxamide (TFA salt) 467 C 24

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [1-methyl-4-(pyridin-2-ylcarbonyl) piperazin-2-yl]pyrimidine-4- carboxamide (TFA salt) 467 I 25

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (4-isopropyl-1-methylpiperazin-2-yl) pyrimidine-4-carboxamide (TFA salt) 404 C 26

2-[1-(N,N-dimethylglycyl)-4- methylpiperazin-2-yl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 447 I 27

2-[1-(N,N-dimethylglycyl)piperazin- 2-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 433  A* 28

tert-butyl 4-(N,N-dimethylglycyl)-3- (4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin- 2-yl)piperazine-1-carboxylate (TFA salt) 533 I 29

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (4-methylpiperazin-2-yl)pyrimidine- 4-carboxamide (TFA salt) 362  A* 30

N-(4-fluorobenzyl)-5,6-dihydroxy- 2-piperazin-2-ylpyrimidine-4- carboxamide (TFA salt) 348  A*

TABLE 22 1

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (4-methylmorpholin-3- yl)pyrimidine-4-carboxamide (TFA salt) 363 C 2

2-(4-benzyl-5-oxomorpholin-3-yl)- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 453 A 3

2-(4-benzylmorpholin-3-yl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 439 C 4

N-(4-fluorobenzyl)-5,6-dihydroxy-2- morpholin-3-ylpyrimidine-4- carboxamide (TFA salt) 349  A*

TABLE 23 1

2-[(2S,4R)-4-(benzyloxy)-1- methylpyrrolidin-2-yl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 453 A 2

2-[(2S,4R)-1-benzoyl-4-hydroxy- pyrrolidin-2-yl]-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 453 I 3

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [(2S,4R)-4-hydroxy-1-methyl- pyrrolidin-2-yl]pyrimidine-4- carboxamide (TFA salt) 363  A* 4

2-[(2S,4R)-1-benzyl-4-(benzyloxy)- pyrrolidin-2-yl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 529 C 5

2-(1-benzoylpyrroidin-2-yl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 437 I 6

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [1-(4-methoxybenzyl)-5-oxo- pyrrolidin-2-yl]pyrimidine-4- carboxamide 467 A 7

N-(4-fluorobenzyl)-5,6-dihydroxy-2- pyrrolidin-2-ylpyrimidine-4- carboxamide (TFA salt) 333  A* 8

2-[(2S,4R)-4-(benzyloxy)-1-(N,N- dimethylglycyl)pyrrolidin-2-yl]-N- (4-fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 524 I 9

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (1-methylpyrrolidin-2-yl)pyrimidine- 4-carboxamide (TFA salt) 347 D 10

2-[(2S,4R)-1-benzoyl-4-(benzyloxy) pyrrolidin-2-yl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4- carboxamide 543 I 11

2-(1-benzylpyrrolidin-2-yl)-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 423 D 12

2-(1-benzoylpyrrolidin-2-yl)-N-(2,3- dimethoxybenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide 479 I 13

tert-butyl (2S,4R)-2-(4-{[(4- fluorobenzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)-4- hydroxypyrrolidine-1-carboxylate 449  A* 14

2-{(2S,4R)-4-(benzyloxy)-1-[4- (diethylamino)benzoyl]pyrrolidin-2- yl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 614 I 15

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [(2S,4R)-4-hydroxypyrrolidin-2-yl]- pyrimidine-4-carboxamide (TFA salt) 349  A* 16

2-[1-(N,N-dimethylglycyl)pyrrolidin- 2-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (TFA salt) 418 I 17

2-{1-[2-(dimethylamino)-2-oxo- ethyl]pyrrolidin-2-yl}-N-(4- fluorobenzyl)-5,6-dihydroxy- pyrimidine-4-carboxamide (TFA salt) 418 D 18

tert-butyl (2S,4R)-4-(benzyloxy)-2- (4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2- yl)pyrrolidine-1-carboxylate 539 A 19

2-[(2S,4R)-4-(benzyloxy)pyrrolidin- 2-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide (HCl salt) 439  A*

TABLE 24 1

N-(1,1′-biphenyl-3-ylmethyl)-5,6- dihydroxy-2-pyridin-2-ylpyrimidine- 4-carboxamide (HCl salt) 399 A 2

N-(3-chloro-4-fluorobenzyl)-5,6- dihydroxy-2-pyridin-2-ylpyrimidine- 4-carboxamide (HCl salt) 375 A 3

N-(4-fluorobenzyl)-5,6-dihydroxy-2- pyridin-2-ylpyrimidine-4- carboxamide (HCl salt) 341 A 4

N-(3-chlorobenzyl)-5,6-dihydroxy-2- pyridin-2-ylpyrimidine-4- carboxamide (HCl salt) 357 A 5

N-(3-chloro-4-methylbenzyl)-5,6- dihydroxy-2-pyridin-2-ylpyrimidine- 4-carboxamide (HCl salt) 371 A 6

N-(2,3-dimethoxybenzyl)-5,6- dihydroxy-2-pyridin-2-ylpyrimidine- 4-carboxamide (HCl salt) 383 A 7

N-(2,3-dimethylbenzyl)-5,6- dihydroxy-2-pyridin-2-ylpyrimidine- 4-carboxamide (HCl salt) 351 A 8

N-(2-chloro-4-fluorobenzyl)-5,6- dihydroxy-2-pyridin-2-ylpyrimidine- 4-carboxamide (HCl salt) 375 A 9

5,6-dihydroxy-N-(2-methoxybenzyl)- 2-pyridin-2-ylpyrimidine-4- carboxamide (HCl salt) 353 A 10

N-benzyl-5,6-dihydroxy-2-pyridin-2- ylpyrimidine-4-carboxamide (HCl salt) 323 A 11

5,6-dihydroxy-2-pyridin-2-yl-N- (pyridin-3-ylmethyl)pyrimidine-4- carboxamide (TFA salt) 324 A 12

5,6-dihydroxy-2-pyridin-2-yl-N- (pyridin-2-ylmethyl)pyrimidine-4- carboxamide (TFA salt) 324 A

TABLE 15B Strucuture name M + 1 Procedure

benzyl 1-[4-({[4-fluoro-2- (methylsulfonyl)benzyl]amino}carbonyl)- 5,6-dihydroxypyrimidin-2-yl]-1- methylethylcarbamate 533 A

2-(1-amino-1-methylethyl)-N-[4-fluoro- 2-(methylsulfonyl)benzyl]-5,6- dihydroxypyrimidine-4-carboxamide 399  A*

2-[1-(dimethylamino)-1-methylethyl]-N- [4-fluoro-2-(methylsulfonyl)benzyl]-5,6- dihydroxypyrimidine-4-carboxamide 427 C

2-(1-aminocyclopropyl)-N-(4- fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 319  A*

2-[1-(dimethylamino)cyclopropyl]-N-(4- fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 347 C

N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1- [(pyrazin-2-ylcarbonyl)amino]- cyclopropyl}pyrimidine-4-carboxamide 425 I

benzyl 1-(4-{[(4- fluorobenzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2- yl)cyclopentylcarbamate 481 A

2-(1-aminocyclopentyl)-N-(4- fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 347  A*

2-[1-(dimethylamino)cyclopentyl]-N-(4- fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 375 C

2-(1-{[(ethylamino)carbonyl]amino}-1- methylethyl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 392 G

2-[1-(benzylamino)-1-methylethyl]-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 411 C

2-[1-(benzoylamino)-1-methylethyl]-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 425 I

2-{1-[benzyl(methyl)amino]-1- methylethyl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 425 C

2-[1-(dimethylamino)-1-methylethyl]-N- (2-ethoxybenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 375 A

N-(2-chlorobenzyl)-2-[1- (dimethylamino)-1-methylethyl]-5,6- dihydroxypyrimidine-4-carboxamide 365 A

N-(2-chlorobenzyl)-2-[1- (dimethylamino)-1-methylethyl]-5,6- dihydroxypyrimidine-4-carboxamide 383 A

N-(5-chloro-2-methylbenzyl)-2-[1- (dimethylamino)-1-methylethyl]-5,6- dihydroxypyrimidine-4-carboxamide 379 A

N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1- methyl-1-[(pyrazin-2-ylcarbonyl) amino]ethyl}pyrimidine-4-carboxamide 427 I

2-{1-(diethylamino)-1-methylethyl]-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 377 K

N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1- methyl-1-morpholin-4- ylethyl)pyrimidine-4-carboxamide 391 K

N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1- methyl-1-piperidin-1- ylethylpyrimidine-4-carboxamide 389 K

N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1- methyl-1-pyrrolidin-1- ylethyl)pyrimidine-4-carboxamide 375 K

N-(4-fluorobenzyl)-5,6-dihydroxy-2- {1-methyl-1-[methyl(pyridin-4- ylmethyl)amino]ethyl}pyrimidine-4- carboxamide 426 C

2-[1-(dimethylamino)-1-methylethyl]- 5,6-dihydroxy-N-[2-(methylthio)benzyl]- pyrimidine-4-carboxamide 377 A

N1,N1-diethyl-N2-[1-(4-{[(4- fluorobenzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)-1- methylethyl]ethanediamide 448

2-[1-(1,4-dioxa-8-azaspiro[4.5]dec-8- yl)-1-methylethyl]-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4-carboxamide 447 K

N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1- methyl-1-{[(1-methyl-1H-imidazol-2- yl)carbonyl]amino}ethyl)pyrimidine-4- carboxamide 429 I

N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1- methyl-1-(4-oxopiperidin-1- yl)ethyl]pyrimidine-4-carboxamide 403 K

N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1- methyl-1-[methyl(pyridin-2- ylmethyl)amino]ethyl}pyrimidine-4- carboxamide 426 C

N-[1-(4-{[(4-fluorobenzyl)amino]- carbonyl}-5,6-dihydroxypyrimidin- 2-yl)-1-methylethyl]-4-methylmorpholine- 2-carboxamide 448 I

2-{1-[acetyl(methyl)amino]-1- methylethyl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 377 I

2-[1-(acetylamino)-1-methylethyl]-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 363 I

2-{1-[4-(dimethylamino)piperidin-1-yl]- 1-methylethyl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide E

N-(2,3-dimethoxybenzyl)-2-[1- (dimethylamino)-1-methylethyl]-5,6- dihydroxypyrimidine-4-carboxamide 391 A

2-[4-(dimethylamino)tetrahydro-2H- pyran-4-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide C

N-(4-fluorobenzyl)-5,6-dihydroxy-2-(7- methyl-7-azabicyclo[2.2.1]hept-1- yl)pyrimidine-4-carboxamide 373 C

2-(7-acetyl-7-azabicyclo[2.2.1]hept-1- yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 401 A

2-(2-acetyl-2-azabicyclo[2.1.1]hex-1- yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 387 A

N-(4-fluorobenzyl)-5,6-dihydroxy-2-(2- methyl-2-azabicyclo[2.1.1]hex-1- yl)pyrimidine-4-carboxamide 359 C

TABLE 17B Structure Name M + 1 Procedure

tert-butyl (2S,4R)-4-(benzyloxy)-2-(4- {[(4-fluorobenzyl)amino]carbonyl}- 5,6-dihydroxypyrimidin-2- yl)piperidine-1-carboxylate 553 A

2-[(2S,4R)-4-(benzyloxy)piperidin-2- yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 453  A*

2-[(2S,4R)-4-(benzyloxy)-1- methylpiperidin-2-yl]-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 467 C

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [(2S,4R)-4-hydroxy-1-methylpiperidin- 2-yl]pyrimidine-4-carboxamide 377 A*

2-[1-acetyl-4-(benzyloxy)piperidin- 2-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 495 I

TABLE 21B Structure Name M + 1 Procedure

2-(1-ethyl-4-methylpiperazin-2-yl)- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 390 A

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [4-methyl-1-(pyrazin-2-ylcarbonyl) piperazin-2-yl]pyrimidine-4- carboxamide 468 A

TABLE 22B Structure Name M+1 Procedure

tert-butyl3-(4-{[(4- fluorobenzyl)amino]carbonyl}5,6-dihydroxypyrimidin-2- yl)thiomorpholine-4-carboxylate 465 A

N-(4-fluorobenzyl)-5,6- dihydroxy-2-thiomorpholin-3- ylpyrimidine-4-carboxamide 365 A*

N-(4-fluorobenzyl)-5,6- dihydroxy-2-(4- methylthiomorpholin-3- yl)pyrimidine-4-carboxamide 379 C

N-(4-fluorobenzyl)-5,6- dihydroxy-2-[4-(pyridin-2- ylcarbonyl)thiomorpholin-3- yl]pyrimidine-4-carboxamide 470 I

2-(4-acetylthiomorpholin-3-yl)- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 407 I

tert-butyl 1-(4-{[(4- fluorobenzyl)amino]carbonyl}5,6-dihydroxypyrimidin-2-yl)-2- methoxyethylcarbamate 437 A

2-[1-(dimethylamino)-2- methoxyethyl]-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 365 C

2-[1-(acetylamino)-2- methoxyethyl]-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 379 I

2-(1-amino-2-methoxyethyl)-N- (4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 337 A*

N-(4-fluorobenzyl)-5,6- dihydroxy-2-{2-methoxy-1- [(pyridin-2- ylcarbonyl)amino]ethyl}pyrimidine- 4-carboxamide 442 I

N-(4-fluorobenzyl)-2-[1- (formylamino)-2-methoxyethyl]- 5,6-dihydroxypyrimidine-4- carboxamide 365 A

N-(4-fluorobenzyl)-5,6- dihydroxy-2-[2-methoxy-1- (methylamino)ethyl]pyrimidine 4-carboxamide 352 A

2-{1-[acetyl(methyl)amino]-2- methoxyethyl}-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 393 I

N-(4-fluorobenzyl)-5,6- dihydroxy-2-{2-methoxy-1- [methyl(pyridin-2- ylcarbonyl)amino]ethyl}pyrimidine- 4-carboxamide 456 I

TABLE 23B Structure Name M+1 Procedure

N-(4-fluorobenzyl)-5,6- dihydroxy-2-[(4R)-3- (pyridin-2-ylcarbonyl)-1,3- thiazolidin-4-yl]pyrimidine- 4-carboxamide 456 I

N-(4-fluorobenzyl)-5,6- dihydroxy-2-[(4R)-1,3- thiazolidin-4-yl]pyrimidine- 4-carboxamide 351 A*

N-(4-fluorobenzyl)-5,6- dihydroxy-2-[(4R)-3-methyl- 1,3-thiazolidin-4- yl]pyrimidine-4-carboxamide 365 C

2-(3-acetyl-1,3-thiazolidin- 2-yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4- carboxamide 393 I

N-(4-fluorobenzyl)-5,6- dihydroxy-2-(3-methyl-1,3- thiazolidin-2-yl)pyrimidine- 4-carboxamide 365 C

TABLE 25B Structure Name M+1 Procedure

N-(4-fluorobenzyl)-5,6-dihydroxy-2- (1,2,4-trimethylpiperazin-2- yl)pyrimidine-4-carboxamide 390 C

2-{2,4-dimethyl-1-(pyrazin-2- ylcarbonyl)piperazin-2-yl]-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 482 C

2-(1-acetyl-2,4-dimethylpiperazin-2- yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 418 C

tert-butyl 1-(4-{[(4- fluorobenzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)-2-methoxy- 1-methylethylcarbamate 451 A

2-(1-amino-2-methoxy-1- methylethyl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 351 A*

2-[1-(acetylamino)-2-methoxy-1- methylethyl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 393 I

2-[1-(dimethylamino)-2-methoxy-1- methylethyl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 379 C

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [2-methoxy-1-methyl-1- (methylamino)ethyl]pyrimidine-4- carboxamide 365 C

N-(4-fluorobenzyl)-5,6-dihydroxy-2- {(2-methoxy-1-methyl-1-[(pyridin-2- ylcarbonyl)amino]ethyl}pyrimidine- 4-carboxamide 456 G

2-(1,2-dimethylpiperidin-2-yl)-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 375 C

2-{1-[acetyl(methyl)amino]-2- methoxy-1-methylethyl}-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 407 C

N-(4-fluorobenzyl)-5,6-dihydroxy-2- {2-methoxy-1-methyl-1- [methyl(pyridin-2- ylcarbonyl)amino]ethyl}pyrimidine- 4-carboxamide 470 I

2-{1- [(cyclohexylmethyl)(methyl)amino]- 2-methoxy-1-methylethyl}-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 461 C

2-{1-[(cyclohexylmethyl)amino]-2- methoxy-1-methylethyl}-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 447 C

2-{1-[(cyclohexylmethyl)amino]-2- methoxy-1-methylethyl}-N-(4- fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 361 A*

2-(4-acetyl-1,2-dimethylpiperazin-2- yl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 418 A

2-(1-acetyl-2-methylpiperidin-2-yl)- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 403 A

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [2-methyl-1-(pyrazin-2- ylcarbonyl)piperidin-2-yl]pyrimidine- 4-carboxamide 467 A

N-(2,3-dimethoxybenzyl)-2-(1,2- dimethylpiperidin-2-yl)-5,6- dihydroxypyrimidine-4-carboxamide 417 C

N-(4-fluorobenzyl)-5,6-dihydroxy-2- [2-methyl-1-(pyridin-2- ylcarbonyl)piperidin-2-yl]pyrimidine- 4-carboxamide 466 A

2-{1-[(2,4-dimethyl-1,3-thiazol-5- yl)carbonyl]-2-methylpiperidin-2-yl}- N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 500 A

2-[(2S)-1-acetyl-2-methylpyrrolidin- 2-yl]-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide 389 A

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, the practice of the invention encompasses all of the usual variations, adaptations and/or modifications that come within the scope of the following claims. 

1. A compound of Formula (I):

wherein R¹ is (1) —H, (2) —C₁₋₆ alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—C₀₋₆ alkyl-N(R^(a)R^(b)), N(R^(a))—C(═O)—C₀₋₆ alkyl-N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b),

 —N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)), or —N(R^(a))C(═O)OR^(b), (3) —O—C₁₋₆ alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—C₀₋₆ alkyl-N(R^(a)R^(b)), N(R^(a))—C(═O)—C₀₋₆ alkyl-N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (4) —R^(k), (5) —C₁₋₆ alkyl-R^(k), wherein the alkyl is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —N(R^(a))C(═O)—C₀₋₆ alkyl-N(R^(b)R^(c)), or —N(R^(a))—C₂₋₆ alkyl-OH with the proviso that the —OH is not attached to the carbon alpha to N(R^(a)), (6) —C₂₋₅ alkenyl—R^(k), (7) —C₂₋₅ alkynyl—R^(k), (8) —C₀₋₆ alkyl-O—C₀₋₆ alkyl-R^(k), (9) —C₀₋₆ alkyl-S(O)n—C₀₋₆ alkyl-R^(k), (10) —O—C₁₋₆ alkyl-OR^(k), (11) —O—C₁₋₆ alkyl-O—C₁₋₆ alkyl-R^(k), (12) —O—C₁₋₆ alkyl-S(O)_(n)R^(k), (13) —C₀₋₆ alkyl-N(R^(a))—R^(k), (14) —C₀₋₆ alkyl-N(R^(a))—C₁₋₆ alkyl-R^(k), (15) —C₀₋₆ alkyl-N(R^(a))—C₁₋₆ alkyl-OR^(k), (16) —C₀₋₆ alkyl-C(═O)—R^(k), (17) —C₀₋₆ alkyl-C(═O)N(R^(a))—C₀₋₆ alkyl-R^(k), (18) —C₀₋₆ alkyl-N(R^(a))C(═O)—C₀₋₆ alkyl-R^(k), (19) —C₀₋₆ alkyl-N(R^(a))C(═O)—O—C₀₋₆ alkyl-R^(k), (20) —C₁₋₆ alkyl which is: (i) substituted with aryl or —O-aryl, wherein the aryl is optionally substituted with one or more substituents each of which is independently halogen, —OH, —C₁₋₆ alkyl, —C₁₋₆ alkyl-OR^(a), —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or aryl; (ii) substituted with —R^(k), —C₁₋₆ alkyl-R^(k), —N(R^(a))—C(═O)—C₀₋₆ alkyl-R^(k), —C₀₋₆ alkyl-N(R^(a))—C₀₋₆ alkyl-R^(k), —C₀₋₆ alkyl-O—C₀₋₆ alkyl-R^(k), or —C₀₋₆ alkyl-N(R^(a))—C(═O)—C₀₋₆ alkyl-R^(k); and (iii) optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, or —N(R^(a)R^(b)), or (21) —C₁₋₆ alkyl, substituted with —O—C₁₋₆ alkyl, and with a substituent selected from the group consisting of —N(R^(a))C(═O)R^(k) and —N(R^(a))C₁₋₆ alkyl-R^(k), R² is —H or —C₁₋₆ alkyl which is optionally substituted with one or more substituents each of which is independently (1) halogen, (2) —OH, (3) —CN, (4) —O—C₁₋₆ alkyl, (5) —O—C₁₋₆ haloalkyl, (6) —C(═O)R^(a), (7) —CO₂R^(a), (8) —SR^(a), (9) —S(═O)R^(a), (10) —N(R^(a)R^(b)), (11) —C(═O)N(R^(a)R^(b)), (12) —N(R^(a))—C(═O)—C₁₋₆ alkyl-N(R^(b)R^(c)), (13) —SO₂R^(a), (14) —N(R^(a))SO₂R^(b), (15) —SO₂N(R^(a)R^(b)), (16) —N(R^(a))—C(R^(b))═O, (17) —C₃₋₈ cycloalkyl, (18) aryl, wherein the aryl is optionally substituted with one or more substituents each of which is independently halogen, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C₀₋₆ alkyl-N(R^(a)R^(b)), or —C₁₋₆ alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently —C₁₋₆ alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or (19) a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heterocycle is optionally substituted with one or more substituents each of which is independently —C₁₋₆ alkyl, —O—C₁₋₆ alkyl, oxo, phenyl, or naphthyl; R³ is —H or —C₁₋₆ alkyl; R⁴ is (1) H, (2) C₁₋₆ alkyl which is optionally substituted with one or more substituents each of which is independently halogen, —OH, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —NO₂,—N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), or —N(R^(a))CO₂R^(b), (3) C₁₋₆ alkyl which is optionally substituted with one or more substituents each of which is independently halogen, —OH, or O—C₁₋₄ alkyl, and which is substituted with 1 or 2 substituents each of which is independently: (i) C₃₋₈ cycloalkyl, (ii) aryl, (iii) a fused bicyclic carbocycle consisting of a benzene ring fused to a C₅₋₇ cycloalkyl, (iv) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, (v) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or (vi) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic, (4) C₂₋₅ alkynyl optionally substituted with aryl, (5) C₃₋₈ cycloalkyl optionally substituted with aryl, (6) aryl, (7) a fused bicyclic carbocycle consisting of a benzene ring fused to a C₅₋₇ cycloalkyl, (8) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, (9) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or (10) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic; wherein each aryl in (3)(ii) or the aryl (4), (5) or (6) or each fused carbocycle in (3)(iii) or the fused carbocycle in (7) is optionally substituted with one or more substituents each of which is independently halogen, —OH, —C₁₋₆ alkyl, —C₁₋₆ alkyl-OR^(a), —C₁₋₆ haloalkyl, —O—C₁₋₆ alky, —O—C₁₋₆ haloalkyl, —CN, —NO₂, —N(R^(a)R^(b)), —C₁₋₆ alkyl-N(R^(a)R^(b)), —C(═O)N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —C₁₋₆ alkyl-CO₂R^(a), —OCO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))C(═O)R^(b), —N(R^(a))CO₂R^(b), —C₁₋₆ alkyl-N(R^(a))CO₂R^(b), aryl, —C₁₋₆ alkyl-aryl, —O-aryl, or —C₀₋₆ alkyl-het wherein het is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with one or more substituents each of which is independently —C₁₋₆ alky, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, oxo, or —CO₂R^(a); each saturated heterocyclic ring in (3)(iv) or the saturated heterocyclic ring in (8) is optionally substituted with one or more substituents each of which is independently halogen, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, oxo, aryl, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, —O and S; and each heteroaromatic ring in (3)(v) or the heteroaromatic ring in (9) or each fused bicyclic heterocycle in (3)(vi) or the fused bicyclic heterocycle in (10) is optionally substituted with one or more substituents each of which is independently halogen, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, oxo, aryl, or —C₁₋₆ alkyl-aryl; or alternatively R³ and R⁴ together with the N to which both are attached form a C₃₋₇ azacycloalkyl which is optionally substituted with one or more substituents each of which is independently —C₁₋₆ alkyl or oxo; each R^(a), R^(b), R^(c), and R^(d) is independently —H or —C₁₋₆ alkyl; R^(k) is carbocycle or heterocycle, wherein the carbocycle or heterocycle is optionally substituted with one or more substituents each of which is independently (1) halogen, (2) —OH, (3) —CN, (4) —C₁₋₆ alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)-—(CH₂)₀₋₂N(R^(b)R^(c)),—SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (5) —O—C₁₋₆ alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (6) —NO₂, (7) oxo, (8) ethylenedioxy, spiro substituted on a ring carbon in a saturated ring of R^(k); (9) —C(═O)R^(a), (10) —CO₂R^(a), (11) —SR^(a), (12) —S(═O)R^(a), (13) —N(R^(a)R^(b)), (14) —C(═O)N(R^(a)R^(b)), (15) —C(═O)—C₁₋₆ alkyl-N(R^(a)R^(b)), (16) —N(R^(a))C(═O)R^(b), (17) —SO₂R^(a), (18) —SO₂N(R^(a)R^(b)), (19) —N(R^(a))SO₂R^(b), (20) —R^(m), (21) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (22) —C₀₋₆ alkyl-N(R^(a))—C₀₋₆ alkyl-R^(m), (23) —C₀₋₆ alkyl-O—C₀₋₆ alkyl-R^(m), (24) —C₀₋₆ alkyl-S—C₀₋₆ alkyl-R^(m), (25) —C₀₋₆ alkyl-C(═O)—C₀₋₆ alkyl-R^(m), (26) —C(═O)—O—C₀₋₆ alkyl-R^(m), (27) —C(═O)N(R^(a))—C₀₋₆ alkyl-R^(m), (28) —N(R^(a))C(═O)—R^(m), (29) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with one or more substituents each of which is independently halogen, —OH, —CN, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (30) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₆ alkyl-R^(m), (31) —N(R^(a))—C(═O)—O—C₀₋₆ alkyl-R^(m), or (32) —N(R^(a))—C(═O)—N(R^(b))—SO₂—C₀₋₆ alkyl-R^(m); carbocycle in R^(k) is (i) a C₃ to C₈ monocyclic, saturated or unsaturated ring, (ii) a C₇ to C₁₂ bicyclic ring system, or (iii) a C₁₁ to C₁₆ tricyclic ring system, wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated; heterocycle in R^(k) is (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring, (ii) a 7- to 12-membered bicyclic ring system, or (iii) an 11 to 16-membered tricyclic ring system; wherein each ring in (ii) or (iii) is independent of or fused to or bridged with or spiro to the other ring or rings and each ring is saturated or unsaturated; the monocyclic ring, bicyclic ring system, or tricyclic ring system contains from 1 to 6 heteroatoms selected from N, O and S and a balance of carbon atoms; and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally be oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized; each R^(m) is independently C₃₋₈ cycloalkyl; aryl; a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; or a 9- to 10-membered bicyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein any one or more of the nitrogen and sulfur heteroatoms in the monocyclic or bicyclic heterocycle is optionally oxidized and any one or more of the nitrogen heteroatoms is optionally quaternized; and wherein the cycloalkyl or the aryl is optionally substituted with one or more substituents each of which is independently halogen, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —N(R^(a)R^(b)), aryl, or —C₁₋₆ alkyl-aryl; and the monocyclic or bicyclic heterocycle is optionally substituted with one or more substituents each of which is independently halogen, —C₁₋₆ alkyl optionally substituted with —O—C₁₋₆ alkyl, —C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, oxo, aryl, —C₁₋₆ alkyl-aryl, —C(═O)-aryl, —CO₂-aryl, —CO₂—C₁₋₆ alkyl-aryl, a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and each n is independently an integer equal to zero, 1 or 2; or a pharmaceutically acceptable salt thereof.
 2. The compound according to claim 1, wherein R¹ is: (1) —H, (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b),

 —N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)), or —N(R^(a))C(═O)OR^(b), (3) —R^(k), (4) —C₁₋₄ alkyl-R^(k), wherein the alkyl is optionally substituted with 1 or 2 substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —N(R^(a)R^(b)), or —N(R^(a))—(CH₂)₂₋₄—OH, (5) —O—(CH₂)₀₋₃—R^(k), (6) —C₁₋₄ alkyl-O—(CH₂)₀₋₃—R^(k), (7) —(CH₂)₀₋₃—S(O)_(n)—(CH₂)₀₋₃—R^(k), (8) —O—(CH₂)₁₋₃—OR^(k), (9) —O—(CH₂)₁₋₃—O—(CH₂)₁₋₃—R^(k), (10) —O—(CH₂)₁₋₃—S(O)_(n)R^(k), (11) —(CH₂)₀₋₃—N(R^(a))—R^(k), (12) —(CH₂)₀₋₃—N(R^(a))—(CH₂)₁₋₃—R^(k), (13) —(CH₂)₀₋₃—N(R^(a))—(CH₂)₁₋₃—OR^(k), (14) —(CH₂)₀₋₃—C(═O)—R^(k), (15) —(CH₂)₀₋₃—C(═O)N(R^(a))—(CH₂)₀₋₃—R^(k), (16) —(CH₂)₀₋₃—N(R^(a))C(═O)—(CH₂)₀₋₃—R^(k), (17) —(CH₂)₀₋₃—N(R^(a))C(═O)—O—(CH₂)₀₋₃—R^(k), (18) —C₁₋₆ alkyl which is: (i) substituted with aryl or —O-aryl, wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄ alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or aryl; (ii) substituted with —R^(k), —(CH₂)₁₋₃—R^(k), —N(R^(a))—C(═O)—(CH₂)₀₋₃—R^(k), —(CH₂)₀₋₃—N(R^(a))—(CH₂)₀₋₃—R^(k), or —(CH₂)₀₋₃—O—(CH₂)₀₋₃—R^(k), or —(CH₂)₀₋₃—N(R^(a))—C(═O)—(CH₂)₀₋₃—R^(k); and (iii) optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or —N(R^(a)R^(b)), (19) —C(CH₃)₂N(R^(a))C(═O)OCH₂R^(k), (20) —C(CH₃)₂N(R^(a))CH₂R^(k), (21) —C(CH₃)₂N(R^(a))C(═O)R^(k), (22) —C(R^(b))(N(R^(a))C(═O)R^(k))(CH₂OR^(c)), or (23) —C(R^(b))(N(R^(a))(CH₂)—R^(k))(CH₂OR_(c)), or a pharmaceutically acceptable salt thereof.
 3. The compound according to claim 2, wherein R¹ is: (1) —H, (2) —C₁₋₄ alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(═O)R^(b),

 —N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)), or —N(R^(a))C(═O)OR^(b), (3) —R^(k), (4) —CH(CH₃)—R^(k), (5) —(CH₂)₁₋₄—R^(k), wherein the —(CH₂)₁₋₄— moiety is optionally substituted with one of —N(R^(a)R^(b)) or —N(R^(a))—(CH₂)₂—OH, (6) —(CH₂)₁₋₂—O—(CH₂)₀₋₁—R^(k), (7) —(CH₂)₁₋₂—S(O)_(n)—(CH₂)₀₋₁—R^(k), (8) —O—(CH₂)₁₋₂—OR^(k), (9) —O—(CH₂)₁₋₂—(CH₂)₁₋₂—R^(k), (10) —O—(CH₂)₁₋₂—S(O)_(n)R^(k), (11) —(CH₂)₁₋₂—N(R^(a))—R^(k), (12) —(CH₂)₁₋₂—N(R^(a))—(CH₂)₁₋₃—R^(k), (13) —(CH₂)₁₋₂—N(R^(a))—(CH₂)₁₋₃-OR^(k), (14) —(CH₂)₀₋₂—C(═O)—R^(k), (15) —C(═O)N(R^(a))—(CH₂)₁₋₂—R^(k), (16) —(CH₂)₀₋₂—C(═O)N(R^(a))—(CH₂)₀₋₂—R^(k), (17) —(CH₂)₁₋₂—N(R^(a))C(═O)—(CH₂)₀₋₁—R^(k), (18) —(CH₂)₁₋₂—N(R^(a))C(═O)—O—(CH₂)₀₋₁—R^(k), (19) —C₁₋₄ alkyl which is: (i) substituted with aryl or —O-aryl wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, methylenedioxy attached to two adjacent carbon atoms, or phenyl; (ii) substituted with —R^(k), —(CH₂)₁₋₃—R^(k), —N(R^(a))—C(═O)—(CH₂)₀₋₃—R^(k), —N(R^(a))—(CH₂)₁₋₃—R^(k), —O—(CH₂)¹⁻²—R^(k), or —N(R^(a))—C(═O)—(CH₂)₀₋₂—R^(k); and (iii) optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or —N(R^(a)R^(b)), (20) —C(CH₃)₂N(R^(a))C(═O)OCH₂R^(k), (21) —C(CH₃)₂N(R^(a))CH₂R^(k), (22) —C(CH₃)₂N(R^(a))C(═O)R^(k), (23) —C(R^(b))(N(R^(a))C(═O)R^(k))(CH₂OR^(c)), or (24) —C(R^(b))(N(R^(a))(CH₂)—R^(k))(CH₂OR^(c)), or a pharmaceutically acceptable salt thereof.
 4. The compound according to claim 1, wherein R^(k) is C₃₋₈ cycloalkyl; aryl selected from phenyl and naphthyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently (1) halogen, (2) —OH, (3) —CN, (4) —C₁₋₄ haloalkyl, (5) —C₁₋₄ alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently —OH, —CN, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (6) —O—C₁₋₄ haloalkyl (7) —O—C₁₋₄ alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently —OH, —CN, —O—C₁₋₆ alkyl, —O—C₁₋₆ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (8) —NO2, (9) oxo, (10) —C(═O)R^(a), (11) —CO₂R^(a), (12) —SR^(a), (13) —S(═O)R^(a), (14) —N(R^(a)R^(b)), (15) —C(═O)N(R^(a)R^(b)), (16) —C(═O)—C₁₋₆ alkyl-N(R^(a)R^(b)), (17) —N(R^(a))C(═O)R^(b), (18) —SO₂R^(a), (18) —SO₂N(R^(a)R^(b)), (19) —N(R^(a))SO₂R^(b), (20) —R^(m), (21) —CH(CH₃)—R^(m), (22) —(CH₂)₁₋₄—R^(m), (23) —(CH₂)₀₋₂—N(R^(a))—(CH₂)₀₋₂—R^(m), (24) —(CH₂)₀₋₂—O—(CH₂)₀₋₂—R^(m), (25) —(CH₂)₀₋₂—S—(CH₂)₀₋₂—R^(m), (26) —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m), (27) —C(═O)—O—(CH₂)₀₋₂—R^(m), (28) —C(═O)N(R^(a))—R^(m), (29) —N(R^(a))C(═O)—R^(m), (30) —N(R^(a))C(═O)—(CH₂)₁₋₃—R^(m), wherein the —(CH₂)₁₋₃— moiety is optionally substituted with one of —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (31) —N(R^(a))—C(═O)—N(R^(b))—(CH₂)1-2—R^(m), (32) —N(R^(a))—C(═O)—O—(CH₂)₁₋₂—R^(m), or (33) —N(R^(a))—C(═O)N(R^(b))SO₂—R^(m); or a pharmaceutically acceptable salt thereof.
 5. The compound according to claim 4, wherein each R^(m) is independently C₅₋₇ cycloalkyl; aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered, saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S; wherein the cycloalkyl or the aryl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —N(R^(a)R^(b)), phenyl, or —(CH₂)₁₋₂-phenyl; the saturated heterocyclic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C₁₋₄ alkyl optionally substituted with —O—C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, —CO₂—(CH₂)₁₋₂-phenyl, a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and the heteroaromatic ring or the bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl, or —(CH₂)₁₋₂-phenyl; or a pharmaceutically acceptable salt thereof.
 6. The compound according to claim 4, wherein R^(k) is cycloalkyl selected from cyclopropyl, cyclopentyl and cyclohexyl; aryl selected from phenyl and naphthyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyranyl, tetrahydrofuranyl, imidazolidinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isooxazolidinyl, and pyrazolidinyl; a 5- or 6-membered heteroaromatic ring selected from thienyl, pyridyl, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxopiperidinyl, oxazolyl, isooxazolyl, oxadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl; or a bicyclic heterocycle selected from indolyl, indolinyl, tetrahydroquinolinyl, quinolinyl, 1,4-dioxa-8-azaspiro[4.5]decyl, azabicyclo[2.2.1]heptyl, azabicyclo[2.1.1]hexyl, tetrahydroisoquinolinyl, isoquinolinyl, 2,3-dihydrobenzofuranyl, 2,3dihydrobenzo -1,4-dioxinyl, and benzo-1,3-dioxolyl; wherein the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently (1) fluoro, (2) chloro, (3) bromo, (4) —CF₃, (5) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently —OH, —CN, —O—C₁₋₄ alkyl, —OCF₃, —N(R^(a)R^(b)), —C(═O)N(R^(a)R^(b)), or N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), (6) —OCF₃, (7) —O—C₁₋₄ alkyl (8) —NO₂, (9) oxo, (10) —C(═O)R^(a), (11) —CO₂R^(a), (12) —SR^(a), (13) —S(═O)R^(a), (14) —N(R^(a)R^(b)), (15) —C(═O)N(R^(a)R^(b)), (16) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), (17) —N(R^(a))C(═O)R^(b), (18) —SO₂R^(a), (19) —R^(m), (20) —CH(CH₃)—R^(m), (21) —CH₂—R^(m), (22) —(CH₂)₀₋₂—N(R^(a))—(CH₂)₀₋₂—R^(m), (23) —O—(CH₂)₁₋₂—R^(m), (24) —(CH₂)—₀₋₁—S—(CH₂)₀₋₂—R^(m), (25) —(CH₂)₀₋₁—C(═O)—(CH₂)₀₋₂—R^(m), (26) —(CH₂)₀₋₁—C(═O)—O—(CH₂)₀₋₂—R^(m), (27) —C(═O)N(R^(a))—R^(m), (28) —N(R^(a))C(═O)R^(m), (29) —N(R^(a))C(═O)—(CH₂)₁₋₂—R^(m), wherein the —(CH₂)₁₋₂- moiety is optionally substituted with —N(R^(a)R^(b)), (30) —N(R^(a))—C(═O)—N(R^(b))—(CH₂)₁₋₂—R^(m), (31) —N(R^(a))—C(═O)—O—(CH₂)₁₋₂—R^(m), (32) —N(R^(a))—C(═O)—N(R^(b))SO₂—R^(m), (33) —OH; or a pharmaceutically acceptable salt thereof.
 7. The compound according to claim 6, wherein each R^(m) is independently aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, thiazolidinyl, and morpholinyl; or a 5- or 6-membered heteroaromatic ring selected from thienyl, pyridyl, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, oxo, phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, or —CO₂—CH₂-phenyl; and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, oxo, phenyl, or —(CH₂)₁₋₂-phenyl; or a pharmaceutically acceptable salt thereof.
 8. The compound according to claim 1, wherein R² is —H or —C₁₋₆ alkyl which is optionally substituted with one of: (1) —N(R^(a)R^(b)), (2) phenyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or —C₀₋₆ alkyl-N(R^(a)R^(b)), or (3) a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently —C₁₋₆ alkyl, —O—C₁₋₆ alky, oxo, or phenyl; or a pharmaceutically acceptable salt thereof.
 9. The compound according to claim 8, wherein R² is (1) —H, (2) —C₁₋₄ alkyl, (3) —(CH₂)₁₋₃—N(R^(a)R^(b)), (4) —(CH₂)₁₋₃-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, or —(CH₂)₁₋₃—N(R^(a)R^(b)); or (5) —(CH₂)₁₋₃R^(t), wherein R^(t) is a 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a pharmaceutically acceptable salt thereof.
 10. The compound according to claim 9, wherein R² is —H or methyl; or a pharmaceutically acceptable salt thereof.
 11. The compound according to claim 10, wherein R² is —H; or a pharmaceutically acceptable salt thereof.
 12. The compound according to claim 1, wherein R³ is —H or —C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof.
 13. The compound according to claim 12, wherein R³ is —H or methyl; or a pharmaceutically acceptable salt thereof.
 14. The compound according to claim 13, wherein R³ is —H; or a pharmaceutically acceptable salt thereof.
 15. The compound according to claim 1, wherein R⁴ is (1) C₁₋₄ alkyl, (2) C₁₋₄ alkyl substituted with from 1 to 3 substituents each of which is independently —OH, O—C₁₋₄ alkyl, or —O—C₁₋₄ haloalkyl, (3) C₁₋₄ alkyl which is substituted with an aryl or with two aryls which are the same or different, and is optionally substituted with —OH, (4) C₁₋₄ alkyl substituted with one of: (i) C₅₋₇ cycloalkyl, (ii) a fused bicyclic carbocycle consisting of a benzene ring fused to a C₅₋₇ cycloalkyl, (iii) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, (iv) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or (v) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic; (5) C₂₋₄ alkynyl optionally substituted with aryl, (6) C₃₋₇ cycloalkyl optionally substituted with aryl, (7) aryl, (8) a fused bicyclic carbocycle consisting of a benzene ring fused to a C₅₋₇ cycloalkyl, (9) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, (10) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or (11) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic; wherein each aryl in (3) or the aryl in (5), (6) or (7) or the fused carbocycle in (4)(ii) or (8) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄ alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —CN, —NO₂, —N(R^(a)R^(b)), —C₁₋₄ alkyl-N(R^(a)R^(b)), —C(═O)N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —C₁₋₄ alkyl-CO₂R^(a), —OCO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))C(═O)R^(b), —N(R^(a))CO₂R^(b), —C₁₋₄ alkyl-N(R^(a))CO₂R^(b), phenyl, —C₁₋₄ alkyl-phenyl, —O-phenyl, or —(CH₂)₀₋₂—Het wherein het is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or —CO₂R^(a); the saturated heterocyclic ring in (4)(iii) or (9) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and the heteroaromatic ring in (4)(iv) or (10) or the fused bicyclic heterocycle in (4)(v) or (11) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, or phenyl; or a pharmaceutically acceptable salt thereof.
 16. The compound according to claim 15, wherein R⁴ is: (1) C₁₋₃ alkyl substituted with 1 or 2 phenyls, and is optionally substituted with an —OH, (2) C₁₋₄ alkyl substituted with one of: (i) cyclohexyl, (ii) naphthyl, (iii) a fused bicyclic carbocycle selected from

(iv) a saturated heterocyclic ring containing from zero to 1 oxygen atoms and from 1 to 3 nitrogen atoms, (v) a 5- or 6-membered heteroaromatic ring containing from zero to 1 heteroatoms selected from O and S and from 1 to 3 nitrogen atoms, or (vi) a fused bicyclic heterocycle selected from

(3) wherein R^(u) is H or phenyl, (4) C₃₋₆ cycloalkyl optionally substituted with phenyl, (5) phenyl or naphthyl, (6) a fused bicyclic carbocycle selected from

(7) a saturated heterocyclic ring containing from zero to 1 oxygen atoms and from 1 to 3 nitrogen atoms, (8) a 5- or 6-membered heteroaromatic ring containing from zero to 1 heteroatoms selected from O and S and from 1 to 3 nitrogen atoms, or (9) a fused bicyclic heterocycle selected from

wherein Z₁ is —H or —OH; each phenyl in (1) or the phenyl in (3) or (4) or (5) or the naphthyl in (2)(ii) or (5) is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, —OH, —C₁₋₄ ally, —CF_(3, —O—C) ₁₋₄ alkyl, —OCF₃, —CN, —NO₂, —(CH₂)₁₋₂—N(R^(a)R^(b)), —C(═O)R^(a), —C₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))CO₂Rb; and is additionally and optionally mono-substituted with phenyl, —(CH₂)₁₋₂-phenyl, —O-phenyl, or —(CH₂)₀₋₂-het wherein het is thiadiazolyl or indolyl, and het is optionally substituted with —C₁₋₄ alkyl, —CF_(3, —O—C) ₁ ₋₆ alkyl, —OCF₃, or —CO₂R^(a); the saturated heterocyclic ring in (2)(iv) or (7) is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ ally, —OCF₃, oxo; and is additionally and optionally mono-substituted with phenyl or a heteroaromatic ring selected from pyridyl, pyrimidinyl, and pyrazinyl; and the heteroaromatic ring in (2)(v) or (8) is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF_(3, —O—C) ₁₋₄ alkyl, —OCF₃, or oxo; and is additionally and optionally mono-substituted with phenyl; or a pharmaceutically acceptable salt thereof.
 17. The compound according to claim 15, wherein R⁴ is:

wherein Q is (1) ethynyl optionally substituted with aryl, (2) C₅₋₇ cycloalkyl, (3) aryl, (4) a fused bicyclic carbocycle consisting of a benzene ring fused to a C₅₋₇ cycloalkyl, (5) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, (6) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or (7) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic; wherein aryl in (1) or (3) or the fused carbocycle in (4) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄ alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —CN, —NO₂, —N(R^(a)R^(b)), —C₁₋₄ alkyl-N(R^(a)R^(b)), —C(═O)N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —C₁₋₄ alkyl-CO₂R^(a), —OCO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))C(═O)R^(b), —N(R^(a))CO₂R^(b), —C₁₋₄ alkyl-N(R^(a))CO₂R^(b), phenyl, —C₁₋₄ alkyl-phenyl, —O-phenyl, or —(CH₂)₀₋₂-het wherein het is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or —CO₂R^(a); the saturated heterocyclic ring in (5) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and the heteroaromatic ring in (6) or the fused bicyclic heterocycle in (7) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, or phenyl; R⁵ is H, methyl, or CH₂OH, with the proviso that when R⁵ is CH₂OH, then Q is aryl; and p is an integer equal to zero, 1 or 2; or a pharmaceutically acceptable salt thereof.
 18. The compound according to claim 17, wherein Q is (1) —C≡C—R^(u) wherein R^(u) is H or phenyl, (2) phenyl or naphthyl, (3) cyclopentyl or cyclohexyl, (4) a fused bicyclic carbocycle selected from the group consisting of indanyl, tetrahydronaphthalenyl, and benzocycloheptyl, (5) a saturated heterocyclic ring selected from the group consisting of tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isooxazolidinyl, and pyrazolidinyl, (6) a heteroaromatic ring selected from the group consisting of thienyl, pyridyl, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl, or (7) a fused bicyclic heterocycle selected from the group consisting of benzothiophenyl, indolyl, pyridoimidazolyl, indazolyl, 2,3-dihydrobenzo-1,4-dioxinyl, dihydrobenzofuranyl, benzo-1,3-dioxolyl, quinolinyl, and isoquinolinyl; wherein the phenyl in (1) or the phenyl or naphthyl in (2) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —CN, —NO₂, —C₁₋₄ alkyl-N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —C₁₋₄ alkyl-CO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —C₁₋₄ alkyl-N(R^(a))CO₂R^(b), phenyl, —(CH₂)₁₋₂-phenyl, —O-phenyl, or —(CH₂)₀₋₂-het wherein het is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isothiazolyl, isooxazolyl, pyridyl, pyrazinyl, thiadiazolyl or indolyl, and het is optionally substituted with —C₁₋₄ alkyl, —CF₃, —O—C₁₋₆ alkyl, —OCF₃, oxo, or —CO₂R^(a); the fused carbocycle in (4) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C₁₋₄ alkyl-N(R^(a)R^(b)), —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —SO₂R^(a), —N(R^(a))CO₂R^(b), phenyl, —(CH₂)₁₋₂-phenyl, or —O-phenyl; the saturated heterocyclic ring in (5) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, phenyl, pyridyl, pyrazinyl, or pyrimidinyl; and the heteroaromatic ring in (6) or the fused bicyclic heterocycle in (7) is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, oxo, or phenyl; or a pharmaceutically acceptable salt thereof.
 19. The compound according to claim 18, wherein Q is phenyl, which is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, —OH, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, —CN, —SR^(a), —(CH₂)₁₋₂—N(R^(a)R^(b)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —(CH₂)₀₋₂—CO₂R^(a)*, —(CH₂)₀₋₂—N(R^(a))CO₂R^(b)*, —NO₂, or phenyl; each R^(a) is independently H, methyl, or ethyl; each R^(b) is independently H, methyl, or ethyl; and each R^(a)* and R^(b)* is independently H or —C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof.
 20. The compound according to claim 19, wherein R⁵ is H and p is zero; or a pharmaceutically acceptable salt thereof.
 21. The compound according to claim 20, wherein Q is phenyl which is optionally substituted with from 1 to 3 substituents, each of which is independently —F, —Br, —Cl, —OH, —C₁₋₄ alkyl, —C₁₋₄ fluoroalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ fluoroalkyl, —CN, —SR^(a) or —SO₂R^(a); or a pharmaceutically acceptable salt thereof.
 22. The compound according to claim 21, wherein Q is p-fluorophenyl or 2,3dimethoxyphenyl; or a pharmaceutically acceptable salt thereof.
 23. The compound according to claim 1, wherein R¹ is —R^(k); R^(k is a) 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently (1) halogen, (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (3) —NO₂, (4) oxo, (5) —C(═O)R^(a), (6) —CO₂R^(a), (7) —C(═O)N(R^(a)R^(b)), (8) —C(═O)—C₁₋₄ alky—N(R^(a)R^(b)), (9) —R^(m), (10) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (11) —C₀₋₄ alkyl-N(R^(a))—C₀₋₄ alkyl-R^(m), (12) —C₀₋₄ alkyl-O—C₀₋₄ alkyl-R^(m), (13) —C₀₋₄ alkyl-S—C₀₋₄ alkyl-R^(m), (14) —C₀₋₄ alkyl-C(═O)—C₀₋₄ alkyl-R^(m), (15) —C(═O)—O—C₀₋₄ alkyl-R^(m), (16) —C(═O)N(R^(a))—C₀₋₄ alkyl-R^(m), (17) —N(R^(a))C(═O)—R^(m), (18) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (19) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₄ alkyl-R^(m), (20) —N(R^(a))—C(═O)—O—C₀₋₄ alkyl-R^(m), or (21) —N(R^(a))—C(═O)—N(R^(b))SO₂—C₀₋₄ alkyl-R^(m); wherein each R^(m) is independently aryl selected from phenyl and naphthyl or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl or oxo; and each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof.
 24. The compound according to claim 23, wherein R¹ is:

wherein X¹ is a single bond connecting the carbonyl carbon to the carbon substituted with X², —O—, or —NH—; X² is —H. —NH₂, or —N(H)CO₂R^(a); Y¹is —H, halo or —C₁₋₄ alkyl; and r is an integer equal to zero, 1 or 2; and R^(6b)is —H or —NO₂; and R⁷ is —H or —C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof.
 25. The compound according to claim 24, wherein R^(6a) and R^(6b) are both —H; and R⁷ is —H or —CH₃; or a pharmaceutically acceptable salt thereof.
 26. The compound according to claim 25, wherein R² is —H or methyl; R³ is —H; and R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; or a pharmaceutically acceptable salt thereof.
 27. The compound according to claim 1, wherein: R¹ is —R^(k); R^(k) is phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently: (1) halogen, (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)),—SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (3) —NO₂, (4) —C(═O)R^(a), (5) —CO₂R^(a), (6) —C(═O)N(R^(a)R^(b)), (7) —C(═O)—C₁₋₄ alkyl-N(R^(a)R^(b)), (8) —R^(m), (9) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (10) —C₀₋₄ alkyl-N(R^(a))—C₀₋₄ alkyl-R^(m), (11) —C₀₋₄ alkyl-O—C₀₋₄ alkyl-R^(m), (12) —C₀₋₄ alkyl-S—C₀₋₄ alkyl-R^(m), (13) —C₀₋₄ alkyl-C(═O)—C₀₋₄ alkyl-R^(m), (14) —C(═O)—O—C₀₋₄ alkyl-R^(m), (15) —C(═O)N(R^(a))C₀₋₄ alkyl-R^(m), (16) —N(R^(a))C(═O)—R^(m), (17) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (18) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₄ alkyl-R^(m), (19) —N(R^(a))—C(═O)—O—C₀₋₄ alkyl-R^(m), or (20) —N(R^(a))—C(═O)—N(R^(b))SO₂—C₀₋₄ alkyl-R^(m); wherein each R^(m) is independently aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently —C₁₋₄ alkyl or oxo, and is additionally optionally mono-substituted with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, or —CO₂—(CH₂)₁₋₂-phenyl; and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl or oxo; or a pharmaceutically acceptable salt thereof.
 28. The compound according to claim 27, wherein R¹ is phenyl which is mono-substituted with one of: (1) fluoro, chloro, or bromo, (2) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently —OH, —O—C₁₋₄ alkyl, —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —N(R^(a)R^(b)), or —C(═O)N(R^(a)R^(b)), (3) —NO₂, (4) —C₁₋₄ alkyl-R^(m), (5) —O—(CH₂)₁₋₂—R^(m), (6) —(CH₂)₀₋₂—S—(CH₂)₀₋₂—R^(m) (7) —N(R^(a))C(═O)—R^(m), (8) —N(R^(a))C(═O)—(CH₂)₁₋₂—R^(m), wherein the (CH₂)₁₋₂ moiety is optionally mono-substituted with —N(R^(a)R^(b)) or —N(R^(a))CO₂R^(b), or (9) —N(R^(a))—C(═O)—N(R^(b))—(CH₂)₁₋₂—R^(m); wherein R^(m) is aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N and O; or a 5- or 6membered heteroaromatic ring containing from 1 or 2 nitrogens; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); and the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently —C₁₋₄ alkyl or oxo; and is additionally and optionally mono-substituted with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, or —CO₂—(CH₂)₁₋₂-phenyl; and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl or oxo; and each R^(a) and R^(b) is each independently —H or —C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof.
 29. The compound according to claim 28, wherein R² is —H or methyl; R³ is —H; and R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; or a pharmaceutically acceptable salt thereof.
 30. The compound according to claim 1, wherein R¹ is —R^(k); R^(k) is a 5- or 6-membered saturated heterocyclic ring containing from 0 to 1 oxygen atoms and from 1 to 3 nitrogen atoms or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated heterocyclic ring containing from 0 to 1 oxygen atoms and from 1 to 3 nitrogen atoms; wherein the saturated heterocyclic ring or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently (1) halogen, (2) —C₁₋₆ alkyl, which is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂N(R^(a)R^(b)), N(R^(a))—C(═O)—(CH₂)₀₋₂N(R^(b)R^(c)),—S₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (3) —NO₂, (4) oxo, (5) —C(═O)R^(a), (6) —CO₂R^(a), (7) —C(═O)N(R^(a)R^(b)), (8) —C(═O)—C₁₋₄ alkyl-N(R^(a)R^(b)), (9) —SR^(a), (10) —S(═O)R^(a), (11) —SO₂R^(a), (12) —N(R^(a)R^(b)), (13) —R^(m), (14) —C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (15) —C₀₋₄ alkyl-N(R^(a))—C₀₋₄ alkyl-R^(m), (16) —C₀₋₄ alkyl-O—C₀₋₄ alkyl-R^(m), (17) —C₀₋₄ alkyl-S—C₀₋₄ alkyl-R^(m), (18) —C₀₋₄ alkyl-C(═O)C₀₋₄ alkyl-R^(m), (19) —C(═O)—O—C₀₋₄ alkyl-R^(m), (20) —C(═O)N(R^(a))—C₀₋₄ alkyl-R^(m), (21) —N(R^(a))C(═O)—R^(m), (22) —N(R^(a))C(═O)—C₁₋₆ alkyl-R^(m), wherein the alkyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —OH, —CN, —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —N(R^(a))CO₂R^(b), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), or —N(R^(a))—C(R^(b))═O, (23) —N(R^(a))—C(═O)—N(R^(b))—C₀₋₄ alkyl-R^(m), (24) —N(R^(a))—C(═O)—O—C₀₋₄ alkyl-R^(m), or (25) —N(R^(a))—C(═O)—N(R^(b))SO₂—C₀₋₄ alkyl-R^(m); wherein each R^(m) is independently aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a 9- to 10-membered bicyclic heterocycle which is saturated or unsaturated and contains from 1 to 3 heteroatoms independently selected from N, O and S; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently —C₁₋₄ alkyl or oxo, and is additionally optionally mono-substituted with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, or —CO₂—(CH₂)₁₋₂-phenyl; and the heteroaromatic ring or the bicyclic heterocycle is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl or oxo; or a pharmaceutically acceptable salt thereof.
 31. The compound according to claim 30, wherein

R⁸ is: (1) —H (2) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently —OH, —O—C₁₋₄ alkyl, —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —N(R^(a)R^(b)), or —C(═O)N(R^(a)R^(b)), (3) —C(═O)R^(a), (4) —CO₂R^(a), (5) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), (6) —SO₂R^(a), (7) —(CH₂)₁₋₂—R^(m), (8) —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m), (9) —C(═O)—O—(CH₂)₀₋₂—R^(m), or (10) —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m); R⁹ is —H, —C₁₋₄ alkyl, or oxo; R¹⁰ is —H, —OH, —C₁₋₄ alkyl, —O—C₁₋₄ alkyl, oxo, or —O—(CH₂)₁₋₂—R^(m); R¹¹ is (1) —H, (2) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently —OH, —O—C₁₋₄ alkyl, —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —N(R^(a)R^(b)), or —C(═O)N(R^(a)R^(b)), (3) —C(═O)R^(a), (4) —CO₂R^(a), (5) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), (6) —SO₂R^(a), (7) —(CH₂)₁₋₂—R^(m), (8) —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m), (9) —C(═O)—O—(CH₂)₀₋₂—R^(m), or (10) —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m); with the proviso that when one of R⁸ and R¹¹ is —(CH₂)₁₋₂—R^(m), —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂—R^(m), —C(═O)—O—(CH₂)₀₋₂—R^(m), or —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m), then the other of R⁸ and R¹¹ is other than —(CH₂)₁₋₂—R^(m), —(CH₂)₀₋₂—C(═O)—(CH₂)₀₋₂R^(m), —C(═O)—O—(CH₂)₀₋₂—R^(m), or —C(═O)N(R^(a))—(CH₂)₀₋₂—R^(m); R^(m) is aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N and O; a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a saturated or unsaturated heterocycle containing from 1 to 3 nitrogen atoms; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, or —N(R^(a)R^(b)); and the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently —C₁₋₄ alkyl or oxo; and is additionally and optionally mono-substituted with phenyl, —(CH₂)₁₋₂-phenyl, —C(═O)-phenyl, —CO₂-phenyl, or —CO₂—(CH₂)₁₋₂-phenyl; and the heteroaromatic ring or the bicyclic heterocycle is optionally substituted with 1 or 2 substituents each of which is independently —C₁₋₄ alkyl or oxo; and each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof.
 32. The compound according to claim 31, wherein R² is —H or methyl; R³ is —H; and R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; or a pharmaceutically acceptable salt thereof.
 33. The compound according to claim 1, which is a compound of Formula (II):

Wherein T is: (1) —H, (2) —OH, (3) —C₁₋₄ haloalkyl, (4) —C₁₋₃ alkyl, optionally substituted with —OH or —O—C₁₋₄ alkyl, (5) —O—C₁₋₄ haloalkyl, (6) —O—C₁₋₄ alkyl (7) —N(R^(a)R^(b)), (8) —N(R^(a))—(CH₂)₂—OH, (9) —N(R^(a))—CO₂R^(b), (10) —N(R^(a))—C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), (11) —R^(k), (12) —(CH₂)₁₋₄—R^(k), (13) —(CH₂)₂₋₀—(CH₂)₀₋₂—R^(k), (14) —(CH₂)₀₋₂—N(R^(a))—(CH₂)₀₋₃—R^(k), or (15) —(CH₂)₀₋₂—N(R^(a))—C(═O)—(CH₂)₀₋₂—R^(k); R^(k) is aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C₁₋₄ alkyl, —C₁₋₄ alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or —N(R^(a)R^(b)); and the saturated heterocyclic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C₁₋₄ alkyl; —C₁₋₄ alkyl-OR^(a); —C₁₋₄ haloalkyl; —O—C₁₋₄ alkyl; —O—C₁₋₄ haloalkyl; —C(═O)R^(a); oxo; ethylenedioxy spiro substituted on a ring carbon; phenyl; —CH₂-phenyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; —CH₂-Saturated heterocycle which is a a 5- or 6-membered ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C₁₋₄ alkyl, —C₁₋₄ alkyl-OR^(a), —C₁₋₄ haloalkyl, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, or oxo; and the bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently —C₁₋₄ alkyl or oxo; R¹² is phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, Br, —C₁₋₄ alkyl, —CF₃, —0—C₁₋₄ alkyl, —OCF₃, methylenedioxy attached to two adjacent carbon atoms, or phenyl; each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl; and s is an integer equal to zero, 1, 2, or 3; or a pharmaceutically acceptable salt thereof.
 34. The compound according to claim 33, wherein R³ is —H; and R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; or a pharmaceutically acceptable salt thereof.
 35. The compound according to claim 33, wherein s is zero, 1 or 2; and with the proviso that when s is 1 or 2, T is —H; or a pharmaceutically acceptable salt thereof.
 36. The compound according to claim 1, which is a compound of Formula (III):

wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; or a pharmaceutically acceptable salt thereof.
 37. The compound according to claim 1, wherein R¹ is (1) —C₁₋₄ alkyl, which is optionally substituted with 1 to 3 substituents each of which is independently fluoro, chloro, —OH, —O—C₁₋₄ alkyl, —O—C₁₋₄ haloalkyl, —C(═O)R^(a), —CO₂R^(a), —SR^(a), —S(═O)R^(a), —N(R^(a)R^(b)), —C(═O)—(CH₂)₀₋₂ N(R^(a)R^(b)), —N(R^(a))—C(═O)—(CH₂)₁₋₂N(R^(b)R^(c)), —SO₂R^(a), —N(R^(a))SO₂R^(b), —SO₂N(R^(a)R^(b)), —N(R^(a))—C(R^(b))═O,

 —N(R^(a))C(═O)N(R^(b)R^(c)), —N(R^(a))C(═O)C(═O)N(R^(b)R^(c)), or —N(R^(a))C(═O)OR^(b), (2) —(CH₂)₁₋₃—R^(k), (3) —(CH₂)₁₋₃—O —(CH₂)₀₋₂—R^(k), (4) —(CH₂)₁₋₃—N—(CH₂)₀₋₂—R^(k), (5) —(CH₂)₁₋₃—N(R^(a))C(═O)—(CH₂)₀₋₂—R^(k), (6) —(CH₂)₁₋₃—N(R^(a))C(═O)—O—(CH₂)₀₋₂—R^(k), (7) —(CH₂)₀₋₃—C(═O)N(R^(a))—(CH₂)₀₋₂—R^(k), or (8) —C(═O)—(CH₂)₀₋₂—R^(k), (9) —C(CH₃)₂N(R^(a))C(═O)OCH₂R^(k), (10) —C(CH₃)₂N(R^(a))CH₂R^(k), (11) —C(CH₃)₂N(R^(a))C(═O)R^(k), (12) —C(R^(b))(N(R^(a))C(═O)R^(k))(CH₂OR^(c)), or (13) —C(R^(b))(N(R^(a))(CH₂)—R^(k))(CH₂OR^(c)), R^(k) is aryl selected from phenyl and naphthyl, with the proviso that when R¹ is —(CH₂)₁₋₃—R^(k), then R^(k) is not phenyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, with the proviso that the bicyclic heterocycle is not benzo-1,3-dioxolyl; wherein the aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently (1) fluoro, chloro, or bromo, (2) —OH, (3) —CN, (4) —CF₃, (4) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently —OH, —O—C₁₋₄ alkyl, —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), or —N(R^(a)R^(b)), (5) —OCF₃, (5) —O—C₁₋₄ alkyl, (8) oxo, (9) methylenedioxy attached to two adjacent ring carbon atoms, (10) —C(═O)R^(a), (11) —CO₂R^(a), (12) —SR^(a), (13) —S(═O)R^(a), (14) —N(R^(a)R^(b)), (15) —(CH₂)₀₋₂—C(═O)N(R^(a)R^(b)), (16) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), or (17) —SO₂R^(a); or a pharmaceutically acceptable salt thereof.
 38. The compound according to claim 37, wherein R² is —H; and R⁴ is —CH₂-Q; wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; each R^(a) and R^(b) is independently —H or —C₁₋₄ alkyl; R^(k) is aryl selected from phenyl and naphthyl, with the proviso that when R¹ is —(CH₂)₁₋₃—R^(k), then R^(k) is not phenyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, with the proviso that the bicyclic heterocycle is not benzo-1,3-dioxolyl; wherein the aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently (1) fluoro, chloro, or bromo, (2) —OH, (3) —CN, (4) —CF₃, (4) —C₁₋₄ alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently —OH, —O—C₁₋₄ alkyl, —OCF₃, —C(═O)R^(a), —CO₂R^(a), —SR^(a), or —N(R^(a)R^(b)), (5) —OCF₃, (5) —O—C₁₋₄ alkyl, (8) oxo, (9) methylenedioxy attached to two adjacent ring carbon atoms, (10) —C(═O)R^(a), (11) —CO₂R^(a), (12) —SR^(a), (13) —S(═O)R^(a), (14) —N(R^(a)R^(b)), (15) —(CH₂)₀₋₂—C(═O)N(R^(a)R^(b)), (16) —C(═O)—(CH₂)₁₋₂—N(R^(a)R^(b)), or (17) —SO₂R^(a); or a pharmaceutically acceptable salt thereof.
 39. The compound according to claim 1, which is a compound of Formula (IV):

wherein Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; or a pharmaceutically acceptable salt thereof.
 40. The compound according to claim 1, which is a compound of Formula (V):

wherein R¹³ is —H or —C₁₆ alkyl; R¹⁴ is —H, —C₁₋₆ alkyl, —C(═O)—C₁₋₆ alkyl, —C(═O)—(CH₂)₀₋₂-J, or —C(═O)—O—(CH₂)₀₋₂-J; wherein J is aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, —CF₃, —C₁₋₄ alkyl, —OCF₃, or —O—C₁₋₄ alkyl; and wherein the saturated heterocyclic ring or heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, —CF₃, —C₁₋₄ alkyl, —OCF₃, —O—C₁₋₄ alkyl, or oxo; R¹⁵ and R¹⁶ are each independently —C₁₋₆ alkyl; or alternatively R¹⁵ and R¹⁶ together with the carbon atom to which they are both attached form C₃₋₈ cycloalkyl; and Q is phenyl optionally substituted with from 1 to 3 substituents each of which is independently —F, —Cl, —Br, —OH, —C₁₋₄ alkyl, —CF₃, —O—C₁₋₄ alkyl, —OCF₃, —CN, —SR^(a), or —SO₂R^(a); and is additionally and optionally mono-substituted with methylenedioxy attached to two adjacent ring carbon atoms, phenyl, or —O-phenyl; or a pharmaceutically acceptable salt thereof.
 41. The compound according to claim 40, wherein R¹⁵ and R¹⁶ are both methyl; or alternatively R¹⁵ and R¹⁶ together with the carbon atom to which they are both attached form cyclohexyl; or a pharmaceutically acceptable salt thereof.
 42. A compound according to claim 1, which is a compound selected from the group consisting of N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-1-(methylamino)ethyl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylmorpholin-3-yl)pyrimidine-4-carboxamide; 2-[1-benzoyl-4 (N,N-dimethylglycyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-benzoyl-4-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methylpiperidin-2-yl)pyrimidine-4- carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-yl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[4-methyl-1-(pyridin-2-ylcarbonyl)piperazin-2-yl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl4-(pyridin-2-ylcarbonyl)piperazin-2-yl]pyrimidine-4-carboxamide; 2-(1-ethylpiperidin-2-yl)-N-(4fluorobenzyl)-5,6-dihydroxypyrimdine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-isopropyl-1-methylpiperazin-2-yl)pyrimidine-4-carboxamide; 2-[1-(acetylamino)cyclohexyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4fluorobenzyl)-5,6-dihydroxy-2-[1-(morpholin4-ylacetyl)piperidin-2-yl]pyrimidine-4-carboxamide; N-(4fluorobenzyl)-5,6-dihydroxy-2-(pyrrolidin-1-ylmethyl)pyrimidine-4-carboxamide; N-(4fluorobenzyl)5,6dihydroxy-2-(1-methylpyrrolidin-2-yl)pyrimidine-4-carboxamide; 2-[1-(N,N-dimethylglycyl)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[(pyridin-2-lcarbonyl)amino]ethyl}pyrimidine-4carboxamide; 2-[1-(dimethylamino)-2-phenylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{1-[(2,4-dimethyl-1,3-thiazol-5-yl)carbonyl]piperidin-2-yl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(3-chlorobenzoyl)-4-methylpiperazin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-4-(methylsulfonyl)piperazin-2-yl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-isopropyl-4-methylpiperazin-2-yl)pyrimidine-4-carboxamide; N-(3-bromo-4-fluorobenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(dimethylamino)cyclohexyl]-N-(4fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4fluorobenzyl)5,6-dihydroxy-2-{1-[(pyridin-2-ylcarbonyl)amino]cyclohexyl}pyrimidine-4-carboxamide; 2-(4benzyl-1-methylpiperazin-2-yl)-N-(4fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(2,3-dimethoxybenzyl)-5,6-dihydroxy-2-[4-(1-piperidin-1-ylethyl)phenyl]pyrimidine-4carboxamide; N-(4fluorobenzyl)-5,6-dihydroxy-2-(2-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl)pyrimidine-4-carboxamide; N-(2,3-dimethoxybenzyl)-2-[1-(N,N-dimethylglycyl)piperidin-2-yl]-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(anilinocarbonyl)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[(2S ,4R)-1-benzoyl-4-(benzyloxy)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)piperidin-2-yl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-(morpholin-4-ylacetyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-phenyl-1-[(pyridin-2-lcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; 2-(1-benzoylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-benzylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-benzoylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5,6hydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6dihydroxy-2-(1-isonicotinoylpiperidin-2-yl)pyrimidine-4-carboxamide; N-(2,3dimethoxybenzyl)-5,6-dihydroxy-2-(1-isonicotinoylpiperidin-2-yl)pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(methylsulfonyl)piperidin-2-yl]pyrimidine-4-carboxamide; 2-(1-benzoyl-1,2,3,4-tetrahydroquinolin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{1-[(N,N-dimethylglycyl)amino]-2-phenylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(2,3-dimethoxybenzyl)-5,6-dihydroxy-2-[4-(piperidin-1-ylmethyl)phenyl]pyrimidine-4-carboxamide; 2-({4-[(diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-4-ylmethyl)piperidin-2-yl]pyrimidine-4-carboxamide; 2-(1-benzoylpyrrolidin-2-yl)-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; tert-butyl 2-(4-{[(4fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)morpholine-4-carboxylate; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-3-ylcarbonyl)piperidin-2-yl]pyrimidine-4-carboxamide; 2-[2-(N,N-dimethylglycyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]-N-(4fluorobenzyl)-5,6-dihydroxypyrimidine-4carboxamide; 2-(1-benzoyl-2,3-dihydro-1H-indol-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(2-benzoyl-1,2,3,4-tetrahydroisoquinolin-3-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-amino-2-phenylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(4-benzylmorpholin-3-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-[(1-methyl-1H-imidazol-2-yl)carbonyl]piperidin-2-yl}pyrimidine-4-carboxamide; N-(2,3-dimethoxybenzyl)-5,6-dihydroxy-2-[4-(morpholin-4-ylmethyl)phenyl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(morpholin4-ylmethyl)pyrimidine-4-carboxamide; N-(4-Fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{4-[({[(2-chlorophenyl)sulfonyl]amino}carbonyl)amino]thien-3-yl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4 carboxamide; N⁴-(4-fluorobenzyl)-5,6-dihydroxy-N²-(pyridin-2-ylmethyl)pyrimidine-2,4-dicarboxamide; 2-Benzyl-N-(4-fluorobenzyl)5-Hydroxy-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide; and pharmaceutically acceptable salts thereof.
 43. A compound according to claim 42, which is a compound selected from the group consisting of N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methylpiperidin-2-yl)pyrimidine-4-carboxamide; 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylmorpholin-3-yl)pyrimidine-4-carboxamide; 2-[(dimethylamino)(phenyl)methyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{4-[(diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5,6-dihydroxypyrimidine-4carboxamide; N-benzyl-5,6-dihydroxy-2-(3-phenylpropyl)pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-(pyridin-2-ylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-yl]pyrimidine-4-carboxamide; and pharmaceutically acceptable salts thereof.
 44. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
 45. A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
 46. A method for preventing or treating infection by HIV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
 47. The method according to claim 46, wherein the compound is administered in combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.
 48. A pharmaceutical composition which comprises the product prepared by combining an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
 49. A combination useful for inhibiting HIV integrase, for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.
 50. A compound according to claim 1, which is a compound selected from the group consisting of benzyl 1-[4-({[4-fluoro-2-(methylsulfonyl)benzyl]amino}carbonyl)-5,6-dihydroxypyrimidin-2-yl]-1-methylethylcarbamate; 2-(1-amino-1-methylethyl)-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(dimethylamino)-1-methylethyl]-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-aminocyclopropyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(dimethylamino)cyclopropyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-[(pyrazin-2-ylcarbonyl)amino]cyclopropyl}pyrimidine-4-carboxamide; benzyl 1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)cyclopentylcarbamate; 2-(1-aninocyclopentyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(dimethylamino)cyclopentyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-{[(ethylamino)carbonyl]amino}-1-methylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(benzylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(benzoylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{1-[benzyl(methyl)amino]-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimdine-4-carboxamide; 2-[1-(dimethylamino)-1-methylethyl]-N-(2-ethoxybenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(2-chlorobenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; N-(2-chlorobenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; N-(5-chloro-2-methylbenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[(pyrazin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; 2-[1-(diethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-morpholin-4-ylethyl)pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-piperidin-1-ylethyl)pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-pyrrolidin-1-ylethyl)pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[methyl(pyridin-4-ylmethyl)amino]ethyl}pyrimidine-4carboxamide; 2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxy-N-[2-(methylthio)benzyl]pyrimidine-4carboxamide; N¹,N¹-diethyl-N˜2˜-[1-(4-{[(4fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-1-methylethyl]ethanediamide; 2-[1-(1,4dioxa-8-azaspiro[4.5]dec-8-yl)-1-methylethyl]-N-(4fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1-methyl-1-{[(1-methyl-1H-imidazol-2-yl)carbonyl]amino}ethyl)pyrimidine-4carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-1-(4-oxopiperidin-1-yl)ethyl]pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{1-methyl-1-[methyl(pyridin-2-ylmethyl)amino]ethyl}pyrimidine-4-carboxamide; N-[1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-1-methylethyl]-4-methylmorpholine-2-carboxamide; 2-{1-[acetyl(methyl)amino]-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4carboxamide; 2-[1-(acetylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{1-[4-(dimethylamino)piperidin-1-yl]-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(2,3-dimethoxybenzyl)-2-[1-(dimethylamino)-1-methylethyl]-5,6-dihydroxypyrimidine-4-carboxamide; 2-[4-(dimethylamino)tetrahydro-2H-pyran-4yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(7-methyl-7-azabicyclo[2.2.1]hept-1-yl)pyrimidine-4carboxamide; 2-(7-acetyl-7-azabicyclo[2.2.1]hept-1-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(2-acetyl-2-azabicyclo[2.1.1]hex-1-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(2-methyl-2-azabicyclo[2.1.1]hex-1-yl)pyrimidine-4-carboxamide; tert-butyl (2S,4R)-4-(benzyloxy)-2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)piperidine-1-carboxylate; 2-[(2S,4R)-4-(benzyloxy)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[(2S,4R)-4-(benzyloxy)-1-methylpiperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimdine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(2S ,4R)-4-hydroxy-1-methylpiperidin-2-yl]pyrimidine-4-carboxamide; 2-[1-acetyl-4-(benzyloxy)piperidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-ethyl4-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4 -carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[4-methyl-1-(pyrazin-2-ylcarbonyl)piperazin-2-yl]pyrimidine-4-carboxamide; tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)thiomorpholine-4-carboxylate; N-(4-fluorobenzyl)-5,6-dihydroxy-2-thiomorpholin-3-ylpyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(4-methylthiomorpholin-3-yl)pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[4-(pyridin-2-ylcarbonyl)thiomorpholin-3-yl]pyrimidine-4carboxamide; 2-(4-acetylthiomorpholin-3-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; tert-butyl 1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-2-methoxyethylcarbamate; 2-[1-(dimethylamino)-2-methoxyethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine -4-carboxamide; 2-[1-(acetylamino)-2-methoxyethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-amino-2-methoxyethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-[(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-2-[1-(formylamino)-2-methoxyethyl]-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-methoxy-1-(methylamino)ethyl]pyrimidine-4-carboxamide; 2-{1-[acetyl(methyl)amino]-2-methoxyethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-[methyl(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(4R)-3-(pyridin-2-ylcarbonyl)-1,3-thiazolidin-4-yl]pyrimidine-4carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(4R)-1,3-thiazolidin-4yl]pyrimidine-4 -carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[(4R)-3-methyl-1,3-thiazolidin4-yl]pyrimidine-4-carboxamide; 2-(3-acetyl-1,3-thiazolidin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(3-methyl-1,3-thiazolidin-2-yl)pyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-(1,2,4-trimethylpiperazin-2-yl)pyrimidine-4-carboxamide; 2-[2,4methyl-1-(pyrazin-2-ylcarbonyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-acetyl-2,4-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine -4-carboxamide; tert-butyl1-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-2-methoxy-1-methylethylcarbamate; 2-(1-amino-2-methoxy-1-methylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine -4-carboxamide; 2-[1-(acetylamino)-2-methoxy-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[1-(dimethylamino)-2-methoxy-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4fluorobenzyl)5,6-dihydroxy-2-[2-methoxy-1-methyl-1-(methylamino)ethyl]pyrimidine-4carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-methyl-1-[(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; 2-(1,2dimethylpiperidin-2-yl)-N-(4-fluorobenzyl)-5,6dihydroxypyrimidine-4-carboxamide; 2-{1-[acetyl(methyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-{2-methoxy-1-methyl-1-[methyl(pyridin-2-ylcarbonyl)amino]ethyl}pyrimidine-4-carboxamide; 2-{1-[(cyclohexylmethyl)(methyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{1-[(cyclohexylmethyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-{1-[(cyclohexylmethyl)amino]-2-methoxy-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(4-acetyl-1,2-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-(1-acetyl-2-methylpiperidin-2-yl)-N-(4-fluorobenzyl5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-methyl-1-(pyrazin-2-ylcarbonyl)piperidin-2-yl]pyrimidine-4carboxamide; N-(2,3-dimethoxybenzyl)-2-(1,2-dimethylpiperidin-2-yl-)5,6-dihydroxypyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5,6-dihydroxy-2-[2-methyl-1-(pyridin-2-ylcarbonyl)piperidin-2-yl]pyrimidine-4-carboxamide; 2-{1-[(2,4-dimethyl-1,3-thiazol-5-yl)carbonyl]-2-methylpiperidin-2-yl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; 2-[(2S)-1-acetyl-2-methylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide; and pharmaceutically acceptable salts thereof. 